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Abstract 
Major common complications of diabetes such as myocardial infarction arise from 
the onset of vascular disease. However, there is also evidence of a direct 
impairment of cardiac contractile function in diabetic individuals in the absence 
of atherosclerosis and hypertension, termed diabetic cardiomyopathy (DCM). This 
is characterised by early diastolic dysfunction that progresses to systolic 
dysfunction and heart failure through a pathological remodelling process. The 
earliest identified mechanism underlying this disease is the onset of metabolic 
perturbations such as cardiac insulin resistance. However, currently there are no 
specific treatments available, partly due to the lack of an appropriate 
experimental model with which translational research could be performed. 
iPSC-CM are a recently developed technology, whereby human dermal fibroblasts 
can be reliably harvested, dedifferentiated into a pluripotent form, and then 
differentiated into cardiomyocytes. These cells have an established intracellular 
calcium handling system and contractile capacity, however are generally 
considered to be at a foetal stage of development. A key aim of this project was 
to characterise the metabolic phenotype of these cells, in order to assess their 
potential suitability as the basis of a novel cellular model of DCM. Specifically, it 
was investigated if these cells exhibited robust insulin stimulated glucose uptake 
through insulin sensitive intracellular trafficking of the glucose transporter GLUT4, 
as impairment of this response is a central feature of any diabetic model. 
After adaptation of a [3H]-2-deoxyglucose uptake assay to a 96-well plate format, 
and optimisation of experimental factors, it was determined that iPSC-CM could 
not display robust insulin (or IGF-1) stimulated glucose uptake. Inhibition of the 
spontaneous contractile capacity of these cells did not induce a response upon 
subsequent insulin stimulation. iPSC-CM were found to express and activate 
central insulin signalling molecules such as Akt and Erk1/2, and also possess 
elements of the GLUT4 trafficking machinery such as the SNARE proteins Syntaxin 
4 and SNAP23. However, the critically limiting factor identified was an 
approximate 10-fold lower expression of GLUT4 in iPSC-CM compared to primary 
adult cardiomyocytes, accompanied by strong expression of GLUT1. This data was 
supported by the finding that inhibition of GLUT4 had no impact on glucose uptake 
in iPSC-CM, whereas inhibition of GLUT1 significantly reduced uptake by ~50%. 
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This phenotype suggests that iPSC-CM are also at a foetal-like stage of 
development with regards to their metabolic capacity, and are currently not 
suitable for modelling DCM.  
Subsequently, initial interventions based upon the literature were implemented 
in order to try and increase iPSC-CM GLUT4 content. However, neither increasing 
metabolic reliance upon fatty acid (rather than glucose) nor exposure to 
triiodothyronine were successful. In contrast, Lipofectamine 2000 mediated 
transfection of a customised GLUT4 plasmid facilitated a reliable 3-5 fold increase 
in iPSC-CM GLUT4 content. This increased basal glucose uptake, however did not 
induce an insulin response. It was concluded that a further increase in expression 
levels may be required. Finally, it was demonstrated that iPSC-CM are highly 
amenable to lentiviral mediated infection, and initial steps were taken towards 
the generation of a virus targeting the overexpression of GLUT4.  
Additionally, SNARE proteins are essential in facilitating insulin stimulated GLUT4 
expression at the plasma membrane. Therefore they represent a possible 
mechanism by which cardiac insulin resistance could occur in disease states such 
as DCM. On account of this, the expression of a wide range of SNARE protein 
isoforms was assessed in cardiac lysates generated from 2 diabetic mouse models 
(db/db and high fat diet induced).  The expression of SNAP29 and VAMP5 were 
found to differ in lysates from the high fat diet model, although the role of these 
proteins in GLUT4 trafficking is unclear. In contrast, in the more severe diabetic 
db/db model GLUT4 protein content was found to be significantly reduced, but 
SNARE protein content was unaffected. 
Finally, there is also an established link between glycemic control and both the 
risk of developing and subsequent prognosis for myocardial infarction (MI). There 
is a line of evidence suggesting that cardiac insulin sensitivity may also be highly 
relevant in this disease context. Accordingly, it was demonstrated that 
cardiomyocytes isolated from a clinically relevant 8-12 weeks post-MI rabbit model 
exhibited impaired insulin stimulated glucose uptake. This strengthens the 
association between MI and cardiac metabolic parameters. However, insulin 
stimulated phosphorylation of Akt, GLUT4 levels, and SNARE protein expression 
were unaffected post-MI. Therefore future work must identify both the underlying 
mechanism and clinical relevance of this finding. 
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1 Introduction 
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1.1 Diabetes 
1.1.1 Diabetes is a growing healthcare burden 
Diabetes is primarily defined by a pathological sustained elevation in blood glucose 
concentration. WHO guidelines published in 2006 indicated that blood glucose cut 
off scores of >7 mmol/L (126 mg/dL) when fasting or >11.1 mmol/L (200 mg/dL) 
2 hours after ingestion of 75 g glucose should be used to diagnose the presence of 
this condition. These guidelines were updated in 2011 to recommend that the 
detection of circulating glycated haemoglobin (HbA1c) above 6.5% is also an 
appropriate marker.  
Recent analysis underlined the rising scale of the challenge diabetes is posing as 
a developing global issue. In 2015, there were an estimated 415 million individuals 
between the ages of 20 and 80 living with diabetes, at a worldwide healthcare 
cost of 673 billion dollars (Ogurtsova et al., 2017). In order to further demonstrate 
the magnitude of this burden, this analysis also estimated that approximately 5 
million deaths that year were primarily attributable to diabetes, which is almost 
equal to the entire population of Scotland. Statistical modelling produced 
predictions that by 2040 the number of individuals impacted by diabetes may rise 
to 642 million, just shy of 10% of the world’s entire population. Therefore, 
diabetes is a growing healthcare problem that requires urgent intervention to both 
reduce its prevalence through preventative measures, and enhanced treatment 
options to reduce associated mortality rates. 
1.1.2 Complications 
The urgency for the development of novel strategies to improve diabetes care is 
strongly linked to the severity of complications of this condition. An acute rise in 
blood glucose concentration is not a critical issue, however prolonged elevation is 
highly toxic to blood vessels and has profound implications for the tissues they 
supply. 
With regards to the effects of diabetes upon microvasculature – small vessels such 
as arterioles and capillary beds that are proximal to target organs and tissues - 
there are 3 main recognised complications. Diabetic retinopathy and nephropathy 
refer to loss of function of the vessels serving the eyes and kidneys respectively, 
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which can result in blindness and kidney failure (Cade, 2008). However, the 
complication perhaps most strongly associated with diabetes is related to 
neuropathy - dysfunction of the microvessels serving nerves - and referred to as 
diabetic foot. A combination of decreased afferent sensation, loss of autonomic 
functions such as sweating, and reduced vascular perfusion in peripheral 
anatomical regions such as the feet lead to not only a significant increase in the 
risk of developing ulcers and infections but also a reduced awareness and ability 
to detect these events, which often delays treatment and results in the only 
available option being amputation (Pendsey, 2010).  
All of these conditions summarised are severely debilitating in advanced forms 
and possibly even life threatening. However, the greatest threat to diabetic 
individuals comes from complications within larger vessels such as arteries. There 
is a long appreciated association between diabetes and the risk of classic 
cardiovascular disease (Kannel and McGee, 1979), and indeed this is the leading 
cause of death in this patient population. Of particular concern is the elevated 
risk of developing atherosclerosis, which is an inflammatory driven remodelling 
process within the vascular wall that results in the formation of a characteristic 
lipid rich lesion/plaque that results in narrowing of the vessel lumen (Fowler, 
2008). Combined with several other factors these changes greatly increase 
diabetic patients risk of sustained elevations in blood pressure i.e. hypertension 
(Sowers et al., 2001), which is a strong independent risk factor for heart failure. 
Alternatively, if atherosclerotic lesions rupture then this can result in total 
occlusion of a vessel and therefore prevention of perfusion of the downstream 
tissue. Where this occurs in the coronary vasculature this is referred to as a 
myocardial infarction (MI), and is immediately life threatening. This condition is 
discussed further in section 1.5.1. 
An important issue to consider is how sustained hyperglycemia can lead to the 
myriad of pathological events described. The physiological mechanisms underlying 
these associations are complex and multifaceted, however one particularly 
important factor is endothelial dysfunction. In healthy individuals, smooth muscle 
vascular tone is regulated by the release of nitric oxide (NO) from associated 
endothelial cells. This provides a mechanism by which blood flow can be directed 
to where it is needed by increasing or decreasing vessel diameter through 
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muscular relaxation or constriction respectively. Additionally, NO is considered 
vasoprotective on the basis of its actions to reduce aberrant smooth muscle cell 
proliferation, the permeability of the vascular wall and the oxidation of lipids (all 
key events in plaque formation), and also to decrease the expression of several 
proteins (e.g. MCP-1 and VCAM-1) that are key in recruiting the inflammatory cells 
that drive the atherosclerosis process (Li and Forstermann, 2000). Experimental 
models have indicated that hyperglycemia may increase mitochondrial superoxide 
production, which in turn increases the production of hexosamines that reduce 
the phosphorylation and therefore activity of eNOS – the enzyme responsible for 
NO production (Du et al., 2001). Reduced NO availability will thereafter reduce 
vascular function and also increase susceptibility to injury.  
1.1.3 Causes 
Diabetes is generally split into 2 distinct categories. Whilst terminology can vary, 
each category has a distinct phenotype related to the action of insulin. Post-
prandially, in response to an increased presence of glucose in the bloodstream at 
the end point of the digestive process, insulin is released from the pancreas in 
order to stimulate the uptake of glucose into peripheral insulin sensitive tissues 
(most notably muscle and fat). This action is necessary to maintain blood glucose 
concentration below approximately 5.5 mmol/L.  
In type one diabetic individuals insufficient insulin is produced by the pancreas, 
therefore they are reliant upon regulated insulin injections in order to maintain 
glycemic control. This condition is an autoimmune disease whereby immune cells 
target and destroy the beta cells of the pancreas that produce insulin. It is largely 
attributed to genetic factors (Todd et al., 2007), however there is an emerging 
belief that there may also be important environmental triggers, for example 
exposure to certain viruses (Knip et al., 2005). In contrast, type two diabetes is 
the predominant form of this condition, whereby the sensitivity of peripheral 
tissues to insulin is significantly reduced. Where this occurs, this is referred to as 
insulin resistance (IR). It is this form of the condition that is of primary interest in 
this thesis. Whilst genetic factors have been cited as influencing an individual’s 
risk of developing type 2 diabetes (Dupuis et al., 2010), this condition is primarily 
associated with lifestyle factors leading to weight gain and the development of 
obesity (Resnick et al., 2000). 
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1.1.4 Treatments 
With regards to managing diabetes, regardless of whether it is type 1 or type 2, 
the key concept is to regularly monitor and maintain blood glucose values within 
an acceptable range. However, the means by which this may be achieved will vary 
between conditions and also between individuals. The primary area of treatment 
for type 1 diabetics is insulin injections, at appropriate times and of sufficient 
dosage to substitute for normal physiological functioning. Individuals with type 2 
diabetes may also eventually require insulin therapy, however during the early 
stages of treatment insulin production is not a primary issue and therefore this is 
not typically required. There are a range of drugs typically prescribed for type 2 
diabetics, each with a specific mechanism(s) of action. For example, metformin 
improves peripheral insulin sensitivity, sulphonylureas enhance insulin release 
from the pancreas, and SGLT2 inhibitors increase the excretion of glucose from 
the body via urine. A systematic review identified that when delivered as a 
monotherapy, metformin was determined to be the most effective and safest 
treatment option, relative to a range of other drugs (Maruthur et al., 2016). This 
was based upon key outcomes, including cardiovascular mortality, HbA1c levels, 
and body weight. This finding supports current clinical practice whereby 
metformin is most commonly delivered as a first-line pharmaceutical therapy. 
Asides from pharmacological strategies, the most important and widely prescribed 
therapeutic interventions for diabetic individuals are lifestyle based. A 
combination of improved diet and exercise regime can be used to target better 
management of blood glucose values and whole body composition, in particular 
aiming for sustained weight (fat) loss. A recent meta-analysis concluded that a 
weight loss of greater than 5% total body weight was required to elicit sustained 
significant metabolic improvements in diabetic patients, and the authors 
suggested that this was a challenging goal to meet for this patient population 
(Franz et al., 2015). However, in scientific literature exercise is often treated as 
a single concept, ignoring the almost unlimited possible combinations of 
duration/frequency/intensity/modality that can be implemented, each providing 
a unique stimulus for adaptation. A 12-week high intensity cycling based interval 
programme significantly improved cardiac function and reduced liver fat content 
in type 2 diabetics, accompanied by small improvements in glycemic control 
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(Cassidy et al., 2016). Therefore, further optimisation of these interventions is 
required, as it is highly likely improved outcomes can be achieved. 
Finally, bariatric surgery is currently receiving widespread attention as a novel 
therapy for obesity by means of regulating food intake by physically reducing the 
size of the stomach. For example, gastric banding led to remission of 73% of 
diabetic patients 2 years after undergoing this procedure, reflected in a reduction 
in fasting blood glucose and Hb1Ac values below diagnostic cut off scores, largely 
attributed to drastic weight loss (20% of body weight) relative to patients 
undergoing a standard course of treatment (Dixon et al., 2008). Similarly 
impressive results have been achieved with alternative forms of bariatric surgery 
(Mingrone et al., 2012). This treatment option holds great promise for the 
treatment of diabetes in general, however longer term outcomes, safety, and 
sustainability as a widespread intervention (considering the prevalence of 
diabetes) require further assessment. 
What can be concluded with confidence is that based upon current prevalence and 
mortality rates associated with diabetes, current treatments are not sufficient. In 
order to change this, research must be performed in order to further our 
understanding of the key physiological processes underlying diabetes. These are 
primarily related to the action of insulin in peripheral tissues. This will require 
innovation and the development of novel experimental models, in order to 
maximise the translational value of generated findings and provide platforms for 
assessing the impact of various derived interventions. 
1.2 Insulin stimulated glucose uptake 
1.2.1 GLUT4 trafficking overview 
Insulin is a critical hormone in the regulation of whole body metabolic 
homeostasis, with multiple effects on several target tissues. For example, it 
suppresses the production and release of glucose within the liver (Puigserver et 
al., 2003), in part contributing to its overall effect of reducing blood glucose 
concentration in order to return it to an optimal set point after transient 
deviations, typically after the digestion of food. This balance is required to ensure 
glucose is constantly available to provide vital metabolic fuel to tissues such as 
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the brain, but does not chronically accumulate to levels that risk the 
complications outlined in section 1.1.2. The primary mechanism through which 
insulin achieves this regulatory action is to stimulate the uptake of glucose into 
peripheral tissues, where it is either used to produce adenosine triphosphate (ATP) 
or is stored as glycogen or in lipid form. Predominantly this uptake refers to 
transport into skeletal muscle, with only approximately 10% of glucose entering 
the bloodstream ending up in adipose tissue. It is important to note that this does 
not undermine the importance of adipose tissue in whole body glucose 
homeostasis. A recently developed understanding of adipose tissue has led to its 
recharacterisation as an endocrine organ, rather than simply an energy storage 
depot, and hormones released by adipose such as adiponectin strongly influence 
systemic insulin sensitivity and therefore blood glucose values (Lihn et al., 2005). 
The mechanism by which insulin stimulates an increase in glucose uptake is 
dependent upon complex interactions between dozens of proteins that regulate 
the subcellular localisation of the glucose transporter type 4 (GLUT4) (Leto and 
Saltiel, 2012). This process is referred to as GLUT4 trafficking and is fundamental 
to metabolic control. Each of the most relevant components of GLUT4 trafficking 
will be detailed in subsequent sections, however Figure 1-1 details the 
fundamental concept to provide an initial basic overview. Under basal conditions, 
the majority of GLUT4 is contained intracellularly within specialised structures 
termed GLUT4 storage vesicles (GSVs). In response to insulin stimulation these 
GSVs are shuttled to the plasma membrane where they dock and fuse in order to 
promote integration of GLUT4, which facilitates the uptake of glucose. After 
cessation of insulin stimulation, GLUT4 is reinternalised into a general endosomal 
system, before being sorted back into GSVs at the trans Golgi network (TGN) 
(Huang and Czech, 2007).  
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Figure 1-1 GLUT4 trafficking overview 
GLUT4 must be expressed at the plasma membrane in order to facilitate cellular glucose 
uptake. After endocytosis it enters a general endosomal recycling pathway. From here it can 
either be cycled back to the plasma membrane, targeted for degradation in the lysosome, or 
sequestered into a specialised insulin sensitive storage pool of GSVs via the TGN. Upon 
subsequent insulin stimulation the primary response is translocation of GSVs to the plasma 
membrane, where they are subsequently tethered in place and ultimately fuse in order to 
promote GLUT4 expression at the cell surface. Insulin also acts to reduce rates of GLUT4 
endocytosis and increase cycling from endosomes back to the plasma membrane. 
1.2.2 GLUT transporters 
Insulin stimulation is required in order to facilitate the uptake of glucose into 
target cells because it cannot simply diffuse across the plasma membrane. Rather, 
specialised glucose transporters are required to perform this function. The SLC2 
genes encode for 14 isoforms of a family of hexose transporters collectively 
referred to as GLUTs, which are each composed of approximately 500 amino acids 
and predominantly vary in their substrate specificity and tissue distribution 
(Mueckler and Thorens, 2013). The structure of these proteins is defined by a 
characteristic series of α-helices that spans the plasma membrane 12 times, a 
central substrate binding site, and N-linked glycosylation on an exofacial domain 
(Mueckler and Thorens, 2013).  
In the context of diabetes and this project, the GLUT isoform that facilitates the 
increase in glucose transport in muscle and adipose in response to insulin 
stimulation is of primary interest. As will be fully explained and evidenced in 
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section 4.1, this isoform is GLUT4. As reviewed by Minokoshi et al. (2003) a variety 
of GLUT4 knockout out rodent models have been generated, and the consistent 
finding regardless of the specific details (such as tissue knockout specificity) is the 
onset of severe systemic IR. The importance of GLUT4 to the regulation of glucose 
metabolism via insulin is also reflected in its near exclusive expression in the 
predominant insulin sensitive tissues of muscle and adipose (Huang and Czech, 
2007). 
The most important factor that regulates the action of GLUT4 is its subcellular 
localisation. Under basal conditions a very small fraction of cellular GLUT4 content 
is located at the plasma membrane, whereas in response to insulin stimulation a 
potent redistribution towards the plasma membrane occurs. Reinternalisation of 
any membrane bound molecule facilitates entry into the general endosomal 
recycling pathway, whereby after initial generation of early endosomes vesicular 
cargo can be targeted to lysosomes for degradation, to the TGN for repackaging, 
or returned to the plasma membrane (Grant and Donaldson, 2009). In rat skeletal 
muscle 2 separate pools of GLUT4 content were identified, one that exhibited a 
limited response to insulin and that colocalised with the transferrin receptor and 
annexin II, which are markers of this general endosomal system, and another that 
did not colocalise with these markers and was highly sensitive to insulin 
stimulation (Aledo et al., 1997). Similarly, only approximately 40% of GLUT4 
containing vesicles from 3T3-L1 adipocytes contained the transferrin receptor, 
and specific ablation of transferrin receptor positive vesicles only depleted around 
40% of cellular GLUT4 content (Livingstone et al., 1996). Combined these studies 
provide strong evidence of a specialised highly insulin sensitive storage pool of 
GLUT4, which we now know to be contained within GSVs. 
Initial characterisation of GSVs has revealed that in addition to GLUT4 they also 
contain IRAP, sortillin, LRP1, and Vesicle associated membrane protein 2 (VAMP2), 
based upon analysis of their protein composition and cotranslocation to the plasma 
membrane in response to insulin (Bogan and Kandror, 2010). Specific knock down 
of IRAP (>90%) in 3T3-L1 adipocytes reveals a crucial role for facilitating sorting 
of GLUT4 into GSVs and therefore basal retention, as an increased content of 
GLUT4 was located in the endosomal system and was able to traffic back to the 
plasma membrane (Jordens et al., 2010). Interestingly corresponding knock down 
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of GLUT4 has no discernible impact upon the trafficking of IRAP (Yeh et al., 2007). 
Similarly, manipulation of sortillin expression in these cells reveals this protein to 
be critical in the biogenesis of GSVs, with a corresponding impact upon cellular 
insulin stimulated glucose uptake capacity (Shi and Kandror, 2005). A proteomic 
screen of GSVs isolated from primary rat adipocytes revealed identification of 
~100 proteins, which underlines the complexity of these vesicles, however LRP1 
was identified as a major component capable of interacting directly with both 
GLUT4 and insulin signalling molecules (Jedrychowski et al., 2010). The exact 
function of LRP1 is still unclear, however its deletion also impacted the capacity 
of 3T3-L1 adipocytes to increase glucose uptake in response to insulin. Finally, 
~90% of cellular VAMP2 content localises to the GSVs (Martin et al., 1996), however 
the action of this protein will be discussed in detail in section 1.2.4. 
The uptake of glucose into muscle and adipose tissue cannot be complete without 
acknowledgement of the role of GLUT1. The expression of this transporter is far 
more widespread in a range of tissues and it is mostly located permanently within 
the plasma membrane rather than under the regulation of any hormone or other 
signalling molecules. In rat muscle, where the expression of GLUT4 is strongly 
linked to the maximal insulin stimulated glucose uptake capacity of that tissue, 
acute changes in GLUT1 expression much more strongly correlate with basal 
metabolic glucose uptake (Kraegen et al., 1993), and indeed this is its generally 
accepted role. Whilst reduced vastus lateralis GLUT1 protein content was 
associated with reduced basal glucose uptake in type 2 diabetic patients (Ciaraldi 
et al., 2005), this transporter is not considered particularly relevant to the 
pathogenesis of IR and diabetes when compared to GLUT4. 
1.2.3 Insulin signalling 
As stated, insulin stimulation is the key factor that initiates rapid redistribution 
of GLUT4 from its specialised internal location to the plasma membrane, in order 
to increase cellular glucose uptake. It achieves this action primarily through the 
action of 2 intracellular signalling cascades, one which is dependent upon the 
activation of phosphoinositide-3-kinase (PI3K), and one which is dependent upon 
APS activation (adaptor protein with pleckstrin homology and Src homology 2 
domains) (Leto and Saltiel, 2012). The key concept is that these pathways either 
directly, or indirectly through the activation of small GTPases (and associated 
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GTPase activating proteins (GAPs)), activate trafficking machinery capable of 
initiating GSV translocation, tethering, and fusion with the plasma membrane 
(Stenmark, 2009). These pathways are depicted in Figure 1-2. 
 
Figure 1-2 Insulin signalling cascades relevant to GLUT4 trafficking 
Key signalling events in the process of insulin stimulated GLUT4 trafficking are depicted. 
Note that this list is not exhaustive, but highlights the best characterised and known 
interactions. A series of phosphorylation/activation events triggered by activation of the 
insulin receptor eventually results in the activation of small GTPases, which interact with 
effector proteins in order to initiate GSV translocation, tethering, and fusion with the plasma 
membrane. Where specific molecular interactions of GTPases (TC10α, RalA, Rab 8/10/13) that 
underpin trafficking events have been identified, these are indicated. For full details see main 
text. 
Insulin initially binds to the 2 α-subunits of its corresponding membrane bound 
receptor, which induces autophosphorylation and activation of the tyrosine kinase 
activity in its internal facing β-subunits (Lee and Pilch, 1994). This leads to 
tyrosine phosphorylation of the insulin receptor substrate (IRS-1), which in turn 
activates PI3K. Disruption of the function of either of these proteins leads to 
impaired insulin stimulated glucose uptake and GLUT4 plasma membrane 
expression in adipocytes (Clarke et al., 1994; Quon et al., 1994). PI3K catalyses 
the conversion of PIP2 to PIP3, which is necessary to recruit PDK1 and protein 
kinase B (Akt) to the cell membrane. Phosphorylation and therefore activation of 
Akt2 by PDK1 is a central step in this cascade. Accordingly, rapid pharmacological 
activation of Akt2 to a physiologically relevant degree was able to induce a level 
of GLUT4 translocation comparable to the action of insulin (Ng et al., 2008).  
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It must be stated that at all points in this process there have been multiple 
additional signalling branches and interactions proposed, however Akt2 dependent 
activation of the RAL-GAP complex and the GAP AS160, each of which regulate 
the activation of distinct GTPases, are consistently cited as particularly important. 
AS160 is associated with GSVs under basal conditions and acts to maintain several 
Rab GTPases in their inactive form in order to sustain the basal retention of 
GLUT4, as exemplified by inhibition of AS160, which enhances plasma membrane 
GLUT4 expression (Larance et al., 2005). One key target of AS160 in adipocytes is 
Rab 10, as not only is an increase or decrease in its expression mirrored in changes 
in GLUT4 plasma membrane expression, but in the AS160 knockdown model just 
described, subsequent additional knockdown of Rab 10 is sufficient to partially re-
establish basal GLUT4 intracellular detention (Sano et al., 2007). There is 
evidence that AS160 signalling through Rab 8 and Rab 13 may assume this role in 
skeletal muscle (Sun et al., 2010), indicative of cell type specific mechanisms in 
the process of GLUT4 trafficking. Similarly, knock down of the RAL-GAP complex 
in adipocytes increased glucose uptake in association with increased activity of 
the downstream Rab RalA (Chen et al., 2011). With regards to relating these 
experimental findings to the in vivo action of insulin, in both cases Akt mediated 
phosphorylation of the respective GAP proteins is thought to relieve their 
inhibitory effects upon their target downstream GTPases, which in turn activate 
different parts of the trafficking machinery. 
The insulin dependent APS pathway is less well defined, however impairment of 
this pathway was also found to significantly blunt insulin stimulated GLUT4 
translocation in 3T3-L1 adipocytes (Liu et al., 2002). Although overexpression of 
APS was found to enhance and prolong insulin receptor autophosphorylation and 
activation of the PI3K pathway (Ahmed and Pillay, 2003), this is not the primary 
mechanism through which it impacts GLUT4 trafficking. In response to cellular 
insulin stimulation, tyrosine phosphorylation of APS increases as it binds directly 
to the insulin receptor, resulting in subsequent activation of the proto-oncogene 
c-Cbl. The downstream target of this pathway is ultimately the GTPase TC10α, 
which displays activation in response to insulin even in the presence of 
pharmacological inhibition of PI3K (Chang et al., 2007). Furthermore, subsequent 
knockdown of TC10α reduced insulin stimulated GLUT4 translocation and glucose 
uptake, without impacting Akt activation (Chang et al., 2007).  
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A key question arising from the described model and mechanisms so far is exactly 
how these PI3K dependent and independent signalling cascades translate 
activation of the insulin receptor into the regulated movement of GSVs. Whilst 
there is evidence that insulin may reduce the rate of reinternalisation of GLUT4 
from the plasma membrane (Czech and Buxton, 1993) and increase the rate of 
exocytosis of GLUT4 from the general endosomal cycle (Muretta et al., 2008), by 
far the major action of this hormone is to increase the rate of exocytosis of GLUT4 
from GSVs. This requires initiation of translocation of GSVs to the plasma 
membrane, docking and tethering at this location, and then finally fusion of the 
membranes to permit integration of GLUT4 at the cell surface. This final fusion 
step is regulated by interactions of SNARE proteins, and will be discussed in section 
1.2.4.  
The integrity and remodelling capacity of microtubule and actin networks are 
essential for the translocation of GSVs to the cell membrane in response to insulin 
stimulation (Olson et al., 2001; Tong et al., 2001). Evidence suggests that insulin 
may stimulate an increase in phosphorylation and therefore activity of the myosin 
ATPase motor protein Myo1C, which in association with enhanced colocalisation 
with GSVs may power movement of this vesicle along developed actin tracks to 
the cell membrane (Bose et al., 2002; Yip et al., 2008). Once GSVs arrive at the 
plasma membrane, prior to fusion they are initially tethered in place via a multi-
protein complex referred to as the exocyst. One of the key components Exo70 
exhibits translocation to the membrane in response to insulin stimulation and its 
mutation reduces insulin stimulated glucose uptake without impairing GLUT4 
trafficking (Inoue et al., 2003). Similarly, two other components of the exocyst 
(Sec6 and Sec8) have also been shown to redistribute towards the plasma 
membrane in response to insulin, and their overexpression enhances insulin 
stimulated glucose uptake without impacting the rate of activity of other 
exocytosis pathways (Ewart et al., 2005). These results suggest that the exocyst 
complex may be specifically involved in the regulation of GLUT4 exocytosis. 
The interactions between GTPases at the end point of insulin signalling cascades 
and these effector proteins are at an early stage of characterisation, however 
already important links have been established. For example, activated TC10α 
interacts directly with Exo70 in order to initiate exocyst complex formation (Inoue 
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et al., 2006). Similarly, RalA has been demonstrated to associate with the GSV 
and interact with both Myo1C and elements of the exocyst complex, suggesting 
that it could initiate GSV translocation and targeted docking at appropriate 
locations at the plasma membrane (Chen et al., 2007). Continued investigation of 
similar mechanisms will facilitate further understanding of the cross over between 
insulin signalling and GLUT4 translocation. 
1.2.4 SNARE proteins 
Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) 
are evolutionary conserved proteins that are vital in the understanding of 
intracellular trafficking and exocytosis due to their primary action of facilitating 
the fusion of biological membranes. Classically, different SNAREs have been 
grouped according to their functional location. SNAREs located on a vesicular 
membrane that are mostly from the VAMP family were referred to as v-SNAREs, 
whereas SNAREs on the target membrane (to where the cargo is being delivered) 
that are typically from the Syntaxin and SNAP families were referred to as t-
SNAREs. VAMP and Syntaxin proteins are anchored to the respective membrane via 
their C-terminus, and each contain one classic SNARE motif, which is a ~60 amino 
acid sequence that is critical to the action of these proteins (Hong, 2005). In 
contrast, SNAP proteins are anchored to the membrane via palmitoylation, and 
contain 2 SNARE motifs. 
The formation of a functional SNARE complex refers to the generation of a highly 
stable 4 α-helix complex derived from 4 SNARE motifs, and therefore at minimum 
require the interaction of one VAMP, one Syntaxin, and one SNAP isoform. At the 
core of this 16 layered structure there is an interaction between one residue from 
each motif referred to as the “0 layer”, and the presence of either a glycine or 
arginine residue from each respective motif has led to the proposed structural 
reclassification of Q or R SNAREs respectively. The SNARE hypothesis dictates that 
the formation of this complex in a “zippering” action from N-terminus to C-
terminus brings the opposing membranes into intimate physical proximity and 
provides the necessary energy for their fusion (Fasshauer, 2003). 
Intracellular trafficking requires a high degree of specificity so that molecules only 
end up at their intended and required destination. A central component of the 
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SNARE hypothesis is that only unique combinations of SNAREs will functionally 
interact in vivo, thus providing a mechanism of regulation (McNew et al., 2000). 
SNARE proteins are critical to the process of insulin stimulated GLUT4 trafficking 
(Cheatham et al., 1996), and identification of the specific isoforms in this process 
and understanding the  regulation of their interactions in a state of both health 
and disease is of importance for the pathophysiological mechanisms underlying 
diabetes. 
With regards to the fusion of GSVs and the plasma membrane, it is widely accepted 
that the t-SNAREs involved are Syntaxin 4 and SNAP23 (Olson et al., 1997; 
Kawanishi et al., 2000). However, on account of the promiscuity of SNAREs both 
in vitro and in vivo (particularly upon overexpression), the VAMP family isoform 
involved in this complex had been the source of greater debate (Bryant and Gould, 
2011). Sadler et al., (2015) underlined this issue by demonstrating that all 7 of 
the known VAMP isoforms were capable of forming the characteristic SDS-resistant 
SNARE complex with SNAP23 and Syntaxin 4. However, based primarily upon 
relative expression levels and subcellular distribution, it was concluded that 
VAMP2 was the v-SNARE involved in this reaction in vivo, at least in 3T3-L1 
adipocytes, which are a widely used experimental model for insulin stimulated 
GLUT4 trafficking.  
Based upon the described mechanism by which SNARE proteins promote membrane 
fusion, it can be appreciated that the primary factor determining their action is 
their intracellular localisation, which in the case of any GSV associated SNARE is 
tightly regulated by insulin, as described in section 1.2.3. However, the ability of 
Syntaxin proteins to participate in SNARE complex assembly is also believed to be 
regulated by proteins from the Sec1p/Munc18 (SM) family. Specifically, Munc18c 
regulates the action of Syntaxin 4 through a direct mechanism, however the exact 
nature of this regulation is unclear and may be partially dependent upon the 
conformation state of Syntaxin 4 upon binding (it can exist in an open or closed 
form) and the phosphorylation status of Munc18 (Laidlaw et al., 2017). To 
underline this confliction, overexpression of Munc18c in 3T3-L1 adipocytes 
impaired insulin stimulated GLUT4 (and IRAP) expression at the plasma 
membrane, suggesting that this protein has an inhibitory action on Syntaxin4-
VAMP2 interactions (Thurmond et al., 1998). In contrast, heterozygous Munc18c 
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knockout mice exhibited impaired systemic insulin sensitivity and skeletal muscle 
GLUT4 plasma membrane translocation, suggesting that it is essential for SNARE 
complex assembly (Oh et al., 2005). 
When considering the involvement of SNAREs in insulin stimulated glucose uptake, 
it is common to only consider the action of Syntaxin 4, VAMP2, and SNAP23. 
However, the efficiency of the intracellular sorting process of GLUT4 after 
reinternalisation (or initial synthesis) back into GSVs in preparation for future 
insulin stimulation is equally critical for the continued efficacy of this response. 
Arguably, and perhaps related to the increased complexity of this process, this 
part of GLUT4 trafficking is less well characterised, however key players have 
been identified.  
For example, in 3T3-L1 adipocytes, whilst Syntaxin 7, 8, and 12/13 were all found 
to colocalise with the GSV to a small degree, approximately 85% of cellular 
Syntaxin 6 was associated with the GSV and also exhibited insulin stimulated 
translocation to the plasma membrane (Perera et al., 2003). Impairment of the 
action of Syntaxin 6 resulted in increased basal glucose uptake, attributed to 
impaired GLUT4 reinternalisation and sorting into GSVs after the cessation of 
insulin stimulation, which would therefore permit spontaneous recycling of GLUT4 
back to the plasma membrane. Similarly, the reduction of Syntaxin 16 expression 
by >90% resulted in a ~30% reduction in cellular GLUT4 content and impaired 
insulin stimulated GLUT4 translocation (Proctor et al., 2006). The cycling of the 
transferrin receptor was unchanged, indicative of no impact upon general 
endosomal trafficking, which strongly suggests that Syntaxin 16 is vital to the 
sequestration of GLUT4 away from general endosomal recycling into its specialised 
GSV pool. It has also been demonstrated that the integrity of a short amino acid 
in the C-terminus of GLUT4 is integral for its efficient sorting into GSVs (Shewan 
et al., 2000), leading to the proposal of a model whereby this sequence enables 
the exit of GLUT4 from the general endosomal system, and Syntaxins 6 and 16 
facilitate subsequent entry into the specialised insulin sensitive pool (Shewan et 
al., 2003). 
It must be acknowledged that the majority of knowledge regarding the action of 
SNARE proteins in insulin stimulated GLUT4 trafficking has been obtained from the 
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study of 3T3-L1 adipocytes. The specific isoforms and actions of these proteins in 
the heart will be discussed in section 5.1.2. 
1.2.5 Theories of insulin resistance 
Whilst the diagnostic criteria for diabetes refers to the levels of glucose (directly 
or indirectly) in the blood, this is largely a reflection of systemic insulin sensitivity. 
Accordingly, given that the vast majority of glucose is transported into skeletal 
muscle, the main phenotype of diabetes is strongly related to the development of 
IR in this tissue. As will become clear, this does not mean that alterations in 
metabolic regulation in other tissues is not of critical importance. However, the 
pathology underlying IR has been widely studied in skeletal muscle, and 
consideration of this literature provides an excellent platform for understanding 
this general concept. 
1.2.5.1 Fatty acid overload? 
Primarily, the development of IR in skeletal muscle has been linked to increased 
fatty acid availability, associated with chronic over feeding and the onset of 
obesity. This general association was demonstrated by study of first degree 
relatives of diabetics, who have an elevated risk of also developing this condition. 
These individuals exhibited elevated resting circulating FFA and insulin 
concentrations relative to control subjects, indicative of a prediabetic phenotype, 
and a significant inverse correlation between FFA levels and systemic insulin 
sensitivity as measured by euglycemic-hyperinsulinemic clamp (Perseghin et al., 
1997). The strength of this association was enhanced by a separate study of a 
similar subject group (predisposed to diabetes but currently within the healthy 
range) that identified that pharmacologically reducing circulating FFA 
concentration up to almost half over the course of 7 days resulted in (and 
correlated with) significantly improved insulin mediated systemic glucose disposal 
and suppression of hepatic glucose production (Bajaj et al., 2004). During 
physiological testing insulin concentrations were unchanged, indicating the 
enhanced responses were due to improved sensitivity and not merely reflective of 
increased production of insulin by the pancreas. Finally, advanced imaging with 
proton nuclear magnetic resonance spectroscopy revealed a significant inverse 
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correlation between skeletal muscle lipid content and whole body insulin 
sensitivity in a group of healthy individuals (Krssak et al., 1999). 
The logical assumption from the described work thus far is that increased skeletal 
muscle lipid content must somehow impair the action of insulin to increase the 
trafficking of GLUT4 to the cell surface. One mechanism through which this could 
be achieved is through a reduction in GLUT4 content, however there is much 
stronger evidence that actually intracellular insulin signalling pathways may be 
impaired. For example, in healthy human subjects acute lipid infusion resulted in 
a significant reduction in skeletal muscle glucose-6-phosphate levels relative to 
controls, associated primarily with a near total loss of activation of IRS-1 and 
therefore prevention of cellular glucose uptake (Dresner et al., 1999). This acute 
study is supported by a wealth of evidence demonstrating reduced activation of 
proximal insulin signalling (IRS-1, PI3K) in samples from type 2 diabetic patients 
(Björnholm et al., 1997; Kim et al., 1999; Bouzakri et al., 2003). In contrast, whilst 
controversial, it has been demonstrated that the expression of GLUT4 is generally 
not altered in the skeletal muscle of diabetic individuals (Garvey et al., 1992). 
1.2.5.2 Impaired oxidative capacity? 
Importantly, merely the presence of elevated intramyocellular lipid content is not 
sufficient to impair insulin sensitivity. This is demonstrated most clearly in 
endurance trained athletes, who exhibit similarly large skeletal muscle lipid 
depots compared with diabetic individuals, yet are highly insulin sensitive 
(Goodpaster et al., 2001). This is largely linked to their enhanced mitochondrial 
oxidative capacity, thereby ensuring an even balance between lipid availability 
and the ability to metabolise it. In contrast, lipid overload in the absence of this 
trained phenotype can rapidly lead to the accumulation of toxic lipids such as 
diacylglycerol (DAG) and activation of corresponding protein kinase C (PKC) 
mediated signalling pathways (Itani et al., 2002). Indeed, in a lipid overload 
induced insulin resistant rat model, a 4-fold increase in PKC-θ in its active form 
was detected in skeletal muscle (Griffin et al., 1999). Direct experimental 
evidence further implicates the involvement of this protein kinase, as PKC-θ 
knockout mice were protected against the onset of lipid induced impairments in 
skeletal muscle IRS-1/PI3K insulin signalling and insulin stimulated glucose 
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transport (Kim et al., 2004). Importantly, in this model activation of the insulin 
receptor was unchanged. 
Increased abundance of other lipid derivatives such as ceramide has been 
associated with IR in human skeletal muscle through inhibition of the activation 
of Akt, however the presence of this mechanism is more controversial (Adams et 
al., 2004; Skovbro et al., 2008). Research in this area is ongoing, and more subtle 
factors are being identified. For example, there is evidence that the subcellular 
localisation of potentially toxic lipids – not just their total cellular accumulation – 
may be of importance with regards to subsequent physiological consequences 
(Perreault et al., 2018). However, further investigation is required as 
experimental interventions have generated contradictory results. For example, 
enhancing skeletal muscle mitochondrial FA uptake in a HFD rat model of IR via 
overexpression of carnitine palmitoyltransferase (CPT) resulted in improved 
insulin sensitivity linked to reduced DAG accumulation and an associated reduction 
in PKC-θ activity (Bruce et al., 2009). In contrast, a separate study identified that 
inhibition of CPT protected mice against the onset of IR induced by a HFD, and 
claimed that enhanced β-oxidation in a state of over feeding could generate 
increased ROS or other metabolites that may impair insulin signalling (Koves et 
al., 2008). Therefore the relationship between increased skeletal muscle lipid 
content and impairments in insulin signalling requires further clarification. 
1.2.5.3 Altered adipokine profile? 
As introduced earlier, adipose tissue is no longer considered to be an inert energy 
store, but rather has important metabolic and endocrine actions. In particular, it 
is proposed that sequestering lipid in adipose stores prevents its accumulation in 
skeletal muscle, and that the secretion of adipokines enhances peripheral insulin 
sensitivity (Guilherme et al., 2008). In the context of obesity, an inflammatory 
response is induced in expanding adipose stores as evidenced by enhanced 
macrophage infiltration and TNF-α production, which can induce adipose specific 
IR (Xu et al., 2003). The primary action of insulin on adipose tissue is to suppress 
lipolysis, and a progressive reduction of this action has been linked to rises in 
circulating fatty acid concentration that may induce skeletal muscle IR 
(Gastaldelli et al., 2017).  
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Additionally, it has been proposed that the adipokine profile is altered in a state 
of adipose IR that may further enhance the development of IR in skeletal muscle. 
For example, adiponectin has been associated with enhanced peripheral insulin 
sensitivity, and in a group of healthy and diabetic subjects circulating levels of 
this hormone was significantly negatively associated with whole body adiposity, 
circulating lipid values, and systemic insulin sensitivity (Blüher et al., 2006). The 
importance of this hormone was highlighted by the observation that adiponectin 
receptors exhibited a compensatory upregulation in skeletal muscle in diabetic 
individuals, and a training programme significantly increased circulating 
adiponectin values in association with improvements in body composition and 
metabolic parameters. Manipulation of adiponectin in diabetic mouse models 
confirms its role in skeletal muscle insulin sensitivity, which is proposed to be 
mediated through enhancing mitochondrial β-oxidation and energy dissipation, 
functioning overall to reduce myocyte lipid content (Yamauchi et al., 2001). 
Additionally, the presence of the cytokine TNF-α has been demonstrated to be 
elevated in the adipose tissue of obese humans (Hotamisligil et al., 1995). In 
contrast to the action of adiponectin, infusion of TNF-α impaired proximal insulin 
signalling and associated glucose uptake in the skeletal muscle of healthy human 
subjects (Plomgaard et al., 2005). 
1.2.5.4 Hyperinsulinemia? 
Whilst lipid mediated mechanisms appear to almost certainly primarily contribute 
to the onset of IR in skeletal muscle, other mechanisms may facilitate 
maintenance or progression of this phenotype towards a full diabetic state. For 
example, the induction of physiologically relevant hyperinsulinemia for at least 
24 hours specifically inhibited the action of glycogen synthase (and therefore the 
synthesis of glycogen) in skeletal muscle (Iozzo et al., 2001). After the initial onset 
of IR, often an elevation in circulating insulin concentration is observed, and 
presumed to be an attempt to regain metabolic control by compensating for the 
reduced potency per unit of insulin released by the pancreas. However, this may 
actually be counterproductive in the long term, and aid the progression from IR 
to diabetes. Therefore, overall it is apparent that the physiology underlying the 
development of IR is multifactorial and complex beyond the initial mechanisms 
introduced, with significant further research required to answer questions that 
will lead to the development of improved novel therapeutic interventions.  
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1.3 Diabetic cardiomyopathy 
As introduced in section 1.1.2., the predominant pathological consequence of 
diabetes is vascular disease, with several notable consequences for the 
downstream tissue. With regards to the heart, this often manifests as either 
progression to heart failure on account of chronic pressure overload associated 
with hypertension, or MI on account of atherosclerosis. However, the 
characteristic changes reflected in blood chemistry in diabetic individuals may 
also exert a direct pathological effect upon the heart, further contributing to the 
cardiovascular burden of this condition. Where reduced cardiac function is 
observed in diabetic individuals with no accompanying vascular disease this is 
referred to as diabetic cardiomyopathy (DCM), and is a key area of study within 
this thesis. 
1.3.1 Key features of DCM 
In any given cardiac cycle, two factors are critical to ensuring an adequate volume 
of blood is pumped from the heart with each beat. These are the ability of the 
heart to rapidly relax and refill with blood (diastole), and its capacity to 
subsequently contract and eject the blood efficiently from the right and left 
ventricles (systole). Disruption of either of these actions can limit blood supply to 
vital tissues around the body, and is therefore of critical concern. In heart failure, 
where cardiac pump capacity can no longer meet the demands placed upon it 
(which could be initiated by one of several pathogenic stimuli), most typically 
systolic function is initially impaired, however a pathological (initially adaptive) 
remodelling process occurs that ultimately ends up debilitating global cardiac 
structure and function (Kemp and Conte, 2012). In contrast, an impairment of 
diastolic contractile function is most often the first detected sign of DCM, before 
ultimate progression to a heart failure phenotype if left untreated (Miki et al., 
2013). 
Whilst there was initially some controversy even regarding the existence of DCM, 
it has now been thoroughly characterised and demonstrated to be present in 
several independent diabetic populations. One of the earliest associations 
between diabetes and cardiac failure came in the Framingham study (Kannel et 
al., 1974). In an 18 year follow up of over 5,000 individuals, the authors noted 
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that the risk of developing heart failure was significantly greater in diabetic 
patients relative to controls, even when controlling for factors such as vascular 
disease, blood pressure, and body weight.  
This work is complemented by more recent studies using advanced in vivo imaging 
techniques. For example, using tissue Doppler imaging (TDI - an improved 
derivative of echocardiography) in combination with older techniques, 75% of a 
diabetic population without pre-existing vascular disease were observed to have 
impaired diastolic function, as indicated by impairment of at least one index of 
diastolic function such as a decrease in the mitral annular E/A ratio (Boyer et al., 
2004). The E/A ratio compares early (E) to late (A) diastolic tissue velocity, with 
a decrease in relaxation capacity reducing the early response and therefore the 
overall ratio. The authors highlighted the importance of obtaining measurements 
such as this due to its independence from cardiac pre-load (Nagueh et al., 1997). 
This essentially means that it can reflect alterations in contractility regardless of 
the left ventricular filling pressure, which is important as an increase in this 
variable could compensate for reduced intrinsic myocardial performance. This is 
on account of the fact that TDI records the velocity of movement of tissue, not 
blood, as with conventional techniques. To underline this point, the authors 
reported that TDI exhibited enhanced diagnostic sensitivity within their 
experimental population compared to previously widely implemented techniques, 
which in hindsight may have underestimated the prevalence of DCM in prior 
literature.  
A second study confirmed the presence of diastolic dysfunction as indicated by an 
impaired E/A ratio via TDI in otherwise asymptomatic diabetic patients (Zahiti et 
al., 2013). Separate work using slightly older parameters (E/A blood flow velocity 
ratio) identified the presence of diastolic dysfunction in 40% of a population of 
305 diabetic individuals, yet only 9% displayed impaired systolic function as 
indicated by left ventricular ejection fraction (Poulsen et al., 2010). Whilst this 
diastolic number may be an underrepresentation for reasons just introduced, it 
still highlights the predominant diastolic dysfunction observed in DCM patients. 
However in an additional study, utilisation of TDI allowing measurement of more 
sensitive indices of systolic function such as peak systolic tissue velocity identified 
significant impairment of function in type 2 diabetic individuals relative to control 
 23 
 
subjects, even though ejection fraction (a common marker of systolic function) 
was within the normal range (Andersen et al., 2003). This research suggests that 
systolic function may not be completely unaffected during the initial stages of 
DCM, as can be portrayed in the literature. 
In combination, this work described indicates that diabetic individuals are at a 
high risk of impaired cardiac diastolic function, which often progresses to impaired 
systolic function and ultimately heart failure. In any cardiac disease where cardiac 
function is initially impaired, a range of adaptive processes may occur in order to 
compensate for this loss of functional capacity (Kemp and Conte, 2012). For 
example, increased release of hormones such as angiotensin and vasopressin act 
to induce vasoconstriction and enhance blood volume (Goldsmith, 2006). These 
adaptations function to maintain peripheral blood pressure and enhance pre-load 
in the ventricles respectively, the latter of which can enhance diastolic filling 
velocity and induce increased stretch on the myocardium to increase systolic 
contractility via the Frank-Starling mechanism (Kemp and Conte, 2012).  
However, over time, the range of chemical, hormonal, and physical stimuli the 
failing diabetic heart is exposed to lead to structural adaptations (Walker et al., 
2016). For example, using cardiac magnetic resonance imaging, concentric left 
ventricular remodelling was observed in a DCM patient group, as determined by 
an increase in the ratio of left ventricular mass to chamber volume (Shang et al., 
2016). This is indicative of left ventricular hypertrophy, which is also observed 
after certain forms of exercise training (Pelliccia et al., 1991). However, after 
exercise training this increase in size is largely reflective of a functional increase 
in myocyte contractile myofilament content driven by IGF-1-Akt signalling that 
contributes to enhanced cardiac performance. In contrast, in the context of 
pathological hypertrophy this increase in myocyte volume is also associated with 
increased deposits of collagen (fibrosis) and cell death driven by activation of 
MAPK and calcium sensitive signalling pathways, which together ultimately lead 
to a decrease in overall contractile capacity (Bernardo et al., 2010). Accordingly, 
a diabetic rat model exhibited increased cardiomyocyte size and cardiac collagen 
content, associated with reduced diastolic contractile function (Huynh et al., 
2010). However, overexpression of the IGF-1 receptor exerted protection against 
this phenotype, underlining both the physiological importance of this hormone, 
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and the role fibrosis has in stiffening the myocardium and therefore contributing 
to reduced contractile function.  
As DCM advances, global cardiac function progressively declines until it reaches a 
clinical heart failure phenotype whereby it can no longer sustain the cardiac 
output required to maintain the necessary delivery of oxygen and nutrients to 
other vital organs. However, it is important to note that an impairment in 
contractile function is observed prior to structural changes (Schannwell et al., 
2002). Therefore, whilst ventricular remodelling is important in the progression of 
this disease, it is limitations in contractility that initially drive DCM. Consequently, 
understanding how diabetes initially impacts cardiac contractility is of great 
experimental, theoretical, and most importantly clinical significance. 
1.3.2 Excitation contraction coupling 
In order to understand how cardiac function may become impaired in any given 
disease, it is imperative to first of all detail the physiological processes that 
determine cardiac contractility in a healthy baseline state. A key parameter often 
used to indicate cardiac function is cardiac output, which is essentially the volume 
of blood being ejected from the heart per minute. This is a product of heart rate 
and stroke volume (the amount of blood ejected per beat), of which the latter is 
far more important in the context of cardiac disease.  
Stroke volume is influenced by a range of factors including the amount of blood 
entering the heart during diastole, the mechanical properties (stiffness) of the 
myocardial tissue, and the volume of contractile myofilaments available to 
generate active contractile force. However, primarily cardiac contractility is 
dependent upon the collective force generation capacity of individual heart 
muscle cells (cardiomyocytes), and it is here that deficits in overall cardiac 
performance primarily originate within the context of DCM. This capacity is 
directly determined by the process of excitation contraction coupling within each 
cardiomyocyte, which is summarised in Figure 1-3. 
 25 
 
 
Figure 1-3 Cardiac excitation contraction coupling 
Cardiomyocyte membrane excitation initiates the opening of L-type calcium channels (LTCC) 
located predominantly within t-tubules, and therefore also entry of a small amount of calcium. 
This binds to ryanodine receptors (RyR) on the sarcoplasmic reticulum and triggers a much 
larger release of calcium from this intracellular store. The availability of calcium and ATP 
(predominantly from mitochondrial β-oxidation) facilitates the active sliding of the thick 
(myosin) and thin (actin) myofilaments relative to one another, that within their striated 
structure functions to initiate cell shortening (contraction). Relaxation is predominantly 
initiated by the reuptake of calcium into the sarcoplasmic reticulum via the SERCA calcium 
ATPase transporter. 
The first step of myocyte contraction, regardless of anatomical location, is 
electrical activation. In contrast to the specific activation of individual skeletal 
muscle fibres via designated motor neurons that facilitates the graded 
recruitment of individual muscles, activation of the heart is a more binary system. 
Pacemaker cells within the sinoatrial node in the right atrium initiate electrical 
excitation that spreads from cell to cell via gap junctions in a highly coordinated 
fashion, in order to initiate contraction within individual myocytes with the 
required order and timing to produce effective whole organ level transient 
structural changes during contraction and relaxation (Lo, 2000). Disruption of this 
process of activation is a common cause of arrhythmia, and can lead to fatal 
sudden cardiac death (Myerburg et al., 1992). 
At the cellular level, activation refers to the rapid exchange of ions 
(predominantly sodium and potassium) across the myocyte membrane that causes 
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a characteristic change in membrane potential referred to as an action potential. 
Invaginations of the myocyte membrane referred to as t-tubules ensure near 
simultaneous activation across the whole cell (Ibrahim et al., 2011). During this 
activation, membrane bound voltage sensitive L-type calcium channels (LTCC) 
open and permit a small influx of calcium. This then binds to and opens ryanodine 
receptors (RyR) on the intracellular sarcoplasmic reticulum (SR), which triggers a 
much larger rise in cytoplasmic calcium concentration through a secondary release 
of calcium from this organelle in a process classically referred to as calcium 
induced calcium release (Fabiato, 1983). The liberated calcium then binds to the 
troponin-tropomyosin complex and initiates a conformational change that permits 
the interaction of the contractile myofilaments actin and myosin. Provided there 
is sufficient ATP availability, a cyclical attachment, sliding, and detachment 
process commonly referred to as a power stroke is initiated, whereby attachment 
and subsequent hydrolysis of ATP on the myosin heavy chain powers the active 
movement of actin and myosin relative to one another (Lombardi et al., 1992). 
Due to the striated global structure of individual muscle cells, this contraction 
functions to shorten the overall muscle within its structural framework. Within 
the myocardium, this functions to compress the chambers of the heart to power 
the movement of blood into the next chamber, or blood vessel, as appropriate. 
Relaxation of cardiomyocytes is not a passive process that facilitates the return 
of chamber dimensions to their baseline state on account of elastic recoil. Rather, 
it relies upon the active, heavily ATP dependent, removal of calcium from the 
cytoplasm. Whilst some calcium is transported back out of the cell altogether or 
can be taken up by mitochondria during diastole, the majority is returned to the 
SR via the sarcoplasmic reticulum calcium ATPase transporter (SERCA) (Periasamy 
and Kalyanasundaram, 2007). The function of SERCA is closely regulated by an 
endogenous inhibitor called phospholamban. The action of SERCA also strongly 
influences systolic function, because end diastolic SR calcium content is a 
powerful regulator of subsequent SR calcium release and therefore also 
contractile capacity (Bassani et al., 1995). Pathological changes in the expression 
and activity of SERCA are strongly implicated in several cardiac disease 
phenotypes (Arai et al., 1994). In general, the cyclical changes in calcium 
concentration associated with excitation contraction coupling are referred to as 
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a calcium transient, and the profile of this transient is a strong predictor of 
cardiomyocyte function. 
Excitation contraction coupling is not a statically defined process, but rather it 
can be adapted depending upon acute and chronic demands. For example, during 
exercise the workload of the heart increases, in order to pump more oxygen and 
nutrients to the activated skeletal muscles. This has to occur within a cardiac 
cycle of reduced duration as heart rate will almost certainly also be increased. 
Therefore, the efficiency of intracellular calcium handling must be transiently 
enhanced in order to meet these demands. An experimental model employing 
Calcium/calmodulin dependent protein kinase II (CamKII) inhibition revealed that 
activation of this kinase during increased workloads (higher frequency stimulation) 
was essential to enhance SERCA activity and therefore also diastolic SR calcium 
reuptake in mouse cardiomyocytes, which could largely account for enhanced 
contractile performance under acute stress (Picht et al., 2007). This finding is 
supported by evidence that a period of exercise training enhanced cardiac SERCA 
protein expression and associated calcium handling in rat cardiomyocytes (Wisløff 
et al., 2001). Interestingly, peak systolic calcium concentration did not increase 
despite enhanced myocyte contractile shortening, indicating myofilament calcium 
sensitivity was improved. A separate study largely replicated these functional 
findings after exercise training in mice, but also identified that the 
phosphorylation of CamKII and phospholamban were chronically elevated (Kemi et 
al., 2007). This would function to alleviate the inhibitory action of phospholamban 
on SERCA, further enhancing its action. Inhibition of CamKII ablated training 
induced improvements in cardiomyocyte contractility, but did not fully abolish 
enhancements in myofilament calcium sensitivity, indicating additional 
mechanisms are responsible for the adaptive response to exercise.   
The plasticity of excitation contraction coupling is also displayed in a more 
permanent manner when comparing skeletal and cardiac muscle. This process is 
responsible for the contraction of both category of myocytes. However, whilst 
they rely on the same principles, they are finely tuned to optimally perform the 
workload required for each cell type. For example, the abundance of mitochondria 
in cardiac muscle is at least 2 fold greater than that of skeletal muscle, in order 
to ensure a constant supply of ATP to power contraction (Park et al., 2014). In 
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contrast, skeletal muscle is adapted for more powerful contractions in order to 
power demanding actions such as locomotion or the lifting of objects. This sort of 
output leads to fatigue and the need for rest and recovery, something that cannot 
be afforded to the heart. This adaptation is reflected in the isoforms of varying 
proteins that are expressed, which vary in maximal activity and efficiency, in 
particular that of the myosin heavy chain and SERCA (Weiss and Leinwand, 1996; 
Periasamy and Kalyanasundaram, 2007). 
1.3.3 Alterations in calcium handling are important in DCM 
When outlining the general progression of DCM in section 1.3.1, reference was 
made to several factors that are associated with the pathophysiological events 
underlying this disease state. It is important to acknowledge that a myriad of 
additional factors related to the general diabetic phenotype have been associated 
with reduced cardiac contractile function and structural remodelling in DCM, 
including increased oxidative stress, activation of the renin angiotensin system, 
inflammation, and many more (Bugger and Abel, 2014). However, whilst the full 
physiological explanation of DCM will undoubtedly be complex and multifactorial, 
there is strong evidence that one of the most critical and early factors is an 
impairment of the excitation contraction coupling process outlined in section 
1.3.2. 
A major limitation in previous studies within this area is the dependence upon 
animal models. However, to some extent this has been unavoidable, and the 
db/db mouse model, which has a mutation in the leptin receptor gene leading to 
over feeding and obesity, recapitulates key features of DCM (Kobayashi et al., 
2000). Crucially, this model reproducibly displays impaired cardiac function 
attributable to impaired intracellular calcium handling. Specifically, collective 
work has demonstrated reduced whole heart contractility from these mice, 
indicated by reduced fractional shortening, stroke volume, and developed 
pressure as measured by echocardiography or Langendorf perfusion (Belke et al., 
2004; Stølen et al., 2009). In all cases, this was attributed to reduced systolic and 
diastolic peak intracellular calcium concentrations, reduced calcium transient 
amplitude, and most importantly slower SR calcium reuptake on account of 
reduced overall SERCA activity. This in turn was attributed to reduced SERCA 
protein expression and increased inhibition by phospholamban. These changes 
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can, at least in theory, fully account for the reduced function of the hearts from 
these mice.  
It is important to state that these findings have been closely replicated in a very 
different diabetic model (insulin resistant Wistar rats induced by a high sucrose 
diet), thereby increasing confidence in their translational relevance (Dutta et al., 
2001). However, one issue with this collective data is the consistent finding that 
systolic contractile function (whole heart or isolated myocyte) is also reduced in 
these models, which does not accurately reflect the human early clinical setting 
where diastolic dysfunction predominates, as described in section 1.3.1. This 
could be related to the observation that in addition to impaired SERCA activity, 
increased SR calcium leak was also observed (Belke et al., 2004; Stølen et al., 
2009). This would further compound the reduction in SR calcium content caused 
by delayed diastolic refilling, and could perhaps account for the discrepancy in 
phenotype between species. 
In summary, available literature suggests that deficits in the reuptake of calcium 
into the SR via SERCA within cardiomyocytes appear to largely account for reduced 
diastolic cardiac contractility in the context of DCM. Interestingly, changes in 
intracellular calcium regulation may also partly explain the onset of structural 
remodelling that drives the progression of this condition. The calcium sensitive 
kinase CamKII has been shown to be activated in heart failure models, and 
manipulation of its expression/activity has been demonstrated to alter the 
progression of structural remodelling in accordance with it being a central 
mediator of this process (Anderson et al., 2011). This is initially surprising given 
its beneficial role in enhancing excitation contraction coupling in response to 
exercise, as described. However, its action and molecular targets may vary greatly 
depending on the mechanism and source of activation, and which specific isoform 
of this protein is being studied. 
1.3.4 The role of metabolism in DCM 
Metabolism is the general process by which cells generate ATP in order to power 
any physiological process requiring active work. There are several factors 
determining the efficiency and productivity of this process, including the primary 
substrate being metabolised. Whereas a single molecule of fatty acid will provide 
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several fold more ATP in comparison to a glucose molecule, the oxidation of 
glucose is more rapid and comes with a lower oxygen cost. In the heart, the 
primary metabolic substrate is fat, with a lesser contribution from glucose (An and 
Rodrigues, 2006). Therefore it is not immediately clear why IR (a key facet of the 
diabetic phenotype) and reduced glucose uptake would significantly impact 
cardiac function. However, there is a strong line of evidence that this initial 
perturbation of metabolic regulation in cardiac tissue is the critical factor 
initiating the onset of cardiomyopathy. 
In skeletal muscle, the impact of ectopic lipid storage upon insulin sensitivity has 
been well defined in experimental models. Similarly, the diabetic heart is defined 
by an increased uptake and utilisation of fatty acids, linked to impaired insulin 
sensitivity. For example, a diabetic rat model exhibited a significant reduction in 
the cardiac accumulation of [3H]-2DG (2-deoxyglucose) in response to insulin 
stimulation, which was linked to a corresponding reduction in the expression and 
activation of GLUT4 and IRS-1 protein (Desrois et al., 2004). Additionally, in hearts 
from both ob/ob and db/db mice, decreased insulin stimulated glucose uptake 
and increased FA utilisation were recorded prior to the onset of systemic 
hyperglycemia (Buchanan et al., 2005).  
Importantly, there is a noted association between these metabolic changes in the 
heart, and impairment of its contractile function. For example, in a sample 
population of obese women, there was a significant association between BMI 
(average of this group was 38 kg/m2) and myocardial oxygen consumption, 
indicating reduced cardiac efficiency (and therefore performance) (Peterson et 
al., 2004). This coincided with IR, which was independently associated with 
increased myocardial fatty acid uptake and utilisation. Similarly, in a diet induced 
rat model of diabetes, decreased cardiac insulin stimulated GLUT4 localisation at 
the plasma membrane and enhanced fatty acid transporter (FATP1) expression 
correlated with reduced stroke volume and ejection fraction (Deng et al., 2007). 
Finally, and perhaps most convincingly, increased myocardial lipid accumulation 
was a direct independent predictor of diastolic cardiac dysfunction in a population 
of asymptomatic type 2 diabetic patients (Rijzewijk et al., 2008). 
The first evidence that these metabolic changes do not merely coincide with but 
actually contribute towards the onset of contractile impairments comes from 
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studying the temporal pattern of development of these physiological events 
underlying DCM. Study of multiple tissues in a high fat diet (HFD) induced mouse 
model of diabetes revealed impaired cardiac insulin sensitivity – as indicated by 
impaired activation of Akt and reduced GLUT4 protein content – and a 
corresponding reduction in glucose uptake occurred prior to systemic markers of 
IR, and also well in advance of impaired cardiac contractility (Park et al., 2005). 
Increases in blood glucose concentration have been cited as capable of directly 
pathologically activating CamKII and therefore contributing towards cardiac 
dysfunction in DCM (Erickson et al., 2013), however this evidence suggests that 
cardiac IR and associated metabolic changes may be an earlier important 
pathogenic factor.  
The nature of the relationship between cardiac IR, increased fatty acid oxidation, 
and the onset of cardiac dysfunction requires further study. There is an 
accumulated body of work describing the impact of lipotoxicity (largely from lipid 
metabolites such as DAG and ceramide) upon insulin signalling and cardiomyocyte 
survival (and therefore cardiac function) (Drosatos and Schulze, 2013). This 
suggests that the only link between IR and reduced cardiac function in DCM is that 
they share a common causal mechanism. However, there is compelling evidence 
that IR per se may directly impair cardiac function. 
In db/db mice, overexpression of cardiac GLUT4 normalised both the perturbed 
metabolic profile described above, and the induced impairment of cardiac 
function observed in this model (Belke et al., 2000). These findings were 
replicated in an independent study, which identified no difference between db/db 
mice overexpressing GLUT4 and appropriate controls in measures of diastolic E/A 
ratio and systolic fractional shortening (Semeniuk et al., 2002). Combined, this 
work strongly implicates the availability of GLUT4 transporters and the ability to 
rapidly increase glucose uptake as being critical to normal cardiac function, and 
that IR is not merely an irrelevant by product of increased fatty acid utilisation. 
In contrast, it suggests that cardiac IR could even be the central mechanism 
underlying cardiac dysfunction in the context of DCM. This evidence is particularly 
valuable as a large body of work in this area is associative, without studying the 
effect of direct manipulation of potentially important variables upon cardiac 
function. 
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A key question arising from this line of investigation is why insulin stimulated 
glucose uptake is so critical to cardiac function, when in a baseline healthy 
condition the heart predominantly metabolises fatty acids. There are 2 leading 
theories, both of which require further study. First of all, the cardiac PCr:ATP 
ratio was found to be significantly reduced in the myocardium of diabetic patients, 
indicative of impaired energy production (Scheuermann-Freestone et al., 2003). 
This is an important observation as this ratio has been shown to be a key predictor 
of cardiovascular mortality in patients suffering from dilated cardiomyopathy 
(Neubauer et al., 1997). Additionally, this suggests that the ability to increase 
glucose uptake and therefore minimise the oxygen cost of ATP production in the 
diabetic heart is essential to sustain ATP output at the required rate. Perhaps this 
is particularly important under times of stress, such as when subclinical alterations 
in vascular and/or cardiac function are increasing demands on the surviving 
healthy myocardium. The activity of SERCA is critically dependent upon sufficient 
ATP availability, therefore this may explain why diastolic dysfunction is the first 
clinical sign of DCM. Whilst the cycling of the contractile myofilaments required 
for systolic contraction is also ATP dependent, compensatory mechanisms such as 
enhanced filling pressures may be able to maintain this action at the required 
level during the initial stages of this condition. 
Secondly, there is experimental evidence that suggests that impairments in the 
activation of myocardial insulin signalling pathways may directly influence 
mitochondrial ATP production, and therefore also cardiac contractile function. In 
a cardiac specific insulin receptor knock out mouse model mitochondrial 
bioenergetics were impaired, linked to increased reactive oxygen species (ROS) 
production and increased uncoupling when fatty acid was the primary metabolic 
substrate (Boudina et al., 2009). This suggests that IR could contribute to impaired 
metabolism of the increased cardiac lipid content, which would only increase the 
accumulation of toxic metabolites that may promote further cardiomyocyte 
dysfunction and death. 
Overall prior literature has built up an overview of the pathophysiological events 
underlying contractile dysfunction in DCM, as summarised in Figure 1-4. However, 
there are still several important unanswered questions. For example, both the 
causal direction of the relationship between increased myocardial fatty acid 
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utilisation and IR, and the primary mechanism linking alterations in metabolism 
and contraction via calcium handling, are unclear. These questions require 
answering in order to develop specific treatments for DCM, which are currently 
lacking yet are urgently needed. Research in this area would benefit from 
improved experimental models, ideally of a human origin, and indeed 
development of such a model is the key aim of this thesis. 
 
Figure 1-4 Proposed model of DCM development 
Key events in the pathogenesis of DCM are highlighted, in addition to contributing factors 
and relevant aspects of the phenotype at each stage. 
1.4 iPSC-CM 
1.4.1 Initial development 
The field of stem cell research is well established, and has thoroughly detailed 
the possible advantages of this technology. Thus far, embryonic stem cells have 
been most widely studied and demonstrated to have the capacity to differentiate 
into almost any cell type, provided they are exposed to the appropriate stimuli, 
which has potential far reaching consequences for the study of tissue specific 
embryonic development (Rippon and Bishop, 2004). Additionally, with the 
capacity to subsequently differentiate these cells into functional specialised cells 
such as cardiomyocytes (Boheler et al., 2002) or neurons (Ban et al., 2006) there 
is also the potential for disease modelling or even therapeutic tissue regeneration, 
however this has been limited by both safety concerns and ethical issues. 
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Induced pluripotent stem cell derived cardiomyocytes (iPSC-CM) are a relatively 
more recent adaptation of this technology that could in theory overcome the 
limitations associated with embryonic cells. The big breakthrough in this field 
occurred in 2006, when it was reported that embryonic or adult mouse fibroblasts 
could be reprogrammed into a phenotype closely resembling that of embryonic 
stem cells through retroviral mediated expression of only 4 transcription factors 
associated with embryonic pluripotency (Oct3/4, Sox2, c-Myc, Klf4), as indicated 
by both cellular morphology and gene expression markers (Takahashi and 
Yamanaka, 2006). This group then extended these findings by successfully using 
this protocol (with minor adaptation) to induce dedifferentiation of human 
derived dermal fibroblasts into a pluripotent stem cell-like form (Takahashi et al., 
2007). As with their foundational work, generated cells expressed genetic markers 
indicative of undifferentiated cells, were highly proliferative, and demonstrated 
the capacity to spontaneously differentiate into a range of cell types both in vitro 
and in vivo (in mice). Critically, they also successfully directed the iPS cells to 
specifically differentiate into contractile cardiomyocytes. 
These findings were ground breaking and opened up the possibility of harvesting 
easily obtainable cells from an adult human and subsequently deriving specific 
cells of interest (with that individuals unique genetic background) for research or 
therapeutic purposes. As reviewed by Batalov and Feinberg (2015), in response to 
recognition of their potential, several protocols targeting the reproducible and 
efficient reprogramming of iPS cells into cardiomyocytes (iPSC-CM) were devised, 
with varying degrees of success. The most effective thus far have employed simple 
2D cell culture whilst exposing cells to physiologically relevant growth factors in 
order to activate relevant developmental signalling pathways, such as BMP4 and 
Wnt, and direct cells down the cardiac lineage. The development of these 
protocols is ongoing, where the central aim is to achieve maximal efficiency and 
reliability of cardiac differentiation. Great progress has been made in a relatively 
short time frame, and the already significant commercial interest in these cells is 
likely to see this rapid pace of development continue. 
1.4.2 iPSC-CM are a potentially valuable research tool 
Our knowledge of the physiology and possible application of iPSC-CM is constantly 
expanding due to the interest and attention they are receiving in the current 
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scientific field. They have been shown to have indirect cardiac benefits with 
regards to predicting cardiotoxic effects of drugs, but perhaps more importantly 
there are 2 main themes through which they could directly transform the 
treatment approach to a range of cardiac conditions. 
Firstly, there is a growing body of evidence that iPSC-CM could partially 
regenerate the heart post-MI. Current treatment options primarily target reducing 
the burden on the surviving myocardium, for example through reducing blood 
pressure. However, substantial evidence generated in a variety of animal MI 
models – from rodents through to monkeys – indicates that direct injection of 
human stem cell derived cardiomyocytes (from an embryonic or somatic origin) 
may be able to ameliorate to some degree the characteristic structural and 
functional changes observed post-MI described in section 1.5.1. (Laflamme et al., 
2007; Chong et al., 2014; Shiba et al., 2016). There is evidence of the inserted 
cardiomyocytes maturing in vivo, and crucially they are able to form a contractile 
graft that functionally couples with the host myocardium in order to make a 
meaningful difference to global cardiac function (Shiba et al., 2012). Indeed 
research is now focussed more upon optimising this process, for example 
addressing how to promote optimal survival and integration of the injected cells 
with interventions such as co-injection of a “pro-survival cocktail” of hormones 
and drugs (Ogasawara et al., 2017). Importantly, this approach could also 
overcome risks associated with the potential immune rejection of embryonic stem 
cell derived tissue.  
In addition to potentially being a treatment option themselves, iPSC-CM should 
also in theory be able to act for the purpose of disease modelling. Indeed, iPSC-
CM generated from patients suffering from cardiac conditions with a defined 
genetic origin such as LEOPARD syndrome and long QT syndrome were able to 
recapitulate key structural and functional features of the disease phenotype, for 
example a prolongation of the action potential (Carvajal-Vergara et al., 2010; 
Itzhaki et al., 2011). This provides the opportunity to study not only disease 
specific pathology but perhaps also patient specific mechanisms, thereby 
facilitating superior identification of the most appropriate treatment option. 
Clearly not all pathophysiological conditions are caused solely by genetic factors. 
Rather, there is a significant contribution of lifestyle factors to the growing burden 
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of cardiometabolic disease that is currently reaching epidemic levels. Therefore, 
there is also an opportunity to induce disease phenotypes and create tissue 
specific cellular models, for example a DCM model in iPSC-CM, through exposing 
these cells to relevant external stimuli. Again this would facilitate the 
identification of underlying pathophysiological mechanisms and provide a safe 
translatable human model upon which novel compounds could be tested. This 
would also reduce the need for animal testing, which is in line with the 
governments’ principles of refinement, replacement and reduction outlined in the 
Animals Scientific Procedures Act 1986.  
Finally, from a practical experimental viewpoint iPSC-CM provide the benefit of 
being able to generate a theoretically unlimited number of cardiomyocytes with 
which experiments could be performed. This is in stark contrast to the current 
study of cardiomyocytes that relies upon the isolation of non-proliferative primary 
cells, which typically do not retain their functional phenotype in vitro for more 
than a few days.  
1.4.3 Characterisation of iPSC-CM phenotype 
In order to achieve the aims discussed in section 1.4.2., it is essential that the 
phenotype of iPSC-CM closely matches that of mature adult cardiomyocytes. Of 
greatest importance is that the process of excitation contraction coupling 
(outlined in section 1.3.2.) is functionally active and responds to relevant stimuli 
in an appropriate manner, which will be underpinned by the expression of relevant 
genes and proteins. 
The first part of excitation contraction coupling is electrical excitation of the 
myocyte membrane. Genetic profiling revealed that generated iPSC-CM expressed 
all 14 of the major membrane bound ion channels that regulate cardiomyocyte 
excitation (sodium and potassium channels) and calcium entry (LTCC) (Liang et 
al., 2013). Just as in primary cardiomyocytes, these channels work together to 
produce an action potential, which in turn initiates contraction. It has been 
claimed, based upon clear differences in specific parameters such as action 
potential duration (APD) and frequency and rate of initial depolarisation, that 
when generating a population of iPSC-CM, subsets of atrial, ventricular, and 
pacemaker like cells will emerge. This assumption has been challenged, and it is 
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claimed that variations in experimental conditions such as plating density may 
strongly impact recorded values, and that action potential characteristics are 
actually normally distributed across one population of iPSC-CM (Du et al., 2015). 
This complicates general comparisons between iPSC-CM and primary cells.  
Prior characterisation of individual channel activity and the overall action 
potential was undertaken by Ma et al., (2011). It is highly challenging to directly 
compare the action potential characteristics of different cells when 
measurements are obtained within different experimental set ups, due to the 
extreme sensitivity of these values to experimental variables. Despite this 
limitation, the authors reported a high degree of correspondence between iPSC-
CM and previously reported values for primary cells with regards to both whole 
cell based measurements such as APD and also the activity of individual channels. 
The biggest issue identified is that iPSC-CM are spontaneously contractile, on 
account of the expression and strong activity of a pacemaker channel.  
Similarly detailed characterisation of the calcium handling capacity of iPSC-CM 
was undertaken by Itzhaki et al., (2011). Once again, the genes encoding for the 
proteins central to this process were expressed, including SERCA, RyR, and LTCC. 
In accordance with the spontaneous activation of iPSC-CM, in the presence of 
external physiological levels of calcium (1.8 mM), spontaneous calcium transients 
were recorded using a fluorescent calcium dye. Critically, in the absence of 
external calcium, or in the presence of a calcium channel blocker (nifedipine), no 
calcium transients were recorded. This suggests that iPSC-CM contractile activity 
is dependent upon voltage gated calcium influx, which is a key feature of adult 
cardiomyocytes. Using a similar experimental approach, inhibition of RyR and 
SERCA demonstrated that the actions of these proteins was as expected in the 
generation of the intracellular calcium transient. Caffeine is a potent stimulus for 
opening of the RyR, and was implemented to demonstrate the presence and vital 
role of SR calcium loading. Overall, it was clear that the basic mechanisms of 
cardiac calcium handling were present and correct in iPSC-CM.  
In contrast, further quantification and characterisation of iPSC-CM calcium 
handling in an independent study revealed that the calcium transient in these cells 
was of smaller amplitude than that of more mature cardiomyocytes, with a slower 
rate of rise and decay, attributable to poor expression of RyR and SERCA (Lee et 
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al., 2011). Critically there was also a lack of synchronicity with regards to calcium 
release across the width of the cell, which is related to associated structural 
immaturity. More recent research indicated that calcium handling was actually 
highly comparable between iPSC-CM and primary isolated adult rabbit 
cardiomyocytes, perhaps due to improvements in iPSC-CM differentiation 
protocols (Hwang et al., 2015). However, this paper still concluded that the rate 
of decay of intracellular calcium via SERCA was still of a slower, immature 
phenotype. This finding is particularly challenging when considering any potential 
model of DCM with these cells, considering impaired diastolic SR calcium reuptake 
is a key feature of this condition.  
The most apparent limitation of iPSC-CM with regards to comparison with mature 
cardiac cells, alongside being spontaneously contractile, is their small circular 
phenotype indicative of a disordered array of myofilaments. This is in clear 
contrast to the larger striated rectangular phenotype of primary adult 
cardiomyocytes. As will be discussed, this may be a product of the unique physical 
and chemical environment cardiomyocytes are exposed to during development in 
vivo. To underline the difference in cell size, cell volumes of iPSC-CM and adult 
mouse ventricular cardiomyocytes have been recorded at 3.96 and 29 pL, 
respectively (Hwang et al., 2015). However, arguably a bigger limitation is that 
stem cell derived cardiomyocytes in general do not exhibit robust expression of T-
tubules, which prevents synchronous excitation of the cell (and therefore also 
synchronous release of SR calcium), and can create a wave like contractile profile 
(Lieu et al., 2009). Indeed, a loss of T-tubule density is a characteristic change in 
myocytes from individuals with heart failure (Lyon et al., 2009).  
Collective consideration of the factors that determine primary cardiomyocyte 
contractility indicate that the fundamental proteins and processes are present and 
functional in iPSC-CM, however they are generally considered to be of an 
immature foetal like phenotype. This generalisation may also extend to the 
metabolic phenotype of these cells, however in comparison to the other aspects 
of iPSC-CM physiology introduced, there is a significant lack of experimental 
evidence in this area. This is surprising given the vital importance of metabolic 
processes to general cellular physiology, not just myocyte contractile capacity. 
This concept will be discussed further in section 4.1.3., and indeed a large section 
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of this thesis is devoted to expanding our knowledge of the iPSC-CM metabolic 
profile. However, a key concept is that iPSC-CM predominantly rely upon glycolysis 
in order to generate ATP, particularly under typical cell culture conditions 
whereby medium is rich in glucose. This is another key marker of foetal physiology, 
and was demonstrated most clearly by essentially unchanged levels of total 
cellular ATP production in the presence of inhibitors of mitochondrial ATP 
production, and was also supported by relatively weak protein expression of the 
mitochondrial oxidative metabolic complexes (Rana et al., 2012).  
The primary function of cardiomyocytes is to contract in order to support the 
overall pump capacity of the heart. However, on account of the limitations in 
excitation contraction coupling described, it is technically challenging to directly 
compare the contractile profile of iPSC-CM with adult cardiomyocytes. In isolated 
adult cells, contraction of the rod shaped myocytes induces a uniaxial shortening. 
The extent and rate of this shortening is most commonly used to indicate 
contractile capacity. However, in iPSC-CM the disordered myofilament content 
prevents direct comparisons with these measurements. Despite this, innovative 
measurements of the contractile function of iPSC-CM have estimated their force 
generation capacity to be 2-6 fold less powerful than that of primary cells, and 
once again more similar in phenotype to foetal cardiomyocytes (Pioner et al., 
2016; Kolanowski et al., 2017). 
1.5 Myocardial infarction  
1.5.1 Overview of MI physiology 
A complete, detailed review of the pathophysiological events underlying MI 
requires intricate explanation of several areas of physiology out with the scope of 
this thesis. As will be discussed and explored in chapter 5, there is a complex yet 
clinically important link between IR/diabetes and the prevalence/outcomes 
related to MI. Therefore, only a brief overview of key aspects of the MI phenotype 
is provided here, before more detailed consideration of these specific issues in 
section 5.1.  
The fundamental event characteristic of an MI is blockage of a coronary vessel, 
usually on account of the rupture of an atherosclerotic lesion, which leaves the 
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downstream myocardium starved of vital oxygen and nutrients. The cellular 
signalling response to ischemia involves a complex combination of multiple 
pathways, but if prolonged enough often results in a significant degree of both 
necrotic and programmed apoptotic cell death (McCully et al., 2004). The ability 
for self-renewal of cardiomyocytes is almost non-existent, which creates a 
significant problem in trying to maintain the overall pump function of the heart 
at the required levels if a considerable number of cells are lost. Rather than being 
able to generate new contractile myocytes, collagen is deposited in order to form 
scar tissue that maintains the structural integrity of the affected chamber wall. 
However, this places a significant burden upon the surviving myocardium in order 
to compensate for the loss of contractile machinery. As alluded to earlier, where 
this occurs in any cardiac disease a range of compensatory mechanisms are 
activated in order to help to maintain cardiac output, however often these 
eventually contribute to ventricular remodelling and the progression to heart 
failure. 
An additional common complication for post-MI patients is the development of 
arrhythmias. As explained earlier, the activation of cardiomyocytes is dependent 
upon cell to cell communication and the tightly coordinated spread of electrical 
excitation. Significant scar tissue development can interrupt this intercellular 
communication and promote aberrant contractile coordination between different 
regions of myocardium, ultimately leading to reduced cardiac output (Stuart et 
al., 2016). Furthermore, the initial clearance of dead cells and initiation of 
fibrotic remodelling is an inflammatory driven process (Frangogiannis, 2014) that 
if excessive in duration and intensity can lead to the deposition of excessive 
collagen (fibrosis) and therefore stiffening of the myocardium (Stuart et al., 
2016), further increasing the burden on the contractile capacity of the heart. 
It must be clearly stated that not all individuals survive the initial myocardial 
ischemic insult associated with MI. Logically, both the chances of surviving and 
long term prognosis are strongly associated with the extent of tissue infarcted, 
and therefore also the duration of the initial blockage/ischemia. Therefore, there 
is an urgency in acute treatment associated with restoring blood flow. Often this 
is achieved with anti-clotting agents and surgical interventions to remove/bypass 
the embolism. However, there is also a well described phenomenon whereby upon 
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reperfusion a second and potentially severe injury may be induced in response to 
revascularisation. This is referred to as ischemia-reperfusion injury, and is thought 
to be mediated primarily through increased cellular ROS in response to ATP 
depletion, overload of intracellular calcium concentration, and reactivation of the 
oxidative metabolic machinery (Dorweiler et al., 2007). This therefore 
complicates the implementation of treatment strategies that must balance swift 
restoration of blood flow without inducing an excessive secondary loss of tissue, 
and then sensitively manage the subsequent remodelling process to delay or even 
prevent the progression to heart failure. 
1.5.2 Demand for novel treatment options 
Similar to the case described for diabetes, the prevalence and mortality rate 
associated with MI – largely linked to rising rates of obesity - creates the urgent 
demand for novel effective therapeutic options. In order to meet this clinical 
demand further comprehension of the infarction process is required, both in terms 
of the underlying physiological processes involved but also the distinct timing and 
order in which they occur.   
Research is still making significant progress in this area, and identifying potential 
novel therapeutic targets. For example, the expression of the transcription factor 
RUNX1 has been observed to be upregulated in surviving cardiomyocytes post-MI, 
functioning to enhance cardiomyocyte calcium handling and therefore limit the 
progression of pathological remodelling (McCarroll et al., 2018). As will be 
discussed in section 5.1, another area requiring further investigation is our 
understanding of the relationship between myocardial insulin sensitivity/glucose 
uptake and cardiac function post-MI. 
1.6 General aims of thesis 
The primary aim of this thesis is to assess the potential of iPSC-CM to act as the 
basis of a novel cellular model of DCM. The most important criteria in order to 
achieve this is to demonstrate that these cells are capable of displaying a robust 
and reproducible insulin stimulated glucose uptake response, of a similar 
magnitude to adult primary cardiomyocytes. Many aspects of iPSC-CM physiology 
have been determined to be at a foetal stage of development, which if extended 
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to their metabolic phenotype would mean exhibiting this response would be 
unlikely. In this event, strategies to mature iPSC-CM will be investigated. 
Additionally, the expression of SNARE proteins in a range of cardiac disease models 
will be assessed, in order to both fully characterise the expression of these 
proteins in primary cardiac tissue for the first time, and assess if changes in their 
expression may contribute to impairments in cardiac glucose transport in either 
DCM or post-MI.  
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2 Materials and methods  
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2.1 Materials 
2.1.1 Commercially derived cells 
Identity Origin 
3T3-L1 Fibroblasts American Tissue Culture Collection, 
Manassas, Virginia, USA 
HEK 293FT American Tissue Culture Collection, 
Manassas, Virginia, USA 
HeLa American Tissue Culture Collection, 
Manassas, Virginia, USA 
iPSC-CM (Cor.4U) 
P/N: Ax-B-HC02-1M 
NCardia (Axiogenesis), Cologne, 
Germany 
iPSC-CM (iCell Cardiomyocytes2) 
P/N: CMC-100-012-000.5 
Cellular Dynamics International (CDI), 
Wisconsin, USA  
XL-1 Blue E.Coli  Agilent Technologies, Santa Clara, 
California, USA 
5-alpha Competent E.coli  
P/N: C2987I 
New England Biolabs, Ipswich, 
Massachusetts, USA 
Table 2-1 List of commercially obtained cells 
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2.1.2 Primary cardiac cells and/or tissue  
Identity           Details Origin 
Db/db and db/m mice Male, 13-15 weeks old, 
homo/heterozygous for mutation 
in leptin receptor gene. 
Gifted by 
Dr Augusto 
Montezano 
High Fat Diet (HFD) 
and control CHOW fed 
mice 
Male, 20 weeks old. Both groups 
were fed normal CHOW diet for 8 
weeks after birth, then HFD mice 
were switched to a diet whereby 
60% of total calories were 
obtained from fat for the next 12 
weeks.  
Gifted by 
Dr Anna White 
Wistar Rats Male, approximately 250 g, 
approximately 20 weeks old. 
Animals were maintained as 
normal for 8 weeks prior to MI 
procedure (or non-operated 
control group), and then 
maintained for a further 12 
weeks.  
Gifted by  
Aline Gurgel 
New Zealand White 
Rabbits 
Male, approximately 3 kg, 
approximately 20 weeks old. 
Animals were maintained as 
normal for 8 weeks prior to MI 
procedure (or sham operated / 
non-operated control groups), 
and then maintained for a further 
12 weeks. 
Gifted by  
Aileen Rankin 
Human myocardial 
segment from single 
donor 
Sample obtained from 56 year old 
white European male undergoing 
transplantation procedure. 
Previous MI and hypertrophic 
cardiomyopathy. 
Gifted by  
Dr Cherry Alexander 
 
Table 2-2 List and description of primary cardiac material used 
All tissues were obtained from the indicated colleagues at the University of Glasgow. 
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2.1.3 Plasmids 
IDENTITY DESCRIPTION SOURCE 
PCDH-CMV-MCS-EF1-HA-
GLUT4-GFP 
Lentiviral plasmid 
containing gene 
sequence for GLUT4 
tagged with green 
fluorescent protein 
reporter 
Generated by Silke 
Machauer 
PCDNA3.1(+)-GLUT4  pcDNA3.1(+) mammalian 
expression plasmid 
containing untagged 
functional GLUT4 gene 
sequence 
Generated by GenScript, 
Piscataway, New Jersey, 
USA 
PCDH-CMV-MCS-EF1-
SX4(Y115/251E), 2P 
Lentiviral plasmid 
containing gene 
sequence for Syntaxin 4, 
with mutations 
mimicking 
phosphorylation on 2 
residues 
Generated by Dr. 
Mohammed Nasser 
Rashid Al-Tobi 
PCDH-CMV-MCS-EF1-
GLUT4 
Lentiviral plasmid 
containing untagged 
functional GLUT4 gene 
sequence 
Generated within this 
project, as reported in 
section 2.5.4 
Table 2-3 List and description of plasmids  
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2.1.4 General materials and reagents 
Listed are key materials used in this project and the corresponding suppliers, with 
the product number (P/N) also detailed where possible. 
AbCam, Cambridge, UK 
Blebbistatin (P/N: ab120425) 
Axiogenesis, Cologne, Germany 
Cor.4U maintenance medium (contains FBS) for Axiogenesis iPSC-CM (P/N: Ax-M-
HC250) 
Cor.4U BMCC serum free medium (does not contain FBS) for Axiogenesis iPSC-CM 
(P/N: Ax-M-BMCC250) 
Bio-Rad Laboratories Ltd., Hertforshire, UK 
Precision Plus Protein All Blue Prestained Protein Standards (P/N: 1610373) 
Cambridge Bioscience, Cambridge, UK 
Ionomycin (P/N: CAY10004974) 
Cellular Dynamics International, Wisconsin, USA  
iCell Cardiomyocytes2 Maintenance Medium (P/N: CMM-100-120-001) 
iCell Cardiomyocytes2 Plating Medium (P/N: CMM-100-110-001) 
Corning Incorporated, Maine, USA 
100mm x 20mm Polystyrene Cell Culture Dish (P/N: 430167) 
12 well polystyrene TC-treated cell culture plate (P/N: 3513) 
24 well TC-treated cell culture plate (P/N: 3524) 
75cm2 Polystyrene Cell Culture Flask (P/N: 430641U) 
96 well clear flat bottom polystyrene TC-treated microplates (P/N: 3596) 
Expedeon, Cambridge, UK 
Instant Blue Coomassie (P/N: ISB1L) 
Fisher Scientific, ThermoFisher Scientific, Leicestershire, UK 
Ammonium Persulfate (P/N: A/6160/60) 
Bovine Serum Albumin (P/N: BP9702-100) 
D-Glucose anhydrous (P/N: G/0500/53) 
Glycerol (P/N: G/0650/17) 
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Potassium Dihydrogen Orthophosphate (KH2PO4) (P/N: P/4800/53) 
Tris Base (P/N: BP152-1) 
Formedium, Norfolk, UK 
Agar (P/N: AGA02) 
Tryptone (P/N: TRP02) 
Yeast Extract Powder (P/N: YEA02) 
Gibco by Life Technologies, ThermoFisher Scientific, Paisley, UK 
Dulbecco’s Modified Eagle Medium (1x) 0 g/L D-Glucose (P/N: 11966025) 
Dulbecco’s Modified Eagle Medium (1x) 1 g/L D-Glucose (P/N: 11885084) 
Dulbecco’s Modified Eagle Medium (1x) 4.5 g/L D-Glucose (P/N: 41965039) 
Dulbecco’s Phosphate Buffered Saline (1x) (P/N: 14190094) 
Fetal Bovine Serum (FBS) (P/N: 10500064) 
L-Glutamine 200mM (100x) (P/N: 25030024) 
MEM Non-Essential Amino Acids Solution (100X) (P/N: 11140-050) 
Newborn Calf Serum (P/N: 16010159) 
OPTI-MEM (1X) Reduced Serum Medium (P/N: 31985062) 
Penicillin-Streptomycin (Pen-Strep) (10,000U/mL) (P/N: 15140122) 
0.05% Trypsin-EDTA (P/N: 25300054) 
MatTek Corporation, Massachusetts, USA 
Glass-bottomed 96-well plates 
Melford Laboratories Ltd., Suffolk, UK 
Dithiothreitol (DTT) (P/N: MB1015) 
Merck, Darmstadt, Germany 
Sodium dihydrogen phosphate (NaH2PO4) (P/N: 106342) 
Akt inhibitor VIII (isozyme-selective Akti1/2) (P/N: 124018) 
Mirus Bio, Wisconsin, USA 
TransIT-TKO Transfection Reagent (P/N: MIR2155) 
New England Biolabs, Massachusetts, USA 
SOC Outgrowth Medium (P/N: B9020S) 
T4 DNA Ligase (P/N: M0202S) 
10X T4 DNA Ligase Reaction Buffer (P/N: B0202S) 
 49 
 
Pall Life Sciences, New York, USA 
BioTrace NT Nitrocellulose Transfer Membrane 0.2µm pore thickness (P/N: 66485) 
Perkin Elmer, Massachusetts, USA 
Deoxy-D-glucose, 2-[1,2-3H (N)] (P/N: NET328A001MC) 
Ultima Gold Liquid Scintillation Counting Cocktail (P/N: 6013326) 
Promega, Wisconsin, USA 
Blue/Orange DNA Loading Dye, 6X (P/N: G1881) 
Buffer H restriction enzyme buffer (P/N: R008A) 
EcoR1 restriction enzyme (P/N: R601A) 
FuGENE HD Transfection Reagent (P/N: E2311) 
1kb DNA ladder (P/N: G5711) 
Not1 restriction enzyme (P/N: R643A) 
Wizard Plus SV Minipreps DNA Purification Systems (P/N: A1330) 
Qiagen, Hilden, Germany 
Nuclease-Free water (P/N: 129115) 
QIAfilter Plasmid Midi and Maxi Kits 
Sartorius, Gottingen, Germany 
Minisart 0.2 um pore size syringe filter (P/N: 16534K) 
Severn Biotech Ltd., Worcestershire, UK 
Acrylamide Bis-Acrylamide Stock Solution, 30% Acrylamide (w/v) Ratio 37.5:1 
(P/N: 20-2100-10) 
Sigma-Aldrich, Dorset, UK 
Ampicillin Sodium Salt (P/N: A0166) 
Bromophenol Blue (P/N: B0126) 
(±)-Carnitine hydrochloride (P/N: C9500) 
Creatine (P/N: C0780) 
Cytochalasin B from Drechslera dematioidea (P/N: C6762) 
2-Deoxy-D-glucose (P/N: D8375) 
Dexamethasone (P/N: D4902) 
Dulbecco’s Phosphate Buffered Saline (DPBS) with MgCl2 and CaCl2 (P/N: D8662) 
Ethidium Bromide Solution (P/N: E1510) 
Fibronectin from bovine plasma (P/N: F1141) 
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HEPES (P/N: H3375) 
Insulin from porcine pancreas (P/N: I5523) 
Insulin-like Growth Factor-1 human (P/N: I3769) 
Insulin-transferrin-sodium selenite media supplement (P/N: I1884) 
3-isobutylmethylxanthine (IMBX) 
Laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane (P/N: 
L2020) 
Linoleic Acid-Oleic Acid-Albumin media supplement (100x) (P/N: L9655) 
Magnesium sulfate (MgSO4) (P/N: M3409) 
Medium 199 (P/N: M7528) 
Nifedipine 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) (P/N: T9281) 
Palmitic acid (P/N: P0500) 
Ponceau S (P/N: P3504) 
Sodium deoxycholate (P/N: D6750) 
Taurine (P/N: 86329) 
3,3’,5-Triiodo-L-thyronine sodium salt (P/N: T6397) 
Triton X-100 (P/N: T9284) 
Trypan Blue Solution (0.4%) (P/N: T8154)  
TWEEN 20 (P/N: P7949) 
Wortmannin 
STARLAB, Milton Keynes, UK 
StarTub Reagent Reservoir 55ml (P/N: E2310-1010) 
ThermoFisher Scientific, Illinois, USA 
Lipofectamine 2000 Transfection Reagent (P/N: 52887) 
Pierce BCA Protein Assay Reagent A (P/N: 23228) 
Pierce BCA Protein Assay, Reagent B (P/N: 23224) 
Pierce Protease Inhibitor Mini Tablets, EDTA Free (P/N: 88666) 
PureLink Quick Gel Extraction Kit (P/N: K210012) 
UltraPure Agarose (P/N: 16500500) 
Tocris Bioscience, Abingdon, UK 
Troglitazone (P/N: 3114) 
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Toronto Research Chemicals, Ontario, Canada 
5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) 
VWR Chemicals, Leicestershire, UK 
Calcium chloride (CaCl2) (P/N: 190464K) 
di-Sodium hydrogen phosphate anhydrous (Na2HPO4) (P/N: 102494C) 
Ethanol absolute (P/N: 20821.330) 
Magnesium chloride hexahydrate (P/N: 25108.260) 
Potassium chloride (KCl) (P/N: 26764.260) 
Sodium chloride (NaCl) (P/N: 27810.295)  
Sodium dodecyl sulphate (SDS) (P/N: 442444H) 
 
2.1.5 Specialised equipment 
Beckman Coulter, High Wycombe, UK 
LS6500 Liquid Scintillation Counter 
Bio-Rad Laboratories Ltd., Hertforshire, UK 
All immunoblotting apparatus - power supplies, gel casting apparatus, 
electrophoresis chamber etc. – was obtained from the Bio-Rad Mini-PROTEAN 
range  
BMG Labtech, Ortenberg, Germany 
FLUOstar OPTIMA Microplate Reader 
Clyde Biosciences, Motherwell, UK 
CellOPTIQ imaging system 
LI-COR Biosciences, Lincoln, Nebraska, USA 
LI-COR Odyssey Sa Infrared Imaging System 
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2.1.6 Recipes for solutions  
All ingredients diluted in distilled water unless otherwise stated. 
Basic Krebs Buffer (Cardiac Isolation) 
130 mM NaCl 
5 mM Hepes 
4.5 mM KCl 
0.4 mM NaH2PO4 
3.5 mM MgCl2 
10 mM Glucose 
140 µM CaCl2 
(pH adjusted to 7.25 prior to use) 
Krebs-Ringer-Phosphate (KRP) Buffer for [3H]-2DG Uptake Assay 
128 mM NaCl 
4.7 mM KCl 
5 mM NaH2PO4 
1.25 mM MgSO4 
1.25 mM CaCl2 
(pH adjusted to 7.4 prior to use) 
2x Laemmli Sample Buffer (LSB) 
100 mM Tris pH 6.8 
4% SDS (w/v) 
20% Glycerol (v/v) 
0.2% bromophenol blue (w/v) 
100 mM DTT 
LB Broth 
1% (w/v) Tryptone 
0.5% (w/v) Yeast Extract 
1% (w/v) NaCl 
(Autoclaved prior to use) 
Phosphate Buffered Saline (PBS) 
137 mM NaCl 
2.7 mM KCl 
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1.8 mM KH2PO4 
10 mM Na2HPO4 
(pH adjusted to 7.4 prior to use) 
Phosphate Buffered Saline with TWEEN 20 (PBS-T) 
PBS containing 0.1% TWEEN 20 (v/v) 
Ponceau S 
0.1 % Ponceau (w/v) 
5% acetic acid (v/v) 
RIPA Buffer 
50 mM Tris pH 8 
150 mM NaCl 
1% Triton X-100 (v/v) 
0.5% Na deoxycholate (w/v) 
0.1% SDS (w/v) 
5 mM DTT 
1x Protease Inhibitor Cocktail Tablet 
TAE Buffer 
40 mM Tris  
1 mM EDTA 
(pH adjusted to 7.2-7.4 prior to use) 
Tris Buffered Saline (TBS) 
20 mM Tris pH 7.5 
137 mM NaCl 
(pH adjusted to 7.4 prior to use) 
Tris Buffered Saline with TWEEN 20 (TBS-T) 
TBS with 0.1% TWEEN 20 (v/v) 
2YT  
1.5% (w/v) Tryptone 
1% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
(Autoclaved prior to use) 
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2.1.7 List of primary antibodies 
Antigen Details Working 
Dilution 
Source 
VAMP 1 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 104002) 
VAMP 2 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 104202) 
VAMP 3 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 43080) 
VAMP 4 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 136002) 
VAMP 5 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 176003) 
VAMP 7 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 232003) 
VAMP 8 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 104302) 
SNAP 23 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 111202) 
SNAP 29 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 111303) 
SNAP 47 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 111403) 
Syntaxin 2 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110022) 
Syntaxin 3 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110032) 
Syntaxin 4 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110042) 
Syntaxin 5 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110053) 
Syntaxin 6 Mouse 1:1000 in 1% 
milk in PBS-T 
BD Biosciences 
(P/N: 610635) 
Syntaxin 7 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110072) 
Syntaxin 8 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110083) 
Syntaxin 16 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
Synaptic Systems  
(P/N: 110162) 
Pan Akt Mouse 
monoclonal 
1:2000 in 3% 
BSA in TBS-T 
Cell Signalling 
Technology (P/N: 2920) 
Phospho-Akt Rabbit 
monoclonal, 
1:1000 in 3% 
BSA in TBS-T 
Cell Signalling 
Technology (P/N: 4058) 
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targeting residues 
of Serine 473 
P44/42 MAPK 
(total Erk1/2) 
Rabbit polyclonal 1:2000 in 3% 
BSA in TBS-T 
Cell Signalling 
Technology (P/N: 9102) 
Phospho-p44/42 
MAPK (Phospho-
Erk1/2) 
Mouse 
monoclonal, 
targeting residues 
of Threonine 202 
and Tyrosine 204 
1:1000 in 3% 
BSA in TBS-T 
Cell Signalling 
Technology (P/N: 9106) 
GAPDH Mouse 
monoclonal 
1:80,000 in 1% 
milk in PBS-T 
Ambion  
(P/N: 4300) 
GLUT 1 Rabbit polyclonal 
 
1:1000 in 1% 
milk in PBS-T 
AbCam  
(P/N: 652) 
GLUT 4 Rabbit polyclonal 1:2000 in 5% 
milk in PBS-T 
AbCam  
(P/N: 654) 
GLUT 8 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
AbCam  
(P/N: 191269) 
GLUT 10 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
ThermoFisher Scientific 
(P/N: PA1-46137) 
GLUT 12 Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
AbCam  
(P/N: 191298) 
CD36 Mouse 
monoclonal 
1:1000 in 1% 
milk in PBS-T 
AbCam  
(P/N: 23680) 
Total OXPHOS 
Human WB 
Antibody Cocktail 
Commercially 
prepared cocktail 
of 5 mouse 
monoclonal 
antibodies 
1:1000 in 3% 
BSA in PBS-T 
AbCam  
(P/N: 110411) 
GFP Rabbit polyclonal 1:1000 in 1% 
milk in PBS-T 
AbCam  
(P/N: 290) 
SERCA 2a Mouse 
monoclonal 
1:1000 in 1% 
milk in PBS-T 
AbCam  
(P/N: 2861) 
Table 2-4 List and description of primary antibodies 
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2.1.8  List of secondary antibodies 
Antigen Details Working Dilution Source 
Rabbit IgG IRDye 800CW 
Donkey anti 
Rabbit IgG  
1:5000-10,000, in 
1% milk in PBS-T 
LI-COR Biosciences 
(P/N: 926-32213) 
 
Mouse IgG IRDye 680LT 
Donkey anti 
Mouse IgG 
1:5000-10,000, in 
1% milk in PBS-T 
LI-COR Biosciences 
(P/N: 926-68022) 
 
Table 2-5 List and description of secondary antibodies 
 
2.2 Cell culture methods 
2.2.1 Growth and maintenance of HEK 293 and HeLa cells 
Both HEK 293 and HeLa cells were grown and maintained in T75 flasks located 
within a sterile humidified incubator. Conditions were kept constant at 37°C and 
5% CO2. Cells were maintained in DMEM (4.5 g/L glucose) supplemented with 10% 
(v/v) FBS, 1% (v/v) L-glutamine, and 1% (v/v) pen-strep. This media was replaced 
every 2-3 days until cells were subjectively judged to be at >80% confluence via 
visual inspection. At this point the cells were either split (passaged) into a new 
set of flasks to facilitate continued growth, or seeded into the relevant multi-well 
plate for use in either a [3H]-2DG uptake assay or in preparation for transfection. 
2.2.2 Passaging and plating of HEK 293 and HeLa cells 
To passage HEK 293 and HeLa cells, first of all the media was aspirated and cells 
were washed once with pre-warmed sterile PBS (pH 7.4, 37°C). Subsequently, 
cells were incubated for approximately 5 min with 2 mL 0.05% trypsin-EDTA in 
order to liberate them from the growth surface. After ensuring the majority of 
cells were detached, this cellular suspension was diluted in fresh pre-warmed 
medium and transferred into as many new flasks as was desired. The volume of 
medium added was determined by how densely populated the new flasks were 
required to be, with approximately 10 mL medium per flask.   
Similarly, when cells were required for use in a [3H]-2DG uptake assay they were 
first washed and trypsinised as described above, and then resuspended in 5 mL 
fresh medium. Then a manual cell count was performed with a hemocytometer to 
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provide an estimate of the total number of cells in the suspension. The volume of 
medium was further adjusted to give the desired number of cells per 200 µL, which 
was then pipetted to each well of a 96 well plate. Final plating density is denoted 
on relevant figures. Assays were performed as soon as was practically possibly post 
plating (typically the next day) in order to limit the difference between the 
number of cells plated into each well, and the number of cells actually present at 
the time of the assay, as these cells replicate rapidly. 
HeLa cells were also used in transfection experiments. Cells were passaged as 
described above, however rather than performing a cell count the approximate 
dilution required to plate cells at a density of 50% growth surface coverage was 
performed. This was achieved through a simple calculation based upon the 
knowledge of the different growth surface areas of the appropriate culture 
vessels. Transfection was performed on both a 12 and 96 well scale, therefore 
volumes were adjusted accordingly. Cells were maintained until they reached a 
confluence suitable for transfection, which according to manufacturer’s 
recommendations was 70-90% confluency. 
2.2.3 Growth and maintenance of 3T3-L1 adipocytes  
In their immature fibroblast-like form 3T3-L1 pre-adipocytes were grown and 
maintained in T75 flasks located within a sterile humidified incubator with 
conditions maintained at 37°C and 10% CO2. The medium contained 10% (v/v) NCS 
and 1% (v/v) pen-strep in DMEM (4.5 g/L glucose) and was replaced every 2 days 
until cells were judged to be at >80% confluence. At this point the cells were 
either split into a new set of flasks, or seeded into a multi-well plate either for 
use in a [3H]-2DG uptake assay or for the purpose of generating lysates.  
2.2.4 Passaging and plating of 3T3-L1 adipocytes 
3T3-L1 fibroblast-like pre-adipocytes were passaged and plated in a highly similar 
manner to HEK 293 and HeLa cells, as detailed above. The 2 key differences were 
the composition of medium used, and also that when plating into a 96-well plate 
in preparation for performing a [3H]-2DG uptake assay, cells were not plated at a 
specific density. Rather they were plated at a subconfluent density and grown to 
confluence, in preparation for differentiation.  
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2.2.5 Differentiation of 3T3-L1 adipocytes 
Prior to use for either measurement of insulin stimulated glucose uptake or protein 
expression, 3T3-L1 adipocytes were required to be differentiated in to their 
mature adult form. Cells were maintained in NCS medium until 100% confluence 
was achieved. 2-3 days later differentiation was initiated by replacing this medium 
with 10% (v/v) FCS, 1% (v/v) pen-strep, 0.5 mM IBMX, 172 nM insulin, 0.25 µM 
dexamethasone, and 5 µM troglitazone in DMEM (4.5 g/L glucose). 3 days later this 
medium was exchanged for 10% (v/v) FCS, 1% (v/v) pen-strep, 172 nM insulin, and 
5 µM troglitazone in DMEM (4.5 g/L glucose). Finally, a further 3 days later this 
medium was exchanged for 10% (v/v) FCS and 1% (v/v) pen-strep in DMEM (4.5 g/L 
glucose). This medium was then exchanged every 2 days up until the day of use, 
which was typically 9-12 days post differentiation.      
2.2.6 Plating of Axiogenesis iPSC-CM 
Cor.4U iPSC-CM were purchased from Axiogenesis (Cologne, Germany) and 
immediately transferred into liquid nitrogen for long term storage upon receipt. 
[During the latter stages of this project Axiogenesis merged with a separate 
company called Pluriomics to form a new company called NCardia. However, the 
Cor.4U product was unaffected.]  
Approximately 3 hours prior to plating, 96-well plates were coated with 70 µL 
fibronectin from bovine plasma diluted 1:100 in PBS (supplemented with MgCl2 
and CaCl2) to give a final concentration of approximately 2 µg/cm2. Cells were 
retrieved from liquid nitrogen and defrosted in a 37°C water bath for approx. 1-2 
min, until only a small volume of solution remained frozen. Then 500 µL pre-
warmed Cor.4U maintenance medium was added to the vial to give a total volume 
of 1 mL. This suspension was then slowly pipetted dropwise into a 50 mL falcon 
tube containing an additional 3 mL of pre-warmed Cor.4U media to minimise the 
risk of heat shock to the cells, and with constant gentle manual agitation in order 
to reduce the risk of cells clumping. The empty vial was rinsed with a further 1 
mL of media in order to harvest any remaining cells and this was also added to the 
suspension. As instructed by manufacturers’ guidelines, great care was taken 
regarding timings and pipetting, as these cells are sensitive to rapid temperature 
changes and shear stress.  
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Once a 5 mL cellular suspension was attained, a live cell count was performed. To 
achieve this, the suspension was gently mixed and a 10 µL sample was withdrawn 
and combined with 10 µL 0.4% trypan blue. This dye penetrates and bypasses the 
plasma membrane of severely damaged and dead cells and stains them blue, 
therefore observation of the internal colour of cells down a light microscope 
permits determination of cell viability. Through manual counting with a 
hemocytometer, an estimation of total number of living cells per mL suspension 
was obtained. Typically >80% of cells were deemed viable. The suspension was 
then diluted as required to give the desired number of cells per mL. Finally the 
PBS was aspirated from each well and 100-200 µL suspension was added as 
required, to each specific well of the 96-well plate(s). Plating density ranged from 
25,000 – 50,000 living cells per well, and is reported on all relevant figures. On 
the few occasions where iPSC-CM were plated into a larger multi-well plate, 
volumes were scaled appropriately based upon relative growth surface areas.  
2.2.7 Plating of iCell CDI iPSC-CM 
iCell iPSC-CM were purchased from CDI and immediately transferred into liquid 
nitrogen for long term storage upon receipt. 3 hours prior to plating, 96-well 
plates were coated with fibronectin as described above. At the appropriate time 
cells were retrieved and the vial was placed in a 37°C water bath for 
approximately 3 min. Subsequently, the contents of the vial were transferred 
directly into a sterile, empty 50 mL falcon centrifuge tube. The vial was then 
rinsed with 1 mL of room temperature CDI plating medium, which was added 
dropwise to the cellular suspension. An additional 3 mL plating medium was 
carefully added to give a final volume of 5 mL. From this, a 10 µL sample was 
withdrawn and a live cell count was performed as described above (section 2.2.6) 
in order to confirm cell count and viability as reported in the certificate of testing. 
The suspension was diluted as required and then immediately after aspiration of 
the PBS 100 µL was pipetted into each well. In all cases CDI iPSC-CM were used at 
the manufacturers recommended plating density of 50,000 viable cells per well of 
a 96-well plate. Finally, medium was replaced with pre-warmed (37°C) CDI 
maintenance medium approximately 4 hours post-plating.  
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2.2.8 Maintenance of Axiogenesis and iCell CDI iPSC-CM 
Both Axiogenesis and iCell CDI iPSC-CM were kept in a sterile humidified incubator 
with conditions maintained at 37°C and 5% CO2. Cor.4U (Axiogenesis) and CDI 
maintenance media were replaced approximately 24 hours post plating and every 
1-2 days thereafter up until the day of use, which was typically 7 (+/- 1) days post 
plating regardless of whether the intended use was for a functional assay or to 
make protein lysates. Where this was not the case, it is detailed within all relevant 
figure legends. Media was generally replaced by manual pipetting rather than use 
of an aspirator, in order to cause minimal disturbance to cells. 
In many experiments, interventions were implemented prior to the day of the 
specified assay in an attempt to alter iPSC-CM phenotype. Primarily, cells were 
cultured in the presence of palmitate (conjugated to BSA), triiodothyronine (T3), 
or maturation medium (MM). Where the data generated from these experiments 
is presented, the conditions are clearly stated with regards to the concentrations 
implemented and the duration of the interventions. In all cases the interventions 
started a minimum of 3 days post-plating, in order to allow recovery of the cells 
after liquid nitrogen storage and adoption of a stable contractile phenotype.  
Conditions were then maintained, with media changes every 1-2 days as required, 
up until the day of use. Interventions involving the introduction of exogenous 
plasmid DNA are detailed separately in section 2.5. 
2.2.9 Plating and maintenance of primary rabbit cardiomyocytes 
Approximately 30 min post-isolation (this protocol is detailed below in section 
2.3.1), septal primary rabbit cardiomyocytes were put through several cycles of 
settling and resuspension in Krebs buffer containing increasing concentrations of 
calcium chloride (0.1, 0.2, 0.5, 1, 1.8 mM). This was performed in order to 
increase the physiological relevance of subsequent experiments and maintain 
optimal functioning of the cells as calcium is critical to several intracellular 
processes (Bers, 2002). Attaining the final concentration via a stepwise 
progression minimised the risk of the well described calcium paradox whereby 
rapid overload of isolated cardiomyocytes with physiological levels of calcium 
induces hypercontraction and cell death. Subsequently, cells were transferred 
into Medium 199 (M199) supplemented with 1 mM L-Glutamine, 5 mM creatine, 5 
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mM taurine, and 5 mM carnitine. A manual cell count was performed to estimate 
the total number of elongated “rod” shaped cardiomyocytes in the cellular 
suspension. Cardiomyocytes that adopt a rounded “ball” phenotype are 
considered likely to be dedifferentiated, dead, or hypercontracted, therefore 
determination of rod number does not provide an estimate of total number of 
living cells, but rather those that are considered likely to still be viable and 
functional (Mitcheson et al., 1998). Cells were plated on 96-well plates at an 
estimated density of 15,000 rods per well in a minimum of 100 µL medium M199. 
Wells had been pre-coated with laminin (1-2 µg/cm2) for a minimum of 2 hours 
and washed 3 times with PBS prior to plating. After initial experimentation with 
different time points (data not shown) it was determined that optimal timing for 
functional assays was approximately 3 hours post plating. 
2.3 Protein methods  
2.3.1 Isolation of primary cardiac samples  
Isolated primary cardiac myocytes/tissue was obtained from a number of sources 
throughout this project. In the case of primary mouse (multiple sources), human, 
and rat tissue, this was received as a stored snap frozen whole organ or large 
sections of intact myocardium. Protein lysates were made directly from these 
samples, without isolation, as described below. In contrast, rabbit samples were 
received as freshly isolated cardiomyocytes, in order to allow measurement of 
glucose uptake and insulin dependent activation of Akt. Lysates used for 
immunoblotting were generated both directly from these isolated myocytes in 
suspension, and also after plating, depending upon the context of the experiment. 
Isolation of primary rabbit cardiomyocytes was performed by Mrs Aileen Rankin 
and Mr Mike Dunne (University of Glasgow). Briefly, rabbits were euthanized by 
injection of 100 mg/kg pentobarbital into the marginal ear vein in accordance 
with the Animal (Scientific Procedures) Act 1986. Subsequently, the heart was 
excised and reverse perfused with Krebs buffer (37°C, pH 7.25) supplemented 
with heparin (5000 U/mL) on a Langendorff rig, in order to prevent clotting and 
clear the vasculature of residual blood. Then Krebs buffer supplemented with 
protease and collagenase was passed through the heart for approximately 15 min, 
until the heart was subjectively judged to be ready for manual processing. 
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Thereafter, the heart was removed from the rig, dissected into distinct anatomical 
regions (e.g. left ventricle/ atria/ septum), and diced with a sterile surgical 
scalpel blade in Krebs buffer supplemented with 1% BSA (w/v). These much 
smaller cardiac segments were then agitated for approximately 10 min. The 
solution was then filtered using a gauze strip into a 15 mL centrifuge tube, in order 
to remove large segments of undigested/unprocessed tissue, and harvest a more 
pure solution of isolated myocytes. Thereafter cells underwent the plating 
procedure described above, or the lysate generation procedure described below. 
In this thesis, isolated cells were provided using this procedure. 
2.3.2 Induction and confirmation of disease phenotypes 
As mentioned above, throughout this project cardiac samples were obtained from 
multiple sources and species. In all cases tissue was obtained from male animals 
in order to minimise the effect of variables such as female hormonal cycles, 
however it is recognised that sex specific differences in physiology and disease 
outcomes may be of great importance in this area of research and must be 
accounted for within future work. Within the present study different models of 
cardiac disease and relevant controls were also provided. In all cases these were 
from well characterised and published models of either diabetes (db/db and HFD) 
or MI, as described in Table 2-2. Appropriate corresponding literature or data from 
the providers of the samples was supplied in order to ensure that the desired 
phenotype was successfully induced. In the case of rabbit and rat models of MI, 
this phenotype was induced by technicians at the University of Glasgow. Briefly, 
animals were anaesthetised prior to thoracotomy and permanent ligation of the 
left anterior descending coronary artery. With regards to the rabbit model, data 
was provided to indicate a reduction of left ventricular fractional shortening 
below 50%, indicative of impaired systolic contractile capacity (data not shown). 
2.3.3 Generation of lysates 
2.3.3.1 Primary cardiac tissue 
Snap frozen whole hearts or segments of myocardium were placed in a 10 cm dish 
on ice in 0.5-2 mL RIPA buffer, dependent upon the size of the sample. Samples 
were then manually diced as much as possible with a sterile scalpel blade. The 
solution, now containing many much smaller segments of tissue, was transferred 
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into a specialised 1.5 mL maximum capacity glass tube, and a Dounce style manual 
tissue grinder was used to further mechanically lyse the cells via exposure to shear 
stress, with 5-10 compressions of the apparatus. The samples were then left on 
ice for approximately 20 min, before another 5-10 compressions of the manual 
homogenisation apparatus to ensure maximal lysis. On one occasion an alternative 
homogenisation protocol was employed. This methodology is described within the 
text preceding Figure 5-3, within section 5.2.1. The sample was then transferred 
to a 1.5 mL capacity eppendorf and spun at 14,000 rpm for 15 min at 4°C. The 
supernatant was then aliquoted and stored at -20°C until required for use, and 
the pellet was discarded. 
2.3.3.2 Isolated rodent primary cardiomyocytes 
When lysed without initial plating, isolated rabbit cardiomyocytes were first of all 
allowed to settle in Krebs solution in a 15 mL centrifuge tube. Subsequently, this 
was aspirated and replaced with 0.5-2 mL RIPA buffer, determined by the size of 
the pellet. This suspension was then transferred into the glass homogenisation 
tube as described above and compressed 5-10 times twice with 20 min break on 
ice in between. Finally, the solution was again centrifuged at 14,000 rpm for 15 
min at 4°C and the supernatant was aliquoted and stored at -20°C. 
2.3.3.3 iPSC-CM 
Regardless of whether iPSC-CM were from Axiogenesis or CDI, lysates were 
generated from a 96-well plate using the same protocol. Initial attempts to 
harvest the cells in RIPA buffer via a method suitable for measuring protein 
concentration from the samples was deemed unsuitable, due to the low protein 
concentrations of the samples that were generated. In contrast, the application 
of 30 µL 2x LSB directly to wells for 20 min whilst the plate was sitting on ice, 
before scraping and harvesting the contents of each well with a P20 pipette tip, 
was found to give a much more concentrated and effective yield of protein 
(Bowman, unpublished results). Finally, samples were heated to 65ºC for 10 min 
and then stored until required for use. Using this technique renders it impossible 
to estimate protein concentration using conventional techniques, therefore this 
increased the importance of using loading controls such as GAPDH expression and 
Ponceau S staining when interpreting the results of any immunoblot containing 
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these samples. However, particularly when comparing between iPSC-CM that have 
undergone different interventions, as long as a similar number of cells are present 
across different wells, and the method of lysate generation remains the same, 
then total protein loaded should be expected to be approximately equal. 
Similar to when describing the plating of iPSC-CM, on occasion lysates were 
generated from cells on a larger scale (e.g. 12 or 24 well plate). In this case the 
general principle of the lysate generation protocol remained the same, but the 
initial volume of 2x LSB applied to each well was scaled appropriately. The aim 
was to add the minimally required volume to cover the surface area, in order to 
generate the most concentrated lysate possible.  
2.3.3.4 HeLa cells, 3T3-L1 adipocytes, and plated primary cardiomyocytes 
The method of generating protein lysates from HeLa cells, 3T3-L1 adipocytes, and 
primary (rabbit) cardiomyocytes that had been plated on a 96-well plate format 
was identical to that as described above for iPSC-CM. 
2.3.4 Phospho-Akt/Erk1/2 assay 
In certain experiments it was assessed if insulin stimulation altered the 
phosphorylation of the central insulin signaling intermediates Akt and Erk1/2 in 
isolated primary rabbit cardiomyocytes and/or iPSC-CM. In all cases this 
experiment was performed on a 96-well plate format. When performing this assay 
with iPSC-CM, cells were incubated in serum free DMEM (4.5 g/L glucose) for a 
minimum of 2 hours prior to insulin stimulation. After this initial serum starvation, 
insulin was added directly to the medium at a final concentration of 860 nM for 
30 min. When performing this assay with primary rabbit cardiomyocytes, serum 
starvation was not performed. Instead approximately 3 hours post plating medium 
was simply replaced with fresh M199 and insulin was directly added, again at a 
final concentration of 860 nM. For both cell types, insulin stimulation was 
terminated by aspiration of the medium and immediate generation of cell lysates 
as described above. In order to assess the primary outcomes, samples were then 
prepared for and run through SDS-PAGE and immunoblotted for phospho Akt 
(ser473) and pan Akt (iPSC-CM and primary rabbit cardiomyocytes), and phospho 
and total Erk 1/2 (iPSC-CM only).  
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2.3.5 Micro BCA assay 
When appropriate, a micro BCA assay was employed to measure protein 
concentrations. 10 µL of each unknown protein sample and a range of BSA protein 
standards (0-10 mg/mL) in duplicate were combined with the manufacturer’s 
micro BCA assay mix, and incubated at 37°C for 30 min. Further duplicates of each 
sample with 50% protein concentration (diluted 1:1 with distilled water) were also 
performed in order to increase confidence in generated estimates and also 
increase the chances of at least one set of duplicates falling within the range of 
the BSA standards. The absorbance at 562 nm was recorded using a microplate 
reader. 
2.3.6 SDS-PAGE 
A polyacrylamide resolving gel was cast using the Biorad mini-Protean III 
equipment. The final percentage of acrylamide was determined by the size of the 
protein of interest, but typically ranged from 10-15%. Other components were 375 
mM Tris (pH 8.8), 0.1% SDS (w/v), 0.1% APS (w/v), and 200 nM TEMED, diluted in 
distilled water. Typical gel thickness was 1.5 mm. The stacking gel was cast on 
top of the resolving gel once it had set. The reagents required to make this gel 
were the same as the resolving gel, but at a final concentration of 5% acrylamide, 
125 mM Tris (pH 6.8), 0.1% SDS (v/v), 0.1% APS(v/v), and 200 nM TEMED. Samples 
were usually electrophoresed at 100V for approximately 2 hours. 
2.3.7 Immunoblotting 
After SDS-PAGE, if the intention was then to immunoblot using antibodies to 
detect specific proteins then samples were transferred onto a nitrocellulose 
membrane. To achieve this, the gel was placed in direct contact with a membrane 
within a tight sandwich of transfer sponges and 3 mm Whatman chromatography 
paper in a transfer cassette. This in turn was placed within a transfer tank that 
was filled with transfer buffer (25 mM tris, 192 mM glycine, 20% ethanol absolute 
(v/v) in distilled water). To initiate transfer, a 200 mA current was applied for 2 
hours. Where required, transfer was also occasionally performed at 30 mA for 15 
hours (overnight), or at 100V for 1 hour (with an ice pack to prevent overheating). 
In general, transfer efficiency was not found to vary between protocols. 
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After transferring was complete, nitrocellulose membranes were incubated with 
the reversible protein stain Ponceau S in order to assess transfer efficiency. This 
was then washed off with PBS-T, and a blocking solution was applied for 30-60 min 
in order to reduce non-specific binding of the primary antibody. This solution was 
typically 5% milk powder (w/v) in PBS-T, apart from when subsequently assessing 
the expression of phospho antibodies such as Akt or Erk1/2, in which case 3% BSA 
in TBS-T was required. After completion of blocking, membranes were then 
incubated with the desired primary antibody on an oscillating roller at 4°C for 16 
hours (overnight) in a 50 mL centrifuge tube, in order to facilitate optimal and 
even antibody binding. Details regarding the preparation of all primary antibodies 
used are found in Table 2-4. Occasionally, particularly if an overnight transfer was 
performed, primary antibody incubation would be performed at room temperature 
for 1-2 hours. 
After incubation with the relevant primary antibody, membranes were washed 3 
times for 5-10 min with PBS-T (or TBS-T as appropriate). Then the fluorescent 
secondary antibody specific to the species in which the primary antibody was 
raised in was applied for 1-2 hours. The details of all secondary antibodies used 
are found in Table 2-4. At this point, and for the remainder of the protocol, the 
50 mL centrifuge tubes containing the membranes were wrapped in tin foil in 
order to prevent exposure to excessive light, as the secondary antibodies are light 
sensitive. After this second incubation, membranes were again washed 3 times for 
5-10 min in P(T)BS-T, before visualisation with the Odyssey infra-red LICOR 
imaging system. Images were only obtained within the linear range of fluorescent 
signal measurement.   
2.3.7.1 Densitometry 
Scanning of nitrocellulose membranes that had undergone the described process 
of immunoblotting was performed at 100 µm resolution and generated a high 
quality composite image of 2 channels of excitation/emission. From this a 
subjective assessment of protein expression from each sample could be gained, 
most notably whether or not the target protein was expressed and/or if any 
intervention had an impact on the level of expression. Where a difference was 
visibly detectable, quantification was performed for further objective assessment. 
This was achieved by importing the image in to Image Studio Lite (Version 5.2), 
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the most up to date software designed by LICOR and recommended for use with 
these images. The analysis feature was used to place a box around each band of 
interest, with settings to record the mean pixel intensity (arbitrary units), which 
is automatically background corrected by this programme. The precise method of 
determining background intensity was altered slightly depending on factors such 
as interference of nonspecific bands, however was kept consistent between bands 
within the same blot. 
2.3.8 Coomassie staining 
Instant Blue Coomassie staining was used to visualise proteins for certain 
applications. Gels were incubated with sufficient Instant Blue solution to 
completely cover them on a shaking platform for a minimum of 1 hour. Thereafter, 
the gel was washed briefly with water to reduce the background signal, before 
being scanned. 
2.4 Cellular methods 
2.4.1 [3H]-2DG uptake assay 
2.4.1.1 General protocol 
[3H]-2DG uptake assays were performed as a surrogate assay of glucose uptake. A 
range of optimisation steps are reported in the results chapters, with a clear 
description of the protocol employed for each experiment for each cell type. 
Therefore only a general overview of the methodology for iPSC-CM is reported. 
First of all, iPSC-CM were incubated in serum free medium for 2 hours. The exact 
medium used varied and is discussed in the appropriate results section. 
Subsequently, plate(s) were transferred to a hot plate (37°C) and washed once in 
prewarmed KRP buffer (37°C, pH 7.4), and incubated for 30 min with all 
combinations of 100 µL KRP +/- 40 µM cytochalasin B (CB) +/- 860 nM porcine 
insulin. Each condition was performed in a minimum of triplicate wells. Following 
this, 100 µL 3H ‘assay mix’ was added for a further 30 min. This contained 2-
deoxyglucose and [3H]-2-deoxyglucose at a final concentration of 50 µM and 0.4 
µCi respectively. The assay was terminated by manually pipetting off the solution 
and washing cells once in ice cold PBS. Subsequently, plates were air-dried before 
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150 µL 1% Triton X-100 was added to each well for a minimum of 1 hour in order 
to promote lysis. Thereafter the solution from each well was individually collected 
and radioactivity levels measured using scintillation counting. 
2.4.1.2 Analysis of [3H]-2DG results 
At minimum, within a typical individual [3H]-2DG uptake experiment, 3 replicate 
samples were obtained within 4 distinct conditions. This raw data was plotted and 
visually inspected to gain an initial impression of the data and assess if there may 
be any outliers or anomalies. The primary (and rare) reason that may be accepted 
to justify exclusion of a data point would be if it were lower than the 
corresponding CB value, as this indicates measurement error. Thereafter, the 
mean CB value for each condition (e.g. +/- insulin) was calculated. Then these 
values were subtracted from each data point from the corresponding condition in 
the absence of CB. This data was thereafter referred to as background corrected, 
and is what is reported in most figures, apart from where the signal to background 
noise ratio was of interest. At this point statistical comparisons could now be made 
between conditions and final graphs were plotted, both using GraphPad Prism.  
2.4.2 Contractility 
As reported in chapter 3.2.3, during one set of experiments within this project 
contractility was recorded from iPSC-CM using the Cell OPTIQ imaging system. 
First of all, cells were plated at 25,000 or 50,000 cells per well and maintained as 
normal until 6 days post plating. At this point, the iPSC-CM were transferred into 
a microscope stage incubator, which maintained constant conditions of 37°C and 
5% CO2. Within this technical set up, the image obtained through the 40x objective 
lens of the microscope could be rapidly redirected from the normal eye piece 
output to a high speed capture camera system, which obtains high resolution 
images at a rate of 100 frames per second from within the field of view. 
Spontaneous contraction of the iPSC-CM within this field of view was video 
recorded for 5 seconds from 3 distinct areas of each well, and in total 8 wells were 
assayed per condition (each specified plating density). The average contraction 
rate of iPSC-CM is approximately 1 Hz, therefore in general 5 contractions (and 
subsequent relaxations) were captured. The location of each recording was 
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subjectively determined, but in general were as far apart as possible. The only 
strict requirement was that the field of view contained a group of cells that were 
contracting in unison, as two distinct contractile profiles within the same trace 
was unusable for the purposes of analysis. The movement of the microscope stage 
was controlled via an external joystick, which facilitated rapid movement of the 
field of view between areas of the same well, or indeed between different wells. 
Therefore the overall time taken to record all measurements was limited, which 
decreased the risk of order effects occurring. This was important because despite 
efforts being made to maintain optimal environmental conditions, any progressive 
change in a relevant variable that may strongly influence myocyte contraction 
(e.g. pH, temperature) could influence the values recorded from each well to a 
different extent, dependent upon the time of measurement after initial removal 
from the incubator.  
After all recordings had been obtained the data was imported into Image J. 
Thereafter, custom designed software written by Dr. Francis Burton (a software 
developer and member of staff at both the University of Glasgow and Clyde 
Biosciences) was used to analyse each video individually and produce the 
contractile output trace displayed in Figure 3-11. From this trace, a range of 
parameters were quantified, most notably the amplitude and frequency of 
contraction, and the speed of contraction and relaxation. These variables are 
explained and discussed further in chapter 3.2.3. However, it is important to note 
that the data for each variable was processed by first of all taking the average 
value for each parameter from every trace (each distinct location within a well). 
Then the mean value of every set of 3 technical repeats was calculated and a 
single value was produced for each well. It is this value that is reported in the 
final output, providing 8 replicate samples for each condition. Finally, all of the 
parameters apart from amplitude of contraction are independent of the number 
of cells from which contraction is recorded. However, amplitude takes in to 
account the total extent of disordered contraction detected. Therefore the final 
output of this parameter had to have a correction factor applied that adjusted the 
data for the number of cells plated per well.   
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2.5 Molecular methods 
2.5.1 Purified protein production 
Within this project, samples of various purified recombinant SNARE proteins were 
required. Some of these were generated as part of this project, however the 
majority of those used and from which results are reported were kindly donated 
by Dr. Jessica Sadler. Therefore, a brief summary of the generation of these 
samples is described below. 
Appropriate DNA plasmids were expressed in BL-21 E.coli and these cells were 
then amplified via serial cultures of increasing volume in appropriate medium 
supplemented with 100 µg/mL ampicillin until a 1 L culture with an optical density 
reading at 600 nm of 0.6 (indicative of optimal growth phase) was obtained. At 
this point the expression of the intended gene and therefore production of 
associated protein was induced by incubating the cells with 0.5 mM Isopropyl B-D-
1-thiogalactopyranoside (IPTG) overnight at 22ºC. The following day cells were 
centrifuged and then resuspended in lysis buffer, which was PBS supplemented 
with a protease inhibitor tablet and lysozyme at a final concentration of 1 mg/mL, 
for 20 min at 4 degrees on a rotating platform. Subsequently, cells were sonicated 
for 4 x 30 sec, centrifuged, and the pellet was discarded. At this point a cell lysate 
was obtained, therefore a method capable of extracting the recombinant protein 
of interest was required. This was achieved by incubating lysates with glutathione 
sepharose beads for 2 hours, as the recombinant proteins were tagged with 
glutathione S-transferase (GST), which binds the protein to the beads. 
Subsequently, the beads were washed with PBS in order to remove unbound 
protein and elution buffer was used to harvest the protein from the beads. 
Once purified recombinant fusion protein samples were obtained, quantification 
of protein concentration was performed against known volumes of BSA through 
SDS-PAGE and coomassie staining. These were then subsequently used as 
standards for the quantification of each target SNARE protein in samples of 
primary cardiomyocyte lysate via SDS-PAGE and immunoblotting. Both of these 
quantification procedures are more fully explained in chapter 5. 
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2.5.2 Amplification of GLUT4 Plasmid DNA 
Within this project a pcDNA3.1(+)-GLUT4 plasmid was purchased from Genscript. 
An important immediate aim was to amplify this DNA stock in order to obtain 
volumes suitable for subsequent aims. It should be noted that all relevant steps 
described in this protocol were performed at a flame in order to work under sterile 
conditions. First of all the plasmid was transformed into XL-1 Blue E.coli. This was 
achieved by incubating 1 µL of the stock plasmid with 50 µL competent cells in a 
1.5 mL capacity eppendorf for 30 min on ice. This solution was then heated at 
42ºC for 45 seconds, and then maintained on ice for a further 2 min. Thereafter, 
900 µL of 2YT medium was added and the solution was shaken vigorously at 37 ºC 
for 45 min. Cells were then briefly centrifuged and resuspended in approximately 
150 µL 2YT. This suspension was then plated out on to antibiotic selection plates 
(all of the plasmids used within this study exhibit ampicillin resistance) and 
incubated overnight at 37ºC. Additionally, one plate contained untransformed 
cells in order to provide a negative control. 
Successful transformation was indicated by growth on intended plates only. 
Thereafter, single colonies were scraped with a P20 pipette tip and grown via 
vigorous shaking at 37ºC in serial cultures of 2YT + 100 µg/mL of increasing volume 
until a confluent 100 mL solution was obtained. A commercially obtained Maxi-
prep kit was then used to extract plasmid DNA. The concentration of this 
preparation was measured via a NanoDrop spectrophotemer. A highly similar 
process was undertaken previously in the lab with the two other home-produced 
plasmids referenced in this thesis, PCDH-CMV-MCS-EF1-HA-GLUT4-GFP (by Silke 
MacHauer) and PCDH-CMV-MCS-EF1-SX4(Y115/251E), 2P (by Dr. Mohammed Al-
Tobi). Where these plasmids are referenced in the following protocols, any 
procedures were performed on these concentrated Maxi-prep DNA stocks unless 
otherwise mentioned. 
2.5.3 Transfection of mammalian cells  
2.5.3.1 Transfection of HeLa cells via Lipofectamine 2000 
HeLa cells were plated onto a 6-well plate and maintained as described previously 
until they reached 70-90% confluence, at which point they were deemed suitable 
for transfection. Lipofectamine 2000 was used with the intention of increasing 
 72 
 
transfection efficiency. In preparation, 6-15 µL Lipofectamine 2000 was diluted in 
150 µL Opti-MEM medium. Then 14 µg of pcDNA3.1(+)-GLUT4 plasmid DNA was 
diluted in 700 µL Opti-MEM medium. Lipofectamine 2000 and plasmid DNA were 
then combined at a ratio of 1:1 (150 µL of each) and incubated for approximately 
5 min at room temperature. Finally, 250 µL of this solution was added to 2 mL 
fresh maintenance medium in each target well. This resulted in the final addition 
of 2500 ng plasmid DNA and 5-12.5 µL Lipofectamine 2000 per well. 2 wells 
received fresh DMEM only and therefore acted as negative controls. Cells were 
incubated at 37°C and 5% CO2 for ~3 days prior to the generation of cell lysates as 
described previously. The expression of GLUT4 in lysates was then assessed by 
SDS-PAGE and immunoblotting (see section 2.3.6.).  
This technique was also performed with HeLa cells on a 12-well plate format when 
transfecting the newly developed pCDH-CMV-MCS-EF1-GLUT4 plasmid. Similar 
principles applied, however the volumes of all components were scaled 
appropriately to give a final volume of 2.5-6.25 µL Lipofectamine 2000 and 1250 
ng plasmid DNA per well. In this experiment an equal number of wells containing 
the stated range of volumes of Lipofectamine 2000 only were also performed.  
2.5.3.2 Transfection of iPSC-CM via Lipofectamine 2000 
A key experimental aim within this project was to develop a protocol that 
facilitated the overexpression of GLUT4 in iPSC-CM via transfection of the 
pcDNA3.1(+)-GLUT4 plasmid. The initial protocol attempted simply followed 
manufacturer’s recommendations, and is described below. Thereafter several 
adaptations to this protocol were made, and these are fully described and 
discussed in chapter 4. 
iPSC-CM were plated and maintained for 3 days on a 96-well plate format. 
Thereafter, 1-2.5 µL Lipofectamine 2000 was diluted in 25 µL Opti-MEM medium. 
Then 2.5 µg of pcDNA3.1(+)-GLUT4 plasmid DNA was diluted in 125 µL Opti-MEM 
medium. Lipofectamine 2000 and plasmid DNA were then combined at a ratio of 
1:1 (25 µL of each) and incubated for approximately 5 min at room temperature. 
Finally, 10 µL of this solution was added to fresh Cor.4U maintenance medium in 
each target well. This resulted in the final addition of 100 ng plasmid DNA and 
0.2-0.5 µL Lipofectamine 2000 per well. Where appropriate, specified wells 
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received equivalent volumes of Lipofectamine 2000 only. Cells were then 
maintained for a further 3 days as normal prior to the generation of cell lysates 
as described previously. Once again the expression of GLUT4 in lysates was then 
assessed by SDS-PAGE and immunoblotting. 
Similar to HeLa cells, this transfection protocol was also performed on a larger 12-
well plate format. However, in this case a final volume of 6 µL Lipofectamine 2000 
+/- 1250 ng plasmid DNA was added to target wells. 
2.5.3.3 Transfection of iPSC-CM and HeLa cells via FuGENE HD and TransIT-
TKO 
Within this project 2 additional transfection reagents were assessed for their 
capacity to efficiently transfect HeLa cells or iPSC-CM. In all cases the standard 
protocol recommended by the manufacturer was employed, and therefore no 
extensive optimisation process occurred as in the case of Lipofectamine 2000 
mediated transfection. As before, in all cases transfection occurred 3-4 days post-
plating for iPSC-CM or at an appropriate density for HeLa cells. 
Briefly, when transfecting iPSC-CM on a 96-well plate format with TransIT-TKO, 
an initial preparation of 100 µL Opti-MEM + 5 µL TransIT-TKO +/- 3 µg plasmid DNA 
was incubated for 10-15 min. Subsequently, 10 µL of this solution was added to 
each target well, achieving final volumes of 0.5 µL TransIT-TKO +/- 300 ng plasmid 
DNA. Similarly, when transfecting iPSC-CM on a 96-well plate format with FuGENE 
HD, an initial preparation of 100 µL Opti-MEM + 6 µL FuGENE HD +/- 3 µg plasmid 
DNA was incubated for 10-15 min. Once again, 10 µL of this solution was added to 
each target well, achieving final volumes of 0.6 µL FuGENE HD +/- 300 ng plasmid 
DNA. When transfecting HeLa cells on a 12-well plate format with FuGENE HD, this 
initial preparation was simply directly added to the specified well(s) in its 
entirety. 
2.5.4 Generation of GLUT4 lentiviral plasmid 
In order to generate a plasmid suitable for subsequent lentivirus development, it 
was required to sub-clone the GLUT4 gene sequence from the pcDNA3.1(+)-GLUT4 
plasmid into the pCDH backbone of the pCDH-CMV-MCS-EF1-HA-GLUT4-GFP 
plasmid. In order to achieve this, first of all plasmids underwent double restriction 
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digest with the enzymes Not1 and EcoR1. This was performed with 7.5-9 units of 
each enzyme, 2 µL of manufacturers 10x reaction buffer, and 2 µL of plasmid DNA 
(2-3 µg per plasmid, in separate reactions), made up to 20 µL total with nuclease 
free water. This reaction was incubated for approximately 2 hours at 37ºC. A 
control reaction was also performed for each plasmid without enzymes present. 
Digests were analysed on agarose gels and the relevant bands excised using a 
scalpel. Fragments were purified using a commercial kit. A small aliquot of these 
fragments were then run through a new 1% agarose gel in order to ensure not only 
that the intended fragment was successfully isolated, but also that no detectable 
contamination from other unwanted DNA fragments had occurred. 
Once purified fragments of the pCDH backbone and GLUT4 insert were obtained, 
ligation reactions were performed in 20 µL total volume. Ligations were incubated 
at 16ºC (in a cooling block) overnight, for a maximum of 24 hours. Appropriate 
control conditions were also performed, most notably individual DNA fragments 
only, with and without ligase. Ligation reactions were transformed into 5-alpha 
competent E.coli. In order to confirm successful ligation, individual colonies were 
selected and grown in 5 mL cultures containing 100 µg/mL ampicillin overnight on 
a shaking platform at 37 ºC. These samples were then mini-prepped and digested 
via the same original restriction enzymes in order to confirm that the backbone 
(pCDH) and insert (GLUT4) were of the correct molecular size. Once this was 
confirmed to be the case, this novel plasmid PCDH-CMV-MCS-EF1-GLUT4 was once 
again transformed into 5-alpha E.coli and amplified in order to provide enough 
DNA to transfect HeLa cells and confirm that it could induce mammalian cells to 
produce robust amounts of GLUT4 protein. 
2.5.5 Infection of iPSC-CM 
Within this project, iPSC-CM were infected with 2 separate lentivirus on a 96-well 
scale. First of all, Dr. Mohammed Al-Tobi generated a lentivirus with the pCDH-
CMV-MCS-EF1-Sx4(Y115/251E), 2P plasmid using reagents and a relevant protocol 
from Clontech (California, USA). Although the concentration of this lentivirus was 
not calculated (in either transducing units/mL (TU) or plaque forming units/mL 
(pfu)), a protocol had been developed by Dr. Al-Tobi that resulted in the successful 
overexpression of Syntaxin 4 in HEK293 cells and 3T3-L1 adipocytes (in both their 
 75 
 
pre-adipocyte and differentiated form). Based upon this, approximately 48 hours 
post plating iPSC-CM were incubated for 4 or 24 hours, in the presence or absence 
of 8 µg/mL polybrene (a reagent designed to improve infection efficiency), with 
fully concentrated or 1:10 diluted lentivirus. Medium was then exchanged and 
lysates were generated approximately 72 hours later. Thereafter, samples were 
probed for Syntaxin 4 expression via SDS-PAGE and immunoblotting. 
Secondly, iPSC-CM were plated on a 96-well plate scale as normal, however this 
time the plates were glass-bottomed as opposed to plastic. Approximately 72 
hours post-plating cells were incubated with a lentivirus based upon the previously 
mentioned pCDH-CMV-MCS-EF1-HA-GLUT4-GFP lentiviral plasmid that was 
commercially generated by Systems Biosciences Inc. Cells were exposed to 
0/2/4/6 µL of this virus in 50 µL medium for approximately 24 hours, which based 
upon the manufacturer’s reported transducing units value reported for the virus 
and the approximate plating density of iPSC-CM resulted in an estimated 
multiplicity of infection (MOI) of 0/35/70/105. Cells were maintained in normal 
maintenance medium for a further 72 hours, prior to imaging of GLUT4-GFP via 
confocal microscopy. As this protein is already modified to be tagged with an 
excitable fluorescent reporter, no extensive protocol requiring labelling with 
secondary antibodies was necessary. Each well containing iPSC-CM was simply 
imaged directly via a Zeiss LSM Pascal Exciter laser scanning confocal microscope 
using a 63x objective lens and the appropriate Zeiss LSM software. Images were 
then exported to Image J and processed for presentation purposes. Finally, after 
being imaged, cells were lysed and probed for GLUT4 and GFP expression via SDS-
PAGE and immunoblotting. 
2.6 Statistical analysis 
In all cases throughout this thesis, the appropriate statistical analysis was 
performed with GraphPad Prism (version 7). In general this was deemed to be an 
unpaired t-test or ANOVA (1- or 2-way) and the level of significance was set at 
P=0.05. Full details are contained within the figure legend of all relevant figures.  
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3 Insulin stimulated glucose uptake in iPSC-CM 
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3.1 Introduction  
The precise matching of ATP synthesis and breakdown is required to maintain 
optimal function of all cells in the body. This matching is particularly important 
in highly energetic organs such as the heart, where maintenance of pump capacity 
is required to transport nutrient and oxygen rich blood around the body, the first 
rate limiting step of ATP generation for most tissues. A mismatch between cardiac 
energy demand and supply could rapidly lead to potentially fatal limitations in 
contractile performance (cardiomyopathy). In diabetic hearts, cardiomyopathy is 
often observed independently of commonly occurring vascular disease (DCM) 
(Boudina and Abel, 2010). This is primarily attributed to reduced efficiency of 
intracellular calcium handling on the level of individual cardiomyocytes coupled 
with organ level structural changes such as fibrosis (Belke and Dillmann, 2004; 
Miki et al., 2013). However, there is a credible line of evidence that indicates that 
the original underlying cause preceding limitations in cardiac contractility is 
metabolic adaptation to chronic energy overload, namely IR (Belke et al., 2000; 
Semeniuk et al., 2002; Park et al., 2005). 
IR in general is a central facet of the overall diabetic phenotype. The current 
leading theory is that cardiac IR occurs due to ectopic fat storage resulting in the 
accumulation of toxic metabolic intermediates/ metabolites such as DAG (Zhang 
et al., 2011). It is proposed that these may inhibit intracellular insulin signalling 
cascades, possibly via PKC mediated inactivation of IRS-1, thereby preventing 
delivery of GLUT4 to the cell membrane in the presence of insulin stimulation 
(Erion and Shulman, 2010). However, ultimately no matter how logical this theory 
may be or how promising initial evidence is, the quality of currently available 
models strongly hinders the confidence in - and ability of - these results to 
translate into clinical outcomes for human diabetic patients. Ideally what is 
required is a controlled environment in which we can study the in depth functional 
and molecular phenotype of human hearts or human cardiomyocytes in the 
presence and absence of diabetes, identify mechanisms underlying pathological 
metabolic and contractile adaptations, and then test interventions. Currently this 
is not possible, however iPSC-CM provide an opportunity to achieve these aims, 
albeit on a cellular level. 
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3.1.1 Could iPSC-CM act as a novel cellular model of DCM? 
Prior to any attempt to induce a DCM like phenotype in iPSC-CM, the standard 
‘healthy’ phenotype with regards to relevant parameters must be established. As 
discussed in the introduction, this has been largely achieved with regards to 
electrophysiological, contractile, and structural parameters (Ma et al., 2011; 
Karakikes et al., 2015). Whilst these are not perfect matches in all cases, the 
difference between baseline and the ultimate model (human adult 
cardiomyocytes) is known. Therefore attempts to bridge this gap through 
maturation protocols can be made, or more simply these can be taken into account 
when analysing the effect of interventions. This scenario does not exist for 
metabolic parameters. There is currently no literature detailing basal or insulin 
stimulated glucose uptake in iPSC-CM, let alone the activation or even just 
expression of key proteins involved in GLUT4 trafficking. Indeed it is not even 
known if these cells express GLUT4. 
There has been one notable prior attempt to induce a DCM phenotype in iPSC-CM 
(Drawnel et al., 2014). To begin with, the authors cultured cells in a medium 
designed to mature the cells. This will be discussed in more detail in chapter 4, 
however the key idea was that the medium contained no glucose, and instead cells 
were forced to rely on fatty acids as the primary metabolic substrate. This was 
designed to mimic more closely the in vivo metabolic environment of developing 
cardiac cells. Primary outcomes were structural parameters and action potential 
dynamics. Excitation of myocyte cell membranes is a prerequisite for contraction. 
This is regulated by the movement of ions across the membrane. Measurement of 
changes in voltage produces a characteristic trace, referred to as the action 
potential. Cells have a resting negative membrane potential, which then rapidly 
increases upon excitation, before being restored to baseline before the next 
contraction. Key parameters, specifically rate of upstroke (rate of increase in 
membrane potential) and duration were found to be increased towards a more 
mature phenotype. Crucially, cells were then cultured in 10 mM glucose because 
this exceeds the fasting blood glucose values determined to indicate diabetes 
(~7mM), in addition to endothelin-1 and cortisol in an attempt to mimic a pre-
diabetic milieu. This was determined to have induced a DCM like phenotype due 
to changes in cellular gene expression and structure consistent with hypertrophy, 
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reduced strength and coordination of contraction, and increased brain natriuretic 
peptide (BNP) release (Drawnel et al., 2014). 
In humans, circulating BNP levels have been inversely correlated with insulin 
sensitivity (Kim et al., 2017) and risk of diabetes (Lazo et al., 2013). Therefore if 
this correlation were extended to the cellular level and applied to these results, 
in isolation it would indicate an improvement in iPSC-CM insulin sensitivity, not 
the onset of diabetes. However, the authors intended purpose of showing this data 
was in reference to the more appreciated positive correlation between BNP levels 
and cardiac hypertrophy, a key marker of cardiomyopathy (Nishigaki et al., 1996). 
Therefore, although this previous study provides many interesting insights and is 
a very useful starting point, it is not credible to claim that a model of DCM had 
been created, primarily because no parameter closely related to insulin 
stimulated glucose uptake or GLUT4 trafficking was studied. Additionally, it is 
surprising that only 10 mM glucose was enough to induce a DCM phenotype, given 
that the cells (along with most cell lines) are normally maintained in 4.5 g/L 
glucose which is equivalent to approximately 25 mM. 
Based upon the accumulated literature described, it appears that iPSC-CM could 
be a useful tool to help fill an unmet clinical need. However, the first step towards 
achieving this end goal is characterisation of key metabolic features, in particular 
basal and insulin stimulated glucose transport, and the expression and activation 
of key GLUT4 trafficking proteins, including GLUT4 itself. In order to assess 
results, these must be compared to a gold standard criteria, which in this case is 
the adult cardiac metabolic phenotype. However, the exact details are much 
harder to specifically define than may be assumed, on account of the range of 
techniques and models reported in the literature. 
3.1.2 Insulin stimulated glucose uptake in isolated 
cardiomyocytes 
When considering the abundance of data generated from isolated adult rodent 
cardiomyocytes, the results and interpretation are clear. In both primary rat and 
mouse cardiomyocytes insulin robustly and consistently activates important 
intracellular targets such as the insulin receptor and Akt, initiates the 
translocation of GLUT4 to the plasma membrane, and most importantly stimulates 
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a several fold increase in 2-deoxyglucose uptake (Fischer et al., 1996, 1997; 
Mazumder et al., 2004; Graveleau et al., 2005; Mora et al., 2005). It is of interest 
to note that two of these studies demonstrated that GLUT1 also translocated to 
the plasma membrane in response to insulin, albeit with a much lower overall fold 
response (Fischer et al., 1996, 1997). In practice, given the much lower overall 
expression of GLUT1 in primary cardiomyocytes the functional contribution of this 
will likely be low. On account of the range of fold responses in glucose uptake 
recorded in response to insulin, most likely linked to variations in protocols for 
myocyte isolation and glucose uptake, it is hard to state with confidence the exact 
response that should be expected from iPSC-CM. However, as a minimum, 
expectations should be for at least a 2-3 fold response. 
A common criticism of data generated from isolated cardiomyocytes – not 
restricted to measurements of glucose transport - is that the digestion protocol 
may alter the physiology of the cells. The quality of this procedure is absolutely 
critical in obtaining a large number of viable, reliable cells (Louch et al., 2011). 
Primarily, membrane damage could occur due to over digestion, preventing 
normal activation of membrane bound receptors such as the insulin receptor. From 
the data discussed above reporting strong responses, this does not seem to be a 
common problem. However, a second and perhaps more difficult to account for 
potential problem is that cardiomyocyte isolation is a technically challenging 
procedure during which a moderate to high percentage of isolated cells die 
(Graham et al., 2013). Through personal experience, many other cells die soon 
after subsequent stimulation, particularly when artificially initiating contraction. 
Therefore there is always a selection process, which could lead to data being 
representative of only a subset of cells from the whole heart. In theory iPSC-CM 
are cultured as a large group of individual cells that are immune from this process. 
Another one of their attractions is that when maintained at confluence they 
become electrically coupled, in a similar phenomenon to what is observed in vivo. 
Additionally, unlike isolated primary cells these cells are spontaneously 
contractile, which is a potent stimulus for glucose uptake. Therefore it is also 
essential to consider the effect of insulin stimulation on glucose uptake in an 
intact, contracting heart in vivo, when setting expectations for the response 
anticipated from iPSC-CM. 
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3.1.3 Insulin stimulated glucose uptake in intact hearts 
In vivo human cardiac glucose uptake studies rely largely upon the euglycemic 
hyperinsulinemic clamp procedure. The key concept is that blood insulin levels 
are externally measured and maintained at an elevated concentration, whilst 
glucose is infused at the rate required to maintain a specified blood glucose 
concentration. The required rate of glucose infusion is directly related to the rate 
of clearance from the blood stream, and is taken as an index of whole body insulin 
sensitivity. Using a similar protocol fluorodeoxyglucose may also be infused, a 
form of 2-deoxyglucose that is tagged suitably for detection via positron emission 
tomography, therefore allowing detection of tissue specific uptake.  
There is a significant - although not universally accepted (Utriainen et al., 1998) 
- body of literature that collectively demonstrate whole body (presumably mostly 
skeletal muscle and adipose) IR in type 2 diabetics due to the lower rate of glucose 
infusion required during the clamp procedure, with a corresponding lower 
accumulation of fluorodeoxyglucose in the myocardium also indicating cardiac IR 
(Voipio-Pulkki et al., 1993; Ohtake et al., 1995; Iozzo et al., 2002; Dutka et al., 
2006; Rijzewijk et al., 2009). Typically a reduction in myocardial transport of ~30% 
is reported, which is relatively small provided conditions are optimised for 
maximal insulin sensitivity (subjects are at rest, fasted, and experience a 
prolonged high exposure to insulin with sustained normal blood glucose values). 
Additionally, it is challenging to separate the contribution of a reduction in basal 
glucose uptake from any impairment in the insulin response when considering the 
global reduction in myocardial glucose uptake recorded using this technique, and 
in no case was an attempt made to measure a fold change in glucose uptake in 
response to insulin stimulation. Therefore apart from working backwards to infer 
that insulin most likely increases myocardial glucose uptake in the intact human 
heart in vivo on account of reduced uptake in presumed insulin resistant diabetics, 
it is difficult to compare this data to that of isolated rodent cardiomyocytes or 
make recommendations regarding the required response to be recorded from iPSC-
CM.  
Fortunately, there is a group of data that acts as an intermediary between single 
cell and whole heart data that completes the required background information 
before working with iPSC-CM. Perhaps the most compelling evidence 
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demonstrating clear GLUT4 dependent insulin stimulated glucose uptake in the 
intact contracting heart was generated by performing the euglycemic 
hyperinsulinemic clamp in conscious rats (Kraegen et al., 1993). Animals were 
then euthanised and [3H]-2DG accumulation in the heart and several skeletal 
muscles was determined. Critically they also measured tissue specific uptake 
under basal conditions, where insulin would have been present at low levels, but 
certainly not at the supra-physiological values used during the clamp procedure. 
This revealed a clear (30-40%) increase in cardiac glucose uptake upon maximum 
insulin stimulation. The fold increase in skeletal muscle was much higher, largely 
due to the much smaller basal uptake values recorded. Crucially, there was a very 
strong (r2 = 0.97) correlation between insulin sensitivity and GLUT4 content across 
the range of muscles studied. This data is supported by demonstration of a clear 
increase in 2DG uptake in isolated mouse hearts in response to insulin stimulation 
(Abel et al., 1999). However, this response was totally abolished in hearts from 
cardiac specific GLUT4 knockout mice. Interestingly, in these mice basal glucose 
uptake increased in a similar manner to GLUT1 protein expression. Finally, studies 
using HFD feeding in C57BL/6 mice have shown the progressive onset of cardiac 
(and whole body) IR using the in vivo measurement technique described, in part 
linked to inhibition in Akt signalling and a reduction in GLUT4 protein content 
(Park et al., 2005; Kowalski et al., 2015). This supports the suggestion that the 
data collected from humans does indeed primarily indicate reduced insulin 
stimulated glucose uptake, rather than decreased basal transport, under 
conditions of diabetes/IR. 
3.1.4 Requirements for iPSC-CM  
Collectively, the aforementioned data determines that a minimum requirement 
of iPSC-CM, in order to be considered to have potential to act as a novel cellular 
model of DCM, is that they must exhibit a clear GLUT4 dependent increase in 2DG 
uptake in response to insulin stimulation, mediated through intracellular 
activation of key insulin signalling molecules such as Akt. Whilst contraction 
mediated uptake may interfere with this, a minimum 2-3 fold response should be 
reliably recorded. As a requisite to meet these biological demands, an appropriate 
assay must be identified and customised that is technically capable of detecting 
both a clear basal glucose uptake signal above background noise, yet does not 
saturate and can therefore also reproducibly record a robust insulin response. 
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3.1.5 Aims of chapter 
The main aim of this chapter of work is to characterise key aspects of the 
metabolic profile of iPSC-CM in order to assess their suitability as a potential novel 
cellular model of DCM. This will be achieved by addressing the following aims; 
 Customisation of an appropriate assay to determine glucose uptake 
 Characterisation of basal and insulin stimulated glucose uptake in iPSC-CM 
 Assessment of importance of contraction mediated glucose uptake in iPSC-
CM 
 Assessment of expression (and where appropriate activation) of essential 
proteins involved in insulin stimulated GLUT4 trafficking   
 Assessment of response of iPSC-CM glucose uptake to maturation medium 
conditioning 
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3.2 Results 
3.2.1 Adaptation of [3H]-2DG uptake assay  
Commercially derived iPSC-CM are expensive and terminally differentiated, 
thereby making it necessary to perform assays as efficiently and on as small a 
scale as is practically possible, without damaging the validity or quality of 
research. When assaying cells that have easily detectable rates of basal glucose 
uptake and a clear reliable insulin response, such as 3T3-L1 adipocytes, typically 
a 12 or 24 well plate format may be used. However, this is simply not a sustainable 
approach for iPSC-CM, and it is also realistic to assume the insulin response of 
these cells (if present) would be much smaller than what is recorded in 3T3-L1s. 
Therefore, prior to assessing the baseline glucose uptake kinetics of iPSC-CM, it 
was first of all assessed if this assay could be adapted to a 96-well plate format. 
Key experimental variables were systematically varied in order to identify 
conditions that facilitated detection of a basal glucose uptake signal above 
background noise in two relatively inexpensive and abundant cell types. 
HEK293 and HeLa cells were plated at a range of densities and [3H]-2DG uptake 
assays performed with a varying number of initial washes in KRP. In all cases the 
uptake shown is background corrected by subtracting values obtained from 
identical conditions in the presence of the GLUT inhibitor CB (Bloch, 1973). The 
average background noise signal was approximately 500 CPM for all conditions. 
There was a highly significant effect of plating density upon measured uptake 
signal (P<0.0001) in HEK293 cells (Figure 3-1). Subjectively, an increased number 
of washes appeared to increase the variability of recorded uptake signals, however 
the effect of this factor was not statistically significant (P>0.05). There was no 
interaction detected between these factors. The trends appear similar for 
identical experiments performed with HeLa cells (Figure 3-2) and indeed there 
was found to be a significant effect of plating density upon [3H]-2DG uptake 
(P<0.01) but no statistically significant effect of number of washes (P>0.05). 
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Figure 3-1 Adaptation of [3H]-2DG uptake assay to 96 well plate format with HEK293 cells 
Background corrected [3H]-2DG uptake was assayed using HEK293 cells plated at 10,000, 
25,000, or 50,000 cells per well. Cells were washed 1, 2, or 3 times in KRP prior to a 30 min 
incubation with [3H]-2DG. Data shown is mean of 3 replicates from one experiment +/- S.D. 
Statistical analysis was performed with a 2 way ANOVA, where the identified experimental 
factors were number of washes and plating density. The level of significance was set at 
P=0.05. 
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Figure 3-2 Adaptation of [3H]-2DG uptake assay to 96 well plate format with HeLa cells 
Background corrected [3H]-2DG uptake was assayed using HeLa cells plated at 10,000, 
25,000, or 50,000 cells per well. Cells were washed 1, 2, or 3 times in KRP prior to a 30 min 
incubation with [3H]-2DG. Data shown is mean of 3 replicates from one experiment +/- S.D. 
Statistical analysis was performed with a 2 way ANOVA, where the identified experimental 
factors were number of washes and plating density. The level of significance was set at 
P=0.05. 
Initial results demonstrated that it was possible to detect a clear cellular basal 
glucose uptake signal using a 96-well plate format, and also provided a starting 
point regarding setting desirable experimental conditions. However, on this scale 
a relatively low number of cells are used which creates a more narrow absolute 
range of detectable values. Therefore the assay was performed with 3T3-L1 
adipocytes, a cell type known to have a robust insulin stimulated glucose uptake 
response (Kohn et al., 1996; Takahashi et al., 2008), in order to assess if both a 
clear basal signal and a clear insulin response could be detected. Additionally, 
data generated with isolated cardiomyocytes from a male adult rabbit are 
presented, which are less insulin sensitive than 3T3-L1s, but more relevant to 
iPSC-CM. 
Insulin stimulation significantly (P<0.0001) increased [3H]-2DG uptake in 3T3-L1 
adipocytes by around 5000 CPM (Figure 3-3; Basal vs Insulin; Means +/- S.E.M: 1134 
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+/- 214 CPM vs 6048 +/- 732 CPM) and by around 5.3-fold. Background noise was 
approximately 300 CPM. Similarly, although to a lesser extent, insulin stimulation 
significantly (P<0.001) increased [3H]-2DG uptake in isolated cardiomyocytes by 
~700 CPM and 1.8-fold (Figure 3-4; Basal vs Insulin; Means +/- S.E.M: 821 +/- 83 
CPM vs 1483 +/- 135 CPM). Background noise was approximately 450 CPM. These 
fold increases in both cell types equate well to published values from a range of 
other groups (Kohn et al., 1996; Graveleau et al., 2005). 
 
Figure 3-3 Insulin stimulated glucose uptake response in 3T3-L1 adipocytes 
Background corrected basal and insulin stimulated glucose uptake in CPM was assayed 
using fully differentiated 3T3-L1 adipocytes. Cells were serum starved (serum free DMEM) for 
4 hours prior to 30 min stimulation with 860 nM insulin. Cells were incubated with [3H]-2DG 
for 10 min. Data shown is mean of 4 replicates from one experiment +/- S.D. Statistical 
analysis was performed with an unpaired t-test, and the level of significance was set at 
P=0.05. * indicates P<0.0001.  
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Figure 3-4 Insulin stimulated glucose uptake response in primary rabbit cardiomyocytes 
Background corrected basal and insulin stimulated glucose uptake in CPM was assayed in 
primary rabbit cardiomyocytes approximately 3 hours post isolation. Cells were stimulated 
with 860 nM insulin for 30 min prior to 20 min incubation with [3H]-2DG. Data shown is mean 
of 9 replicate samples obtained from one animal +/- S.D. Statistical analysis was performed 
with an unpaired t-test, and the level of significance was set at P=0.05. * indicates P<0.001. 
3.2.2 Characterisation of iPSC-CM insulin stimulated glucose 
uptake 
After determination of an appropriate technique, initial characterisation of the 
insulin stimulated glucose uptake response of iPSC-CM was performed. Figure 3-5 
displays insulin stimulated glucose uptake in the presence and absence of 
inhibitors targeting the key intracellular insulin signalling molecules Akt (Akti) and 
PI3K (wortmannin). Overall, in the Akti experiments, insulin significantly 
increased glucose uptake (P<0.0001). This signal was significantly (P<0.001) 
reduced in the presence of Akti, although not fully back down to basal levels as 
there was still a significant difference (P<0.01) between basal glucose uptake and 
uptake in the presence of insulin and Akti. Similarly, wortmannin significantly 
(P<0.001) reduced glucose uptake in the presence of insulin relative to when 
insulin alone was present. In both cases there was a highly significant (P<0.0001) 
effect of experimental day on the recorded CPM for each condition. 
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Figure 3-5 iPSC-CM can exhibit a PI3K and Akt dependent insulin response 
Background corrected basal and insulin stimulated [3H]-2DG uptake was measured in iPSC-
CM. Prior to uptake cells were incubated for 30 min with 100 nM insulin, 100 nM insulin and 1 
µM Akti (A), 100 nM insulin and 100 nM wortmannin (B), or no additional compounds (basal). 
Data shown is mean of 3 replicate samples +/- S.E.M, from 2 independent experiments. 
Statistical analysis was performed with a 2 way ANOVA, where the identified factors were 
drug treatment and experimental day. The level of significance was set at P=0.05. 
This data suggested that iPSC-CM may be capable of exhibiting an insulin 
stimulated glucose uptake response. However, out with the data presented in 
Figure 3-5 the response of these cells appeared subjectively weak and unreliable 
between batches despite only minor adaptations in protocol. To quantitatively 
assess this observation, data from 6 independent experiments was pooled and 
analysed. In this dataset background noise values (CB +/- insulin) are also 
presented in order to display the signal to noise relationship for each assay. 
Conditions were not completely identical between experiments performed on 
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different days, with subtle alterations in variables such as insulin concentration 
or length of incubation with [3H]-2DG. However analysing the data with a 2-way 
ANOVA, where drug treatment and day effects are considered, takes these minor 
differences in to account. The data is displayed in 2 ways. First of all a summary 
of each individual experiment is presented (Figure 3-6A) in order to facilitate 
comparison across different experiments. Secondly, an overall summary of the 
effects of CB and insulin is presented (Figure 3-6B), with key statistical summaries 
in Table 3-1. 
Overall, basal [3H]-2DG uptake was statistically significantly higher by an average 
of 154 CPM compared to uptake measured in the presence of CB (Table 3-1; Basal 
vs Basal + CB; Means +/- S.E.M: 682 +/- 105 CPM vs 528 +/- 79 CPM; P<0.0001; 95% 
CI of difference between means: 82-226 CPM). Similarly, [3H]-2DG uptake in the 
presence of insulin alone was also statistically significantly higher by an average 
of 304 CPM than when both insulin and CB were present (Table 3-1; Insulin vs 
Insulin + CB; Means +/- S.E.M: 840 +/- 135 vs 537 +/- 98 CPM; P<0.0001; 95% CI of 
difference between means: 232-376 CPM). Finally, insulin statistically significantly 
elevated glucose uptake by an average of 158 CPM above basal only values (Table 
3-1; Basal vs Insulin; Means +/- S.E.M:  682 +/- 105 vs 840 +/- 135 CPM; P<0.0001; 
95% CI of difference between means: 86-230 CPM). 
The 95% confidence intervals presented suggest that whilst significant effects of 
insulin and CB were recorded, the estimated true magnitude of these effects in a 
wider population of iPSC-CM is uncertain. In support of this, there were highly 
significant (P<0.0001) day and interaction effects. 
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Figure 3-6 Summary of initial insight into insulin stimulated glucose uptake in iPSC-CM 
Individual experiments (A) and an overall summary (B) of [3H]-2DG uptake in iPSC-CM under 
basal conditions +/- 860 nM insulin +/- 40 µM CB in 6 independent experiments are presented. 
Data presented is mean of 3 replicate samples +/- S.E.M. from each experimental day (A) or 
mean of the 6 independent experiments +/- 95% confidence intervals (B). Statistical analysis 
was performed with a 2-way ANOVA, taking experimental day and drug incubation as 
experimental factors. The level of significance was set at P=0.05. 
 
Table 3-1 Key statistical comparisons of initial iPSC-CM transport data 
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As shown in Figure 3-6, there was a large amount of variation with regards to both 
the absolute counts recorded for each condition and the magnitude of relative 
insulin response between different experimental days. Logically, it is likely that 
this variation is primarily attributable to either technical aspects of the assay, or 
is inherent to the iPSC-CM. This was tested by comparing replicate assays with 
3T3-L1 adipocytes across several independent experimental days. Assessing the 
variation in absolute counts and fold response from these cells, and also variation 
in [3H]-2DG assay mix standards, will provide insight into the reliability of this 
technique. 
Across 3 independent experiments, insulin overall significantly (P<0.0001) 
increased [3H]-2DG uptake (Figure 3-7A). Whilst there was also a significant 
(P<0.0001) effect of experimental day on the recorded values, post-test multiple 
comparisons revealed that the only individual significant difference between basal 
values or between insulin values on different experimental days was between 
insulin values on experimental days 2 and 3 (P<0.0001). This indicates a higher 
reliability of this assay when performed with 3T3-L1 adipocytes compared to iPSC-
CM. 
Additionally, 4 different volumes of [3H]-2DG assay mix, normalised as CPM per 
µL, were highly similar both within and between experimental days (Figure 3-7B). 
As a reminder, 100 µL of this assay mix is added per well of a 96-well plate during 
the assay, regardless of cell type. This indicates a high reliability of the 
scintillation counting measurement system and preparation of the assay mix. 
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Figure 3-7 Assessment of reliability of [3H]-2DG uptake assay with 3T3-L1 adipocytes 
A: Background corrected basal and insulin stimulated [3H]-2DG uptake was measured from 
3T3-L1 adipocytes. Prior to uptake cells were serum starved for 3 hours prior to stimulation 
with 860 nM insulin for 20 min and subsequent incubation with [3H]-2DG for 10 min. Data 
shown is mean of 12 replicate samples for each experimental day +/- S.E.M, from 3 
independent experiments. Statistical analysis was performed with a 2 way ANOVA, where the 
identified factors were insulin stimulation and experimental day. The level of significance was 
set at P=0.05. B: Comparison of [3H]-2DG assay mix standards, normalised per µL, within and 
between different experimental days. 
As a final preliminary insight into iPSC-CM, the impact of short term palmitate 
conditioning upon glucose transport was studied. This was designed to mimic the 
effect of a HFD and obesity on the heart. As demonstrated in Figure 3-6, at this 
point of the project the cells were producing weak glucose uptake signals and an 
unreliable insulin response. Although after reoptimisation (explained below) in 
this set of experiments a strong set of basal signals were detected, no insulin 
response was observed. Therefore, Figure 3-8 depicts basal glucose uptake only in 
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iPSC-CM maintained in manufacturer’s media supplemented with palmitate and 
BSA or BSA only (control), across 3 independent experiments. Overall, palmitate 
significantly reduced basal glucose transport (P<0.05). However, post-test 
multiple comparisons revealed that this effect was primarily attributable to the 
effect observed in experiment 3. The lack of a recorded insulin response was not 
due to the presence of BSA (data not shown). 
 
Figure 3-8 The effect of palmitate conditioning upon basal glucose transport in iPSC-CM 
Background corrected basal [3H]-2DG uptake was assayed in iPSC-CM maintained in either 
manufacturers media supplemented with BSA alone, or BSA and palmitate, in 3 independent 
experiments. Data presented is mean of 3 replicate samples for each experimental day +/- 
S.E.M. Palmitate/BSA incubation lasted approximately 4 days and was commenced 3 days 
post plating. Palmitate and BSA concentration varied from 440 to 1000 µM and 2-4.5 mg/mL 
respectively. Background noise was approximately 2000 CPM. Statistical analysis was 
performed with a 2 way ANOVA, where the identified factors were experimental day and 
palmitate conditioning. The level of significance was set at P=0.05. 
3.2.3 Manipulation of experimental conditions 
After initial characterisation of iPSC-CM, it was deemed necessary to further adapt 
the assay more specifically to the unique physiology of these cells. The aim was 
to identify conditions that facilitated a reliable, strong basal signal (e.g. >30% 
above background noise, >300 CPM) and, if possible, also an insulin response. 
Therefore experimental variables predicted to influence glucose uptake rate and 
the recorded signal were identified and systematically manipulated. 
Most prominently, the effects of altering the duration for which iPSC-CM were 
incubated with the [3H]-2DG assay mix, and the plating density of cells per well, 
were studied. In this first instance, the primary focus was upon identifying 
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conditions that stimulated a desirable basal signal. In some of the experiments 
presented insulin stimulation was also performed, however no reliable response 
was recorded. Given that stimulation was not performed in all experiments, this 
data is not shown in the following figures. 
Figure 3-9A depicts basal [3H]-2DG uptake in iPSC-CM from 3 independent 
experiments, where cells were incubated with [3H]-2DG for either 15 or 60 min. 
[3H]-2DG uptake is presented as CPM, and background CB signals are also 
presented in order to evaluate the signal to noise ratio. Figure 3-9B depicts 
background corrected basal [3H]-2DG uptake from the same 3 independent 
experiments. Finally, Figure 3-9C shows the same data but now converted to 
absolute uptake in estimated picomoles of 2-deoxyglucose taken up per minute 
per million cells. It is anticipated that cellular [3H]-2DG uptake should increase 
with longer incubation durations. However, high uptake rates could deplete 
intracellular ATP levels because of the ATP-dependent action of hexokinase in 
phosphorylating 2DG immediately upon entry into the cell. ATP synthesis would 
be limited as 2DG does not undergo metabolism. This would prevent further 
uptake, and the amount of [3H]-2DG internalised per cell per unit time would 
decrease. It is essential that measurements are taken within the linear range -
prior to ATP depletion – otherwise differences in uptake between conditions may 
not be detected.  
Statistical analysis revealed that overall, incubation duration significantly 
increased adjusted absolute [3H]-2DG uptake (P<0.05). However, this effect was 
weak, as post-test multiple comparisons revealed no significant difference in 
uptake between 15 and 60 min in any individual experiment. There was also a 
highly significant (P<0.001) effect of experimental day upon the recorded values. 
This suggests saturation of uptake did not occur over the measured range of 
incubation durations.  
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Figure 3-9 The effect of incubation duration upon [3H]-2DG uptake in iPSC-CM 
Basal uptake was recorded from iPSC-CM incubated with [3H]-2DG for 15 or 60 min +/- 40 µM 
CB. Data is shown as raw uncorrected data (A), background corrected (B), or adjusted in 
picomoles per minute per million cells (C). In all cases data shown is mean (+ S.E.M.) of 3 
replicate samples for each experimental day, from 3 independent experiments. Statistical 
analysis was performed with a 2 way ANOVA on the final adjusted data (C), where the 
identified factors were experimental day and incubation duration. The level of significance 
was set at P=0.05. 
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Whilst performing the initial experiments described so far, in general cells were 
plated at approximately the density recommended by the manufacturers (~30,000 
cells per well). However, this was not adhered to rigidly. Subjectively it appeared 
as though cell density was influencing the recorded [3H]-2DG uptake with more 
power than would be expected from a linear increase in signal relative to the 
number of cells that were present in the well. Therefore, Figure 3-10A and Figure 
3-10B depict basal [3H]-2DG uptake from cells plated at either a low density (in 
experiment 1 this is 37,500 cells per well, in experiments 2 and 3 this is 25,000 
cell per well) or a high density (in all cases 50,000 cells per well), with and without 
background correction. In Figure 3-10C this background corrected data is then 
normalised per cell and displayed as a relative percentage of the mean low density 
value obtained in each experiment. Ideally this final figure would have been 
presented as absolute uptake (picomoles per minute per million cells) but 
technical error prevented this from being possible. Statistical analysis revealed a 
highly (P<0.001) significant effect of plating density upon the background 
corrected and adjusted recorded uptake signal. 
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Figure 3-10 The effect of plating density upon [3H]-2DG uptake in iPSC-CM 
Basal [3H]-2DG uptake in iPSC-CM plated at 25,000/37,500 cells per well (low density) or 50,000 
cells per well (high density) expressed as full uncorrected data +/- 40 µM CB in CPM (A), 
background corrected in CPM (B), or as a percentage of the mean value obtained in the low 
density condition (C). In experiments 1 and 3 data shown is mean (+ S.E.M.) of 3 replicate 
samples, whereas in experiment 2 data shown is mean (+ S.E.M.) of 6 replicate samples. 
Statistical analysis was performed with a 2 way ANOVA, where identified factors were 
experimental day and plating density, and was performed upon normalised background 
corrected data prior to expression as a relative percentage of the low density data. The level 
of significance was set at P=0.05. 
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Based upon the data collected in Figure 3-10 it was considered possible that an 
increase in glucose uptake per cell at higher plating densities may be at least 
partly linked to changes in contractile activity. Contraction is heavily ATP 
dependent, and in turn the capacity to increase ATP synthesis (to match 
contraction induced breakdown) is directly linked to substrate availability. 
Therefore it follows that increases in contractile demand could increase the 
uptake of the main metabolic substrate in iPSC-CM – glucose. This increased 
contractility in theory could occur due to increased electrical coupling between 
cells at higher densities. 
To test this, iPSC-CM were plated at 25,000 or 50,000 cells per well, and key 
parameters of contraction were measured via CellOPTIQ from 8 separate wells for 
each condition, as described in methods sections 2.4.2. A typical field of view of 
the CellOPTIQ microscope is displayed in Figure 3-11. Figure 3-12 shows an 
example output trace from the associated analysis software, whereby 5 
contractions of an identically sized area of a well (not an individual cell) have 
been recorded over a 5 second period. Key quantified parameters include 
amplitude of contraction, which refers to the total extent of contraction. To be 
explicit, this is analogous to but not interchangeable with fractional shortening, 
which is typically reported when referring to the contractility of individual 
myocytes and refers to relative shortening of the cell on account of well-defined 
and structured myofilaments. Rather, this is an index of the total extent of the 
disordered contraction of all iPSC-CM in the field of view, with upwards of 10 cells 
present. From this, other important measurements are the time from 10-90% 
contraction (Up90), time from 10-90% relaxation (Down90), time from 50% 
contraction to 50% relaxation (CD50), and time between contractions (Interval). 
Combined, these measurements inform us regarding the frequency, overall 
amount, and velocity of contraction. 
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Figure 3-11 Representative field of view of CellOPTIQ imaging system 
Cells were plated at 25,000 cells per well, and maintained until 6 days post-plating. 
 
Figure 3-12 Example CellOPTIQ iPSC-CM contraction output trace 
5 spontaneous contractions from iPSC-CM within the field of view at the expected rate of 
approximately 1 Hz were captured and analysed via CellOptiq software over a 5 second 
period. The trace is collated from the activity of several cells, which is possible due to the 
electrical coupling between cells and therefore synchronicity of contraction. 
No statistically significant difference was detected between conditions when 
assessing the measurements of contractile activity likely to most strongly 
influence metabolic demand; beat to beat interval (Figure 3-13A; 25,000 vs 
50,000; Means +/- S.E.M.: 939 +/- 37 ms vs 1002 +/- 23 ms; P>0.05) and total 
amplitude of contraction (Figure 3-13B; 25,000 vs 50,000; Means +/- S.E.M.: 679 
+/- 71 A.U. vs 658 +/- 48 A.U.; P>0.05). 
In contrast, more subtle measurements of contractile dynamics revealed 
conflicting results. Markedly, there was a highly significant difference in CD50 
between conditions (Figure 3-14A; 25,000 vs 50,000; Means +/- S.E.M.: 287 +/- 4 
ms vs 320 +/- 7 ms; P<0.01) despite no significant difference in either Up90 (Figure 
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3-14B; 25,000 vs 50,000; Means +/- S.E.M.: 70 +/- 2 ms vs 74 +/- 5 ms; P>0.05) or 
Down90 (Figure 3-14C; 25,000 vs 50,000; Means +/- S.E.M.: 242 +/- 15 ms vs 223 
+/- 5 ms; P<0.01). 
This conflict was investigated further by analysing the raw data presented in Table 
3-2 where the time to reach different percentages of total contraction or 
relaxation is reported, expressed in ms after initiation of contraction. This permits 
assessment of the difference between conditions in a more in-depth and specific 
manner. It reveals a significantly slower progression from 90% contraction to 10% 
relaxation in cells plated at 50,000 cells per well, which is then sustained until 
approximately 50% relaxation, at which point an acceleration in relaxation occurs 
in order to return values to an equal setting by 75% relaxation. This suggests a 
longer time under near maximal tension for cells plated at a higher density. 
 
Figure 3-13 Frequency and extent of contraction in iPSC-CM plated at a high or low density 
iPSC-CM were plated at either 25,000 or 50,000 cells per well and then maintained for 
approximately 1 week. Thereafter contractility was measured via CellOptiq video based 
analysis software in order to produce quantification of beat to beat interval (A) and 
contraction amplitude (B). Values are reported as 8 replicate samples corresponding to the 
average of 3 recordings from geographically distinct locations in 8 separate wells. Individual 
data points are shown in addition to mean +/- S.E.M. Statistical testing was performed using 
an unpaired t-test, where the level of significance was set at P=0.05. 
 102 
 
 
Figure 3-14 Speed of contraction and relaxation in iPSC-CM plated at a high or low density 
iPSC-CM were plated at either 25,000 or 50,000 cells per well and then maintained for 
approximately 1 week. Thereafter contractility was measured via CellOptiq video based 
analysis software in order to produce quantification of CD50 (13A), Up90 (B), and Down90 (C). 
Values are reported as 8 replicate samples corresponding to the average of 3 recordings from 
geographically distinct locations in 8 separate wells. Individual data points are shown in 
addition to mean +/- S.E.M. Statistical testing was performed using an unpaired t-test, where 
the level of significance was set at P=0.05. * indicates P<0.05 
 
Table 3-2 Speed of contraction and relaxation in iPSC-CM plated at a high or low density 
All values are expressed as time (ms) after initiation of contraction and are mean (S.E.M.) of 
the 8 replicate samples described in the preceding figures. Statistical testing was performed 
between the 2 groups at each point using an unpaired t-test, where the level of significance 
was set at P=0.05. 
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After optimisation of plating density and incubation duration, a range of 
conditions had been identified that facilitated the reliable detection of suitable 
basal [3H]-2DG uptake, significantly above background noise but not at risk of 
saturating cellular uptake capacity. Thereafter, the focus was to manipulate key 
experimental variables that may be able to elicit an insulin response. Firstly, the 
effect of stimulating cells with insulin like growth factor 1 (IGF-1) in comparison 
to insulin was assessed. IGF-1 can activate the insulin receptor directly, in addition 
to its own separate receptor, both of which activate intracellular Akt related 
signalling cascades (Stitt et al., 2004). The relative effect of insulin and IGF-1 on 
a given cell type is related to the relative expression of the receptors, which in 
turn may be governed by maturation status (Boucher et al., 2010). However, 
neither IGF-1 nor insulin was found to significantly increase [3H]-2DG uptake in 
iPSC-CM across 2 independent experiments (Figure 3-15).  
 
Figure 3-15 IGF-1 vs insulin stimulated glucose uptake in iPSC-CM 
[3H]-2DG uptake was assayed in iPSC-CM stimulated for 30 min with either 860 nM porcine 
insulin or 25 ng/mL IGF-1, relative to basal only values, across 2 independent experiments. 
[3H]-2DG incubation was performed for 20 min. Values are expressed as a percentage of the 
mean basal uptake value recorded on each experimental day (+S.E.M.). Statistical analysis 
was performed on raw data with a 2-way ANOVA, where the identified factors were 
experimental day and drug stimulation. The level of significance was set at P=0.05. 
A second experimental factor thought to influence the insulin sensitivity of iPSC-
CM was the presence or absence of serum in the medium prior to performing the 
[3H]-2DG uptake assay. Serum starvation is a tool widely used to enhance 
reproducibility of measurements but also more importantly it is used to enhance 
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physiological responses, as many growth factors and hormones are present in 
serum that activate intracellular signalling pathways and physiological processes. 
Serum starvation was performed for 2-3 hours in some of the earlier experiments, 
but not consistently. In some cases serum free medium provided by the company 
Axiogenesis (BMCC) was used, and in other cases serum free DMEM (4.5 g/L) was 
used. The presence of other interventions or conditions makes this collated data 
difficult to fairly compare, therefore an independent experiment was performed. 
The data presented in Figure 3-16 is a representation of a typical insulin response 
recorded from iPSC-CM after experimental optimisation. A tight and clear basal 
uptake signal was recorded significantly (P<0.0001) above background noise over 
20 minutes incubation duration, which we know from Figure 3-9 will not have 
saturated the uptake capacity of the cells. However, 15 mins 860 nM insulin 
stimulation, after 3 hours serum free DMEM incubation, failed to significantly 
increase the recorded [3H]-2DG uptake signal after background correction (Figure 
3-16; Basal vs Insulin; Means +/- S.E.M.: 2277 +/- 33 CPM vs 2447 +/- 54 CPM; 
P>0.05). 
 
Figure 3-16 Insulin stimulation in serum starved iPSC-CM 
[3H]-2DG uptake was measured in iPSC-CM maintained in serum free DMEM (4.5 g/L) for 3 
hours prior to 20 min stimulation with 860 nM porcine insulin or unstimulated basal control. 
Individual data points for each replicate sample are shown, in addition to mean +/- S.E.M. for 
each condition. Statistical analysis was performed with a 1-way ANOVA. Background 
corrected basal and insulin stimulated uptake (data not shown) was then compared with an 
unpaired t-test. In all cases the level of significance was set at P=0.05. *** denotes P<0.0001. 
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It can be inferred from the results displayed thus far that, regardless of 
experimental conditions, iPSC-CM very rarely exhibit a robust insulin response on 
top of a robust basal signal. To quantify this observation, all experiments 
recording basal and insulin stimulated [3H]-2DG uptake only, performed with 
untreated (e.g. without drug stimulation or altered media conditions) iPSC-CM, 
were pooled and analysed (Table 3-3). Out of 38 total experiments, 25 basal 
signals >300 CPM were recorded, which was determined to be the minimally 
acceptable threshold. In total, 12 experiments had a fold insulin response >50%, 
which was also determined to be the minimally acceptable response. However, 
only 3 experiments met both of these criteria. Despite a large range of conditions 
and therefore basal uptake signals, the average insulin response (regardless of 
fold change) was remarkably consistent at 303.5 CPM. This demonstrates why the 
majority of acceptable fold insulin responses were recorded only when the basal 
signal was lower than 300 CPM (9/12 experiments). 
 
Table 3-3 Overview of basal and insulin stimulated [3H]-2DG transport experiments 
 
3.2.4 Insulin stimulated [3H]-2DG uptake in quiescent iPSC-CM 
In addition to insulin, contraction is a potent stimulus for glucose uptake in muscle 
(Kramer et al., 2006). As discussed in the introduction, in intact contracting 
myocardium it is still possible to detect an increase in glucose uptake in response 
to insulin stimulation. However, it could be that the spontaneous contractile 
activity of iPSC-CM could mask a smaller – but still robust – response in this cell 
type. Therefore basal and insulin stimulated glucose uptake was measured in non-
contracting iPSC-CM. 
To achieve this quiescent state, cells were treated with the drug blebbistatin, 
which selectively inhibits contractile myofilament interactions by targeting the 
myosin ATPase, but avoids interfering with other aspects of excitation contraction 
coupling such as intracellular calcium handling (Farman et al., 2008). For optimal 
insight, blebbistatin was serially diluted to its working concentration and applied 
for the duration of the serum starvation prior to the main [3H]-2DG uptake assay. 
This drug is fast acting, however it was deemed necessary to expose the iPSC-CM 
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for a prolonged period in advance of measuring glucose uptake to give time for 
any metabolic changes to occur and reach a new steady state. Cessation of 
contractile activity was confirmed through visual inspection via a standard light 
microscope. As described, the first step of the assay involves washing cells, to 
remove residual media. This would also remove the blebbistatin and rapidly 
reverse its action. Therefore it was reapplied at the same time insulin stimulation 
was initiated, preventing reinitiation of contraction until termination of the assay.   
Blebbistatin incubation for 3 hours prior to, and during the assay, significantly 
reduced [3H]-2DG uptake in the presence (P<0.001) and absence (P<0.001) of 
insulin stimulation (Figure 3-17). However, there was no significant effect of 
insulin upon transport rates either in the presence (P>0.05) or absence (P>0.05) 
of blebbistatin. Nifedipine, a calcium channel blocker that also inhibits myocyte 
contraction, was found to have a similar effect (n=1, data not shown). 
 
Figure 3-17 The effect of blebbistatin on [3H]-2DG uptake in iPSC-CM 
Cells were incubated with 3-10 µM blebbistatin for 3 hours prior to and also throughout the 
assay. Cells were stimulated for 20-30 min with 860 nM insulin and incubated with [3H]-2DG 
for 15-20 min. Data shown is mean (+S.E.M.) of 3 replicate samples for each experimental day, 
across 3 independent experiments. Statistical analysis was performed on raw data with a 2-
way ANOVA, where the identified factors were drug incubation and experimental day. The 
level of significance was set at P=0.05. 
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3.2.5 The expression of GLUT4 trafficking proteins in iPSC-CM 
After extensive experimental optimisation and manipulation of contraction it 
became clear that iPSC-CM were not capable of producing the required response. 
Therefore, investigation into identifying why this was the case began. First of all, 
it was assessed if iPSC-CM express the necessary proteins to facilitate the cellular 
process of GLUT4 trafficking. This demands the expression and capacity to 
activate intracellular insulin signalling cascades, the expression of key SNARE 
proteins, and most fundamentally the expression of GLUT4. 
Relative to primary rodent cardiomyocytes, iPSC-CM were found to express low 
levels of GLUT4, and high levels of GLUT1 (Figure 3-18). The data shown are from 
one biological sample, however the same trend was observed in 5 independent 
replicates (data not shown). The precise amount of iPSC-CM lysate loaded could 
not be accurately estimated due to the method of lysate generation preventing 
the opportunity to perform a micro BCA assay or equivalent. However, from the 
GAPDH and ponceau signals, an approximately equal amount of total protein 
appears to be present. Even if no loading control were available, an identical 
volume of the same samples were loaded for each immunoblot, therefore the 
relative difference in signals between blots still supports the conclusion reached. 
Issues such as the validity of GAPDH as a loading control between samples from 
different species and quantification of GLUT1/4 levels in iPSC-CM relative to adult 
cells are addressed in chapter 4. At this stage the key conclusion was that iPSC-
CM appear to be foetal like with regards to their GLUT isoform expression. For all 
of the following blots, borders between sections of the same blot indicate that 
images have been cropped for presentation purposes, however the images are 
taken from the same blot, with no alteration to brightness or contrast settings 
between segments. 
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Figure 3-18 GLUT1 and GLUT4 protein expression in iPSC-CM 
Representative immunoblot depicting 30 µL iPSC-CM lysate and approximately 25 µg of 
lysates generated from primary adult rat (Rt) and mouse (Ms) cardiomyocytes that were 
subjected to SDS-PAGE and immunoblotting, probing for the expression of GLUT1 and 
GLUT4. GAPDH, in combination with Ponceau S staining, acted as relative loading controls. 
Data from a typical experiment is shown, with 5 independent experiments performed in total. 
The approximate position of molecular weight markers is indicated. 
Syntaxin 4 and SNAP23 are integral membrane bound t-SNAREs critical for the 
fusion of GSVs and the plasma membrane (see chapter 1) (Kioumourtzoglou et al., 
2014). Immunoblotting of 3 independent samples indicated that iPSC-CM express 
both of these proteins (Figure 3-19). The expression of Syntaxin 4 was variable, 
whereas the expression of SNAP23 was more consistent. On account of the 
consistent signal obtained from 3T3-L1 adipocyte lysate, it is likely that this 
reflects the actual protein expression, rather than just variable antibody binding. 
 
Figure 3-19 The expression of key SNARE proteins in iPSC-CM 
Representative immunoblots depicting 20/30 µL of 3 biologically independent iPSC-CM 
lysates that were subjected to SDS-PAGE and immunoblotting, probing for the expression of 
SNAP23 or Syntaxin 4 respectively. 5 µL 3T3-L1 adipocyte lysate was also loaded in order to 
act as a positive control, and GAPDH acted as an indicator of relative loading.  
Activation of intracellular signalling cascades provides the link between 
stimulation of the plasma membrane bound insulin receptor and the movement of 
GLUT4 to the cell surface in order to increase glucose uptake. There are dozens 
of intermediates involved in these pathways, including Akt. ERK1/2 have also been 
implicated in insulin sensitivity in human skeletal muscle (Rajkhowa et al., 2009). 
Figure 3-20 reveals that not only do iPSC-CM express these proteins, but they are 
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also phosphorylated and activated in response to insulin. In total, activation was 
assessed and/or detected in 3 biologically independent samples for Erk 1/2 and 7 
biologically independent samples for Akt. The reason so many more repeats were 
performed for Akt is that a large amount of variability was detected in the 
response, which appeared to be primarily linked to the relatively strong basal 
phosphorylation of Akt. Subjectively this appeared most strongly related to 
whether or not cells were serum starved prior to the assay. To properly address 
this issue, iPSC-CM were insulin stimulated either after serum starvation or normal 
incubation in Cor4U medium, and the activation of Akt was quantitatively assessed 
(Figure 3-21). The presented graph allows assessment of the reliability of 
phosphorylation measurements in all conditions, and how it changed in response 
to serum starvation or insulin stimulation. Serum starvation clearly reduced basal 
phosphorylation, however a similar fold response to insulin (approx. 1.5 fold) was 
observed between conditions. 
 
Figure 3-20 Expression and activation of Erk 1/2 and Akt in iPSC-CM 
Representative immunoblots depicting the expression of total and phosphorylated Erk 1/2 
and Akt in lysates from iPSC-CM that had been stimulated for 30 min with 0 (basal control) or 
860 nM insulin and then subjected to SDS-PAGE and immunoblotting. The Erk 1/2 images 
depict basal and insulin stimulated lysates from 2 biologically independent replicates, 
whereas the Akt image depicts 2 technical replicates of basal and insulin stimulated lysates 
from 1 biological sample. Data from a typical set of experiments is shown, and in total 3 
biological replicates were performed for Erk 1/2, and 7 biological replicates were performed 
for Akt. 
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Figure 3-21 The effect of serum starvation upon basal and insulin stimulated 
phosphorylation of Akt in iPSC-CM 
A: Representative immunoblot depicting the expression of total and phosphorylated Akt in 
lysates generated from iPSC-CM that had been stimulated for 0 (basal control) or 30 min with 
860 nM insulin, +/- 2.5 hours serum starvation in DMEM (4.5 g/L glucose), and then subjected 
to SDS-PAGE and immunoblotting. B: Quantification of the immunoblot displayed in panel A 
was performed via densitometry, expressed as the ratio of phosphorylated to total Akt in each 
lysate. 
3.2.6 The effect of maturation medium on iPSC-CM glucose 
transport  
The relative expression of GLUT1 and GLUT4 in iPSC-CM indicate the possibility of 
metabolic immaturity in this cell type. Therefore, MM conditioning as described 
by (Drawnel et al., 2014) was implemented, whereby cells were forced to rely on 
fatty acid metabolism rather than glucose to support ATP generation with the aim 
of promoting maturation, and the impact on glucose transport was assessed. This 
intervention was performed on 4 separate occasions, and was found to be toxic to 
cells. This increased the variation observed in results. Therefore, findings from 
only one of these experiments are reported, where an increased number of 
technical replicates were performed in order to gain a more robust and valid 
insight. However, the general findings can be applied to all independent assays 
performed (data not shown). 
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MM conditioning significantly reduced [3H]-2DG transport into iPSC-CM in the 
presence or absence of insulin (P<0.01) (Figure 3-22). As alluded to, rather than 
indicating a reduction in glucose uptake per cell, this is almost certainly primarily 
attributable to a reduced total cell number at the time of assay in conditioned 
cells. Insulin stimulation did not significantly increase [3H]-2DG uptake in either 
control or conditioned cells (P>0.05). 
 
Figure 3-22 The effect of maturation medium upon glucose transport in iPSC-CM 
iPSC-CM were plated and maintained in normal Cor.4U medium for 3 days. Subsequently, 
cells were either kept in Cor.4U medium (control) or maturation medium (MM) as described 
by Drawnel et al. for 4 days. Basal and insulin stimulated [3H]-2DG uptake was then measured. 
Cells were incubated for 30 min with 860 nM insulin, prior to a 20 min incubation with [3H]-
2DG. Data is mean of 3 (control) or 5 (MM) replicate samples (+S.E.M.). Statistical analysis 
was performed with a 1-way ANOVA, where the level of significance was P=0.05. 
3.2.7 Insulin sensitivity and GLUT expression in CDI iPSC-CM 
All of the data displayed and discussed thus far was generated with iPSC-CM 
purchased from Axiogenesis. It was considered possible that cells from a different 
company, who may employ alternative differentiation protocols or selection 
procedures, could be at a more advanced stage of maturation. Therefore, key 
assays were repeated with iPSC-CM purchased from Cellular Dynamics 
International (CDI). 
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Basal [3H]-2DG uptake was readily detectable in CDI cells, however there was no 
significant (P>0.05) increase in this signal in response to insulin stimulation (Figure 
3-23). Additionally, relative to primary cardiomyocyte lysate, CDI iPSC-CM 
expressed much higher levels of GLUT1 protein and much lower levels of GLUT4 
protein (Figure 3-24). However, a clear increase in phosphorylation of Akt in 
response to insulin stimulation was detected in lysates generated from these cells 
(Figure 3-25). In all cases these measurements were performed in 3 biologically 
independent samples. 
 
Figure 3-23 Insulin stimulated glucose uptake in CDI iPSC-CM 
[3H]-2DG uptake was assayed using CDI iPSC-CM plated at 50,000 cells per well. Cells were 
incubated with 860 nM insulin for 20 min prior to a 10 min incubation with [3H]-2DG. Cells were 
serum starved for 4 hours prior to the assay. Data shown is mean (+S.E.M.) of 6 replicate 
samples for each experimental day, across 3 independent experiments. Statistical analysis 
was performed with a 2-way ANOVA, where the identified factors were experimental day and 
insulin. The level of significance was set at P=0.05. 
 
Figure 3-24 GLUT1 and GLUT4 expression in CDI iPSC-CM 
Representative immunoblots (of 3 independent biological replicates) probing for total GLUT1 
and GLUT4 protein expression in 1 or 2 samples of cell lysate generated from CDI and 
Axiogenesis iPSC-CM, and primary mouse cardiomyocytes. An equal amount of samples was 
loaded between immunoblots (20 µL iPSC-CM, 5 µg total protein mouse), and GAPDH 
expression is also shown to indicate relative loading. Note that 20 µL iPSC-CM corresponds 
to lysate generated from approximately 20,000 cells.  
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Figure 3-25 Insulin stimulated phosphorylation of Akt in CDI iPSC-CM 
Representative images depicting total and phosphorylated Akt expression in lysates 
generated from CDI iPSC-CM that were stimulated with 0 (basal control) or 860 nM insulin for 
30 min, and then subjected to SDS-PAGE and immunoblotting. Cells were serum starved for 
3 hours prior to the assay, and 20 µL lysate was loaded for each sample. GAPDH expression 
was also probed in order to indicate relative loading. This is a representative immunoblot 
showing 3 replicate samples for each condition within one experimental day, and in total 3 
independent experiments were performed. 
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3.3 Discussion 
3.3.1 Insulin stimulated [3H]-2DG uptake can be measured on a 
96-well plate format 
In order to maximise the progress and viability of this project the measurement 
of glucose uptake had to be adapted to a 96-well plate format. Real-time assay of 
glucose uptake via 2-(N-(7-Nitronez-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose 
(2-NBDG) was attempted. However, this was unsuccessful as the rapid 
photobleaching of this fluorescent glucose derivative prevented reliable detection 
of uptake. Hence, we turned to a radioactive based assay widely used in the field. 
Results from Figure 3-1 and Figure 3-2 indicate that this assay was successful in a 
96-well plate format as a clear basal glucose uptake signal was detected above 
background noise in both HEK293 and HeLa cells. There are no universally 
accepted guidelines for determination of what is or is not an acceptable signal to 
noise ratio using this technique, however experience of this assay and common 
practice dictate that a basal signal should certainly be at least 25% above 
background noise. In addition to a relative margin, a difference of at least 300 
CPM should be expected. These were set as standard criteria in the determination 
of whether glucose uptake had actually been detected. It is easily possible to 
detect a signal statistically significantly greater than background but still within 
the noise of the assay in real terms. For example, if a signal was significantly 
greater by 50 CPM over a background of 1000 CPM it is not credible to claim uptake 
has been sufficiently detected and then make any subsequent conclusions about 
a fold insulin response. 
In both experiments with HEK293 and HeLa cells there was a significant effect of 
plating density upon recorded [3H]-2DG uptake. This is to be expected, as a 
greater number of cells per well should lead to a greater absolute amount of [3H]-
2DG uptake/well, and therefore in turn a greater detected signal. The relationship 
between cell number per well and detected uptake signal appeared linear across 
the range of plating densities tested (10-50,000 cells per well). Additionally, a 
background corrected signal of 500-1000 CPM was recorded at 25,000 cells per 
well. Combined, these observations were valuable gauges for working with iPSC-
CM, as they suggest that a strong basal uptake signal should be detectable at the 
recommended plating density for iPSC-CM (25-30,000 cells per well), without risk 
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of saturating cellular uptake capacity. It was thought possible that the number of 
washes prior to [3H]-2DG uptake would also impact the signal recorded. If glucose 
contained in maintenance media is not adequately washed away prior to the assay 
then this could inhibit [3H]-2DG uptake, thereby leading to a lower detected 
signal. However, excessive washing could lead to the detachment of cells and a 
lower and noisier signal, particularly for the somewhat more fragile iPSC-CM. 
Whilst there was no statistically significant effect of the number of washes, 
subjectively it does appear as though the relationship between plating density and 
uptake was indeed noisier when 3 washes were performed prior to the assay, 
compared to when only 1 was performed. 
Critically, basal and insulin stimulated [3H]-2DG uptake values for 3T3L1 
adipocytes and primary rabbit cardiomyocytes (Figure 3-3 and Figure 3-4) 
recorded on the same 96-well plate format clearly indicated that this assay can 
detect a robust, statistically significant insulin response, if the cells are capable 
of producing it. For both cell types, the responses recorded were within the 
typically reported range of responses in the literature, albeit perhaps towards the 
lower end of the spectrum for the isolated rabbit cardiomyocytes. This could be 
largely attributable to a high volume of dead cells that are more difficult to wash 
away when trapped in the wells of a 96-well plate. These cells could not be 
filtered out of the sample in any way prior to plating, and could increase the 
likelihood of trapping [3H]-2DG uptake in the extracellular space, thereby 
increasing the noise of the results. The key point is that based on this collective 
data it can be concluded that if no insulin response is recorded in iPSC-CM then it 
is unlikely to be due to an inherent inability to detect it using this experimental 
technique. 
3.3.2 iPSC-CM exhibit poor insulin stimulated glucose uptake 
The most important and consistent feature of any diabetic model is an impairment 
of insulin stimulated glucose uptake, therefore to have any potential to act as a 
novel model of DCM, iPSC-CM must exhibit a robust baseline insulin response. Data 
from Figure 3-5 provided an initially favourable evaluation. Insulin significantly 
increased the rate of glucose uptake approximately 2-fold above basal values in 
the first set of experiments, and trended towards significance in the second set 
of experiments. The basal uptake values in experiment 1 of Figure 3-5B seem 
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erroneously elevated, however no justifiable reason could be provided for 
exclusion. Regardless, Akti and wortmannin significantly reduced glucose uptake 
in the presence of insulin. This is logical as Akt and PI3K are known to be central 
intracellular insulin signalling pathway molecules important in the insulin-
stimulated delivery of GLUT4 to the plasma membrane (Kohn et al., 1996).  
As described in the introduction, myocardial glucose uptake is impaired in human 
diabetic patients in the presence of insulin, relative to healthy control subjects. 
This reduction in glucose transport likely reflects a combination of the onset of IR 
and a reduction in basal transport, although the exact relative contribution of 
each is unclear. In the dataset presented in Figure 3-8 no insulin response was 
recorded in control cells, therefore any development of IR could not be assessed. 
Presented results suggest that acute (3-4 days) incubation with palmitate may 
decrease basal glucose uptake in iPSC-CM. However, this effect was small and the 
underlying mechanism was not tested, therefore caution must be drawn when 
stating the wider importance of this individual dataset. 
Despite several favourable observations of this initial data drawing comparison 
between iPSC-CM and the relevant published literature, Figure 3-6 reveals a 
couple of crucial issues. Whether looking at summaries of individual experiments 
or at the 95% confidence intervals of conditions in the overall dataset, the 
variation in both the absolute counts recorded and the relative effect of insulin 
appears to be considerable. This observation is supported by the finding that 
values differed significantly between experimental days. One possible explanation 
is to attribute this primarily to inherent variation of the assay, perhaps in the 
process of scintillation counting or dilution of the [3H]-2DG stock. However, there 
was a significant interaction effect between experimental day and insulin, 
suggesting that the response of the cells to the [3H]-2DG and particularly the 
insulin was indeed more pronounced on certain days and the primary cause of 
variation within the assay. This conclusion is strongly supported by the recording 
of highly similar basal and insulin stimulated counts across 3 independent 
experimental days with 3T3-L1 adipocytes (Figure 3-7A). Additionally the 
extremely tight experimental standard readings indicate that both the preparation 
of the assay mix and the output of the scintillation counter are consistent (Figure 
3-7B). 
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In isolation, variation in results is not disastrous. However, an equally important 
observation from Figure 3-6 is the poor signal to noise ratio between conditions 
+/- CB. The central problem when background corrected CPM values are so small 
is that the ‘insulin response’ essentially represents the detection of some glucose 
uptake against no detection of glucose uptake, rather than a robust increase from 
one rate to another. This is an issue because we are interested in establishing a 
model whereby we can measure a reliable >2 fold response over and above a 
strong and stable basal signal. If the basal value is very low or even negligible, 
then this leaves open the possibility of small variations in absolute counts creating 
a disproportionate and misleading large range of fold responses. There is more of 
a buffer against this if basal counts are more substantial. 
Table 3-1 reveals that the mean basal glucose uptake signal was around 22% higher 
than background, and hence fell below the required threshold of 25%. 95% 
confidence intervals also indicate the difference may be as little as 81 CPM in a 
wider population of cells under similar conditions. If following normal protocol 
then the mean background subtracted insulin stimulated increase in glucose 
uptake values represents essentially a 2-fold response, bringing it in line with data 
from primary rodent cardiomyocytes (Figure 3-4). However, given the variation 
and low basal CPM this would be an unjustifiable conclusion. 
As stated, the true magnitude and biological relevance of the apparent insulin 
response recorded in Figure 3-6 is hard to interpret. This causes problems when 
progressing to the ultimate aim in the development of any biological model 
whereby attempts are made to manipulate the observed response and assess the 
effect of different interventions. All that could practically be achieved in this case 
is an inhibition/increase in the insulin response, or not. These concerns are 
heightened by the observation that no insulin response was recorded in control 
cells during the palmitate conditioning experiments. These experiments were 
performed with modified conditions that facilitated a much larger and more 
reliable basal glucose uptake signal, and are discussed in detail below. It is 
possible that the true insulin response of these cells is very small and only 
apparent when compared to a similarly weak basal signal. This underlines the 
importance of assessing both the absolute and relative effect of insulin on glucose 
uptake values, not just the fold response alone. 
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3.3.3 Manipulation of experimental conditions strongly impacts 
the recorded uptake signal from iPSC-CM, but not their 
insulin sensitivity 
Initial characterisation of iPSC-CM was performed under a range of experimental 
conditions based upon the pilot data in HEK293 and HeLa cells. Despite recording 
a statistically significant insulin stimulated glucose uptake response that may be 
regulated by similar pathways as in mature cells, it was clearly necessary to re-
optimise experimental conditions in order to assess if the same fold insulin 
response could be recorded in the presence of a more robust basal signal. As 
alluded to in the results section, this was a 2 step process. First of all variables 
thought to influence basal glucose uptake in iPSC-CM were systematically 
examined in order to reliably obtain the desired signal. This was successfully 
achieved, however this resulted in no insulin response being observed. Therefore 
further variables were examined to ascertain whether this was a reflection of an 
inherent lack of an insulin response, or due to confounding experimental 
conditions relating to iPSC-CM. 
The first experimental variable identified was the duration for which iPSC-CM 
were incubated with the [3H]-2DG assay mix. Intuitively, longer incubations should 
allow more time for [3H]-2DG uptake and therefore a larger recorded signal; 
however at longer time points, ATP may be rate limiting and 'uptake' rates may 
then not reflect uptake but rather metabolism of 2DG. With a longer incubation 
duration we would also anticipate the signal to noise ratio to improve. The results 
from Figure 3-9 clearly indicate that across a range of 15-60 min, both the [3H]-
2DG uptake signal and the signal to noise ratio increased with time as expected. 
Critically, the rates normalised against cell number and time do not differ greatly 
between conditions, indicating a linear relationship between incubation duration 
and [3H]-2DG uptake over the range tested. These data show that saturation of 
2DG uptake was not a problem under the conditions employed. All glucose uptake 
measurements are presented as average rates across the duration for which cells 
were incubated with the [3H]-2DG. Real-time assays of glucose uptake may have 
been useful and more insightful, but as noted above live glucose uptake using 2-
NBDG was unsuccessful as the rapid photobleaching of this fluorescent glucose 
derivative prevented reliable detection of uptake. 
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In contrast to incubation duration, manipulation of cell density had a more 
powerful influence over the recorded uptake signal (Figure 3-10). The amount of 
recorded glucose uptake per cell increased by an average of almost 100% between 
conditions. This means that even minor variations in cell density can strongly 
increase or decrease the recorded basal signal, therefore making regulation of this 
factor critical. Interestingly it also suggests that saturation of the uptake signal 
did not occur even in cells plated at 50,000 cells per well, confirming further that 
a lack of insulin response is most likely due to a limitation within the cells and not 
the assay. 
Consideration of why uptake may vary so strongly with plating density leads to 
several theories. The most intriguing is related to possible changes in contractile 
activity. iPSC-CM do not function as individual cells, sitting in isolation. Rather, 
they interact with their environment, particularly neighbouring cells. Just as 
occurs in vivo, functionally coupled networks of cardiomyocytes that beat in 
unison are formed. In contrast to mature cells, iPSC-CM do not need extrinsic 
excitation, and instead maintain a spontaneous contractile rate of around 1 hertz. 
It is credible to suggest that an increased degree of coupling between cells in a 
plate may alter the rate and/or strength of contraction, thereby having a direct 
impact on ATP requirements in each cell. The data presented in Figure 3-13, 
Figure 3-14, and Table 1-2 suggest this could be the case. Rather than altering the 
rate or strength of contraction it appears that the length of time that the cells 
were generating maximal tension (90-100% contraction) significantly increased. 
Additionally, to maintain the total duration of contraction, an acceleration of 
relaxation occurred. Both of these changes would increase ATP demand 
significantly, and therefore increase the demand for uptake of the primary 
metabolic substrate glucose. It is particularly feasible to suggest changes in 
coupling and contraction may occur between the densities that were chosen, 
because iPSC-CM only form a fully coupled monolayer at approximately 30-35,000 
cells per well. 
However, there are alternative theories that could account for changes in glucose 
uptake recorded per cell with alterations in cell density. Primarily, the stated 
densities are approximate plating densities, not a definitive measure of the 
number of cells that are still present at the time of the assay. It could be that 
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these cells are more healthy (or exhibit reduced stress responses) in confluent 
monolayers and therefore there is a reduction in the inevitable loss of some cells 
at higher densities over the course of a 1 week culture. Additionally, these cells 
are differentiated from a fibroblast like phenotype, and although a puromycin 
selection step is undertaken due to resistance to this antibiotic being artificially 
genetically linked to the insertion of cardiac specific genes as a marker of 
successful manipulation, it is probable that some fibroblasts survive and may 
proliferate. The extent to which this impacts overall cell number will depend upon 
how many cells are plated. Therefore combined these issues could lead to an even 
bigger difference in cell number at the time of assay than is assumed, and 
therefore normalisation against plating density could result in misleading 
differences in uptake arising. From visual inspection of the cells this is unlikely, 
but it cannot be discounted without consideration. For the practical purposes of 
the assay, explanation of the relationship between density and recorded uptake 
signal is not vital, as long as it is practically understood and managed. 
Based upon this work, it was determined that a plating density of approximately 
35,000 cells per well and an incubation duration of 20 min would facilitate the 
reproducible detection of the desired basal glucose uptake signal. Therefore, 
attempts were made to alter other experimental variables in the hope of revealing 
an insulin response. However, unfortunately neither stimulation of cells with IGF-
1 nor serum starvation prior to the uptake assay had any effect of note on the 
insulin response (Figure 3-15 and Figure 3-16). Whilst it was always unlikely that 
these fairly simple interventions would induce a 2-fold insulin response or more, 
the absence of any effect suggested that these cells were perhaps entirely 
incapable of producing this, and that no particular detail of the protocol was a 
critically limiting factor. 
3.3.4 Contraction is a potent stimulus for glucose uptake in iPSC-
CM 
The coupling of contractile activity and glucose uptake in muscle tissue is a logical 
mechanism to ensure that the highly energetic demands of excitation contraction 
coupling are met. The contrast in glucose uptake between resting and maximally 
contracting conditions will likely be far greater in skeletal muscle because of the 
ability of this tissue to completely rest, unlike the heart. Indeed, less than a 50% 
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increase in myocardial glucose uptake is typically reported in vivo in response to 
maximal insulin stimulation. When relating these findings to iPSC-CM, it is highly 
unlikely that this assumed contraction mediated elevation in basal glucose uptake 
(relative to a non-contracting state) would be sufficient to mask the required 2-3 
fold insulin response. Indeed, Figure 3-17 confirms this to be the case. Blebbistatin 
mediated inhibition of contraction reduced detected glucose uptake by >50%, yet 
subsequent insulin stimulation did not significantly increase this signal. This 
strongly suggests, as would be expected, that contraction plays a vital role in 
regulating metabolic demand in these cells, however insulin does not. 
Additionally, a concept introduced previously is supported by this dataset. In all 
of the independent experiments, the recorded basal glucose uptake signal was 
well in excess of 500 CPM, and insulin increased this signal by less than 10%. 
However, if this basal signal had been much lower and in the range of values 
typically recorded prior to experimental optimisation, then a robust fold response 
would have been recorded. This demonstrates fairly conclusively that any insulin 
response recorded in these cells is indeed minor, and not significantly inhibited 
by contraction mediated uptake. 
3.3.5 iPSC-CM are metabolically immature  
The fundamental limitation of iPSC-CM with regards to developing a novel cellular 
model of DCM is that they cannot produce a reliable and/or robust insulin 
stimulated glucose uptake response. The primary reason for this appears to be 
very low levels of expression of GLUT4 protein, the predominant insulin sensitive 
glucose transporter in mature muscle tissue (Figure 3-18). This observation, 
coupled with high levels of GLUT1 protein expression, are strongly indicative of 
metabolic immaturity in this cell type. This is consistent with limitations cited in 
other aspects of iPSC-CM physiology, for example their elevated resting membrane 
potential that contributes towards their spontaneous contractile activity, or 
poorly developed t-tubule network (del Álamo et al., 2016). The difference 
observed in Figure 3-18 is subjective, yet conclusive. Whilst the relationship 
between GAPDH and total protein has not been confirmed to be identical between 
the different species/cell types implemented here, comparison with Ponceau S 
staining provides confidence that the GLUT signals are from similar amounts of 
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protein. However, even accounting for slight discrepancy, the difference in GLUT4 
expression appears large. 
These findings relate favourably to the [3H]-2DG transport data displayed. GLUT4 
is the predominant insulin sensitive transporter in muscle, therefore its low 
expression in iPSC-CM probably accounts for the very poor insulin response 
recorded. The occasional small and unsignificant absolute increase in glucose 
uptake in response to insulin stimulation could be partly accounted for by the 
GLUT4 that is present. Alternatively, it could also be due to the high levels of 
GLUT1, which also exhibits insulin-stimulated translocation to the plasma 
membrane in many cell types (e.g. Fischer et al., 1996, 1997). Perhaps of more 
interest is the observation that contraction is clearly an important regulator of 
glucose uptake in iPSC-CM, yet there is very little GLUT4 present, which we would 
typically expect to mediate this response in adult cells. This strongly suggests that 
GLUT1 may be predominantly responsible for contraction mediated glucose uptake 
in iPSC-CM. In turn, this suggests that after progressing through development to a 
final fully mature state, GLUT4 expression not only gives cells the ability to 
mediate glucose uptake more selectively via insulin, but that it also takes over 
other responsibilities of GLUT1. Together these suggest that GLUT4 is used to 
more tightly couple metabolic demand and uptake, whereas GLUT1 is used to 
generally increase glucose uptake during the highly energetic initial stages of 
development. 
It is possible that low GLUT4 expression is not the only factor limiting iPSC-CM 
increasing glucose uptake in response to insulin stimulation. The process of insulin 
stimulated GLUT4 trafficking requires the presence and sufficient activation and 
interaction of multiple signalling and effector proteins. It would be challenging to 
characterise and assess every single necessary relevant interaction. However, 
iPSC-CM do express, and can phosphorylate (and therefore activate) in response 
to insulin, the central signalling intermediate Akt (Figure 3-20). Additionally, they 
can also activate Erk 1/2, which has been proposed to mediate insulin sensitivity 
in human muscle populations (Rajkhowa et al., 2009). The extent to which Akt 
was activated varied across a range of independent assays, primarily due to 
variations in basal Akt phosphorylation levels. Serum starvation prior to the assay 
was found to reduce this basal signalling (Figure 3-21), which increases the 
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chances of detecting a more robust insulin response. SNARE proteins are of 
particular importance in insulin-stimulated GLUT4 translocation to the plasma 
membrane. Syntaxin 4 and SNAP 23 are widely accepted to be the target t-SNAREs 
located on the plasma membrane (Kioumourtzoglou et al., 2014). It appears that 
iPSC-CM express both of these proteins, albeit to an unclear extent (Figure 3-19). 
Together, this data confirms that intracellular signalling networks are activated 
to at least some degree by insulin, and that integral parts of the fusion machinery 
are present, suggesting the central limiting factor may indeed be limited GLUT4 
availability. 
3.3.6 ‘Maturation Medium’ conditioning did not improve iPSC-CM 
insulin sensitivity 
Whilst it would be an overstatement to conclude that absolutely no insulin 
response had been recorded from iPSC-CM, it was clearly far short of what was 
required. Therefore, a protocol recommended specifically for this cell type in 
order to stimulate maturation was employed. Essentially, by supplying iPSC-CM in 
culture with fatty acids rather than glucose, rapid maturation of a range of 
parameters has been reported (Drawnel et al., 2014). However, as exemplified in 
Figure 3-22, when this approach was mimicked in this project with Axiogenesis 
iPSC-CM, the only clear effect was a reduction in detected basal [3H]-2DG uptake. 
This was attributed to acute toxicity of the applied medium, and it certainly did 
not induce any insulin response. It is possible that iPSC-CM do not possess the 
necessary machinery to effectively metabolise fatty acids, and that the palmitate 
therefore accumulated intracellularly and essentially acted as a metabolic poison. 
Whilst this initial intervention had unexpected outcomes, the principle of this 
approach remained valid and was therefore explored in much greater detail in 
chapter 4. 
3.3.7 The characterised phenotype may be ubiquitous to iPSC-CM 
All of the data presented in chapter 3 from iPSC-CM up until Figure 3-23 was 
generated with cells purchased from Axiogenesis. This company was selected 
primarily on the basis of extensive work (mostly studying electrophysiological and 
structural parameters) in the lab of Prof Smith, which has determined this source 
to be the best available option in terms of reliability of phenotype and 
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representation of adult physiology. However, it is important to note that these 
cells are always produced from a single donor line and hence may be limited by 
the physiological status of the donor or affected by epigenetic factors which we 
cannot control. Replication of key assays performed with cells from an alternative 
commercial source returned broadly similar results arguing against this being of 
major concern. There were subtle differences in the data generated from 
Axiogenesis and CDI iPSC-CM, although the overall conclusions were the same. For 
example, basal glucose uptake was possibly slightly greater in CDI iPSC-CM, and 
was certainly more reliably detectable (Figure 3-23). Furthermore, the 
phosphorylation of Akt in response to insulin was far more pronounced in these 
cells, in part due to much lower basal phosphorylation (Figure 3-24). However, 
overall it was concluded that these cells are similarly metabolically immature, 
which was exemplified by the equally poor expression of GLUT4 protein (Figure 3-
25). The decision was made to primarily keep working with Axiogenesis iPSC-CM 
on the basis that it is likely their limitations apply to iPSC-CM generally and also 
due to the more extensive characterisation of these cells, both within this project 
and the lab as a whole. 
3.3.8 Methodological considerations 
There were several limitations associated with the work described. First of all, 
primarily due to the expense of iPSC-CM and their inability to proliferate, the 
opportunity to perform extensive replicate experiments whilst still making 
significant overall progress is limited. The general approach taken to ensure a 
balance of reliability and confidence in generated data and forward progression 
was to perform independent experiments to address each identified question at 
least 3 times, with sufficient replicates (minimum of 3) within each experiment. 
This was adapted depending upon the noise of the relevant assay or clarity in the 
response recorded. Secondly, the decision to record the majority of results 6-8 
days post-plating could in theory have led to recordings being made outside of an 
optimal window. However, based upon manufacturers recommendations and prior 
work in the lab it was found that iPSC-CM reach a stable reproducible global 
phenotype 48-72 hours post plating, and maintain this for 12-14 days thereafter 
(personal communication with Prof Smith). Therefore approximately 7 days post 
plating was identified as an ideal time point for experimental use. Finally, when 
measuring [3H]-2DG uptake, recorded values could at best only be normalised 
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against plating density, rather than the number of cells present at the time of 
assay. It is possible, or perhaps even likely, that less than 100% of cells will survive 
one week in culture. This could generate misleading data, hence why unless 
explicitly required, data is present in raw CPM or as a percentage of control. 
3.3.9 Conclusion and outline of further work required 
In conclusion, a [3H]-2-deoxyglucose uptake assay was adapted to a 96-well plate 
format and used to characterise the insulin sensitivity of iPSC-CM. Despite 
optimisation of experimental variables and inhibition of spontaneous contractile 
activity (and associated glucose uptake) no robust or reliable increase in glucose 
uptake was detected after insulin stimulation. Analysis of glucose transporter 
isoform expression indicates that this may primarily be due to iPSC-CM being 
metabolically immature. This conclusion is consistent with previously published 
data assessing the expression of a wide range of genes and proteins in this cell 
type that is suggestive of iPSC-CM displaying a general phenotype that corresponds 
to a foetal stage of cardiac development, as discussed in chapter 1.4.3. 
Consequently, in their current form these cells are not suitable to use as the basis 
for a novel cellular model of a complex metabolic condition such as DCM. 
Encouragingly, these cells do possess some of the core insulin sensitive machinery 
required to produce the desired response that is a key feature of adult 
cardiomyocyte physiology. Preliminary attempts to invoke maturation were 
unsuccessful, therefore this must be the primary focus of future work. 
Specifically, it is of importance to study the consequence of increasing GLUT4 
expression in iPSC-CM, with regards to fundamental functional parameters and the 
underlying expression of relevant proteins. 
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4 Increasing GLUT4 protein expression in iPSC-
CM 
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4.1 Introduction 
Diabetes is a leading global healthcare challenge with pronounced direct 
pathological consequences for the heart. This project is concerned with evaluating 
the potential of iPSC-CM to act as a novel cellular model of DCM. As introduced in 
chapter 3 this has been attempted once previously, whereby Drawnel and 
colleagues (Drawnel et al., 2014) detected structural and functional changes 
corresponding to cardiomyopathy after culturing cells in a ‘pro-diabetic milieu’. 
However, their model made no reference to the detection of IR, which is a vital 
and requisite feature of any phenotype related to diabetes. This is a significant 
problem given that after initial characterisation and assessment of iPSC-CM 
physiology in this project (reported in chapter 3) it became clear that this cell 
type cannot produce an insulin stimulated glucose uptake response in the baseline 
condition, therefore at present they cannot be used to credibly model IR or by 
extension DCM. 
4.1.1 GLUT4 is integral to insulin stimulated glucose uptake 
As outlined in chapter 1, the increase in glucose uptake in (insulin sensitive) cells 
in response to insulin involves a highly complex network of interactions between 
dozens of proteins. Accordingly, manipulation of proximal insulin signalling has a 
knock on effect upon insulin stimulated glucose uptake. For example, preventing 
the inhibitory effect of the inositol pyrophosphate IP7 on Akt in a mouse model 
resulted in in vivo insulin hypersensitivity, improved glycemic control, and most 
importantly reduced weight gain and prevention of the onset of IR seen in control 
mice in response to a HFD (Chakraborty et al., 2010). More directly, and in 
compliment of this work, disruption of the Akt gene in mice resulted in systemic 
IR (Cho et al., 2001). Similarly, mutations of the insulin receptor and IRS genes in 
mice have been shown to result in severe IR in peripheral tissues and pancreatic 
beta cell hypertrophy, both key features of the diabetic phenotype (Tamemoto et 
al., 1994; Kido et al., 2000). 
However, at the most fundamental level, the theory underlying insulin stimulated 
glucose uptake is that the glucose transporter GLUT4 is trafficked from an 
intracellular retention site to the cell surface. Based upon this it would therefore 
be predicted that the degree of expression of GLUT4 also has a critical influence 
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upon the effectiveness of this response, and indeed a range of insight from the 
literature supports this concept. For example, GLUT4 expression was found to be 
reduced in the adipose tissue of human type 2 diabetic patients, relative to 
controls (Hussey et al., 2011). This association between GLUT4 expression and 
insulin sensitivity was strengthened by the observation that 4 weeks exercise 
training significantly increased GLUT4 protein expression, and coincided with 
improvements in a range of clinically relevant metabolic parameters (Hussey et 
al., 2011). In further support of this work, both generic, muscle specific, and 
adipose specific downregulation of the GLUT4 gene in mice has been reported to 
induce systemic metabolic alterations consistent with diabetes, including 
hyperglycemia, hyperinsulinemia, and IR (Stenbit et al., 1997; Minokoshi, et al., 
2003). Interestingly, in a heterozygous muscle specific GLUT4 knockout model 
proximal insulin signalling (IRS-1, Akt) was found to be significantly impaired (Kim 
et al., 2005), suggesting that it is challenging to completely separate the roles of 
insulin signalling and GLUT4 expression when studying an integrated physiological 
action such as insulin stimulated glucose uptake. To add a further degree of 
complexity, adipose or muscle specific GLUT4 knockout mouse models resulted in 
IR in both tissues, suggesting that there is a degree of cross communication 
(Minokoshi, et al., 2003) 
Overall, based upon the current literature it can be concluded that both fully 
functional signalling networks and appropriate GLUT4 protein content are 
required to elicit insulin stimulated glucose uptake into the cells of target tissues. 
When this response is impaired in diabetic individuals both of these factors are 
certainly implicated although there is conflicting evidence with regards to their 
relative importance in different tissues (Garvey et al., 1992; Kampmann et al., 
2011), perhaps related to at what stage of progression the diabetic phenotype is 
at time of measurement and the relative roles of the wide variety of possible 
pathological stimuli. Similarly, the specific molecular mechanisms impairing the 
complex insulin signalling networks may be specific to certain experimental 
models/the original pro-diabetic stimulus (Boucher, et al., 2014).  
In the context of the lack of response recorded from iPSC-CM, preliminary 
evidence presented in chapter 3 indicated that low levels of GLUT4 protein 
expression could be the primary issue. To strengthen this conclusion and provide 
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a more accurate description of the iPSC-CM metabolic phenotype, quantification 
of the difference in glucose transporter isoform expression between iPSC-CM and 
mature primary cardiomyocytes would be highly informative. Additionally, this 
would also enable identification of the specific modifications required to mature 
iPSC-CM into an adult-like phenotype. For example, it is possible that a 2-fold 
increase in iPSC-CM GLUT4 expression would represent a significant increase, but 
still fall well short of the expression recorded in primary cardiomyocytes.     
Initial insight reported in chapter 3 also identified that GLUT1 protein expression 
is readily detectable in iPSC-CM and therefore appears different from 
measurements of primary adult cardiomyocytes. Consequently, it could be argued 
that addressing the imbalance in expression of GLUT1 between iPSC-CM and the 
cells they are meant to model could be of equal importance to intervening with 
regards to GLUT4. However, as just outlined, GLUT4 is essential in eliciting insulin 
stimulated glucose uptake, whereas GLUT1 is not. Similarly, GLUT4 expression can 
strongly influence cardiac contractility (Belke et al., 2000). DCM is primarily 
defined by IR and impaired contractility of the heart, therefore it is logical and 
appropriate to first of all target GLUT4 in iPSC-CM. 
4.1.2 Regulation of GLUT4 expression 
In order to design appropriate and effective interventions to increase GLUT4 
expression, the normal physiological regulation of this transporter must be 
elucidated. There are a range of transcription factors and stimuli that have been 
cited as having a possible role in the transcriptional regulation of GLUT4 (Zorzano, 
et al., 2005). However, evidence indicates that there may be 3 key binding sites 
within the promoter region that have a critical influence over GLUT4 expression 
in muscle. Specifically, manipulation of the expression of the transcription factors 
MyoD, MEF2, and the thyroid hormone receptor (TRα1) and their target binding 
sites was shown to powerfully impact the activation of the GLUT4 gene in several 
myocyte cell culture models (Santalucía et al., 2001).  
This data is supported by a range of evidence that is more translatable and/or 
activates signalling networks further up the respective pathways, in order to 
identify multiple molecular targets. For example with regards to the role of MEF2, 
GLUT4 gene expression significantly increased in L6 and C2C12 myoblasts upon 
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overexpression of the coactivator PGC-1, which was found to be dependent upon 
the integrity of the MEF2 sequence in the GLUT4 promoter region (Michael et al., 
2001). In a separate cell culture model, exposure of isolated adult rat 
cardiomyocytes to IGF-1 resulted in the restoration of GLUT4 gene and protein 
expression, which spontaneously decreases in culture (Montessuit et al., 2004). 
This effect was found to be mediated through the activation of p38 MAPK, and 
ultimately MEF2. Finally, an in vivo mouse model identified that changes in MEF2 
protein expression and associated binding of the MEF2 DNA sequence was strongly 
linked to both an experimental diabetes induced reduction - and then subsequent 
insulin treatment induced increase - in skeletal and cardiac muscle GLUT4 gene 
expression (Thai et al., 1998). 
Similarly, there is a body of in vivo evidence that the thyroid hormone T3 has a 
powerful role in GLUT4 expression. It is a key and characteristic feature of foetal 
to early post-natal development that the relatively high/low cardiac expression 
of GLUT1 and GLUT4 are reversed. The experimental induction of early 
hypothyroidism prevented this switch in rats, yet had no impact on GLUT4 protein 
expression when animals were fully mature (Castelló et al., 1994). Furthermore, 
injection of T3 at various stages of early development rapidly induced strong 
overexpression of GLUT4 mRNA and subsequently protein, with a corresponding 
repressive effect upon GLUT1, although this was less striking (Castelló et al., 
1994). As alluded to, this suggests direct transcriptional regulation of cardiac 
GLUT isoform expression by T3. Similarly, short term (3 days) injection of high 
doses of T3 have been found to enhance skeletal (fast and slow twitch) muscle 
GLUT4 protein content, which was associated with improved insulin stimulated 
glucose uptake in healthy rats, and significantly reduced circulating insulin levels 
in the obese zucker rat model of diabetes (Weinstein et al., 1994; Torrance et al., 
1997). 
Finally, perhaps the best known stimulus for increasing myocyte GLUT4 expression 
(and general metabolic health) is exercise. For example, a single swimming 
endurance training session was enough to significantly increase GLUT4 protein 
expression in the skeletal muscle of rats, and repetition of this workout the 
following day raised expression further to double baseline values (Rens et al., 
1994). Similarly, in humans a single acute exercise bout was enough to induce a 
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rapid (3 hours) and robust (100%) increase in GLUT4 mRNA and protein, regardless 
of exercise intensity (40 vs 80% VO2 peak) (Kraniou et al., 2006). Furthermore, a 
week long exercise training regime enhanced skeletal muscle GLUT4 expression 
and whole body insulin stimulated glucose disposal in type 2 diabetic patients 
(O’Gorman et al., 2006). This link between muscular contractile activity and 
GLUT4 protein expression is strengthened further by denervation based studies. 
For example, 3 days post sciatotomy, GLUT1/4 expression was approximately 
doubled/halved respectively, in the extensor digitorum longus and soleus from 
Sprague-dawley rats (Coderre et al., 1992). 
The mechanism by which exercise exerts this effect is likely also partly through 
activation of MEF2. For example, 60 min cycling at a moderate intensity was found 
to increase MEF2 DNA binding 2-fold in the vastus lateralis of human subjects 
(McGee et al., 2006). Using the same protocol, a separate study identified that 
increased association of MEF2 with PGC-1 and (phosphorylated) p38 MAPK coupled 
with reduced association and nuclear localisation of an inhibitory histone 
deacetylase was primarily attributable to enhanced MEF2 activity post-exercise 
(McGee and Hargreaves, 2004). The upstream signalling pathways require further 
examination, but AMPK was suggested to have an important role. Additionally, a 
wheel running exercise programme in mice was found to restore skeletal muscle 
GLUT4 protein content that had been originally decreased in association with the 
onset of obesity (Gurley et al., 2016). However, this occurred independently of 
any change in GLUT4 mRNA, suggesting that exercise may also act via post-
transcriptional mechanisms to regulate GLUT4 protein expression. One possible 
factor could be micro-RNAs, which are known to regulate the translation of mRNA, 
and have been receiving attention in the context of diabetes research recently 
(Esteves et al., 2017). 
4.1.3 Previously attempted strategies to mature iPSC-CM 
The observation that iPSC-CM express low levels of GLUT4 and high levels of GLUT1 
is clear evidence that they significantly differ from adult cardiomyocytes and 
could even be viewed as foetal-like. However this is not the only example of 
divergence between iPSC-CM and adult cardiomyocyte phenotypes. Most notably, 
the variable size and shape of iPSC-CM with poorly defined and disorganised 
sarcomeres and an unstable electrophysiological phenotype that leads to 
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spontaneous contraction contrasts starkly with the large rectangular appearance 
of isolated adult cardiomyocytes that have clear striations and t-tubules and only 
contract rhythmically upon external stimulation. These features, combined with 
a poorly developed calcium handling system, mean that the contractility of iPSC-
CM is significantly less powerful compared to mature primary cardiomyocytes 
(Kolanowski et al., 2017). On account of these differences and more, several 
previous attempts have been made to mature iPSC-CM, which may guide the 
approach implemented in the present project. 
The first approach centres upon the metabolic environment that cells are cultured 
in. Typically, iPSC-CM are maintained in an unphysiologically high glucose 
concentration (4.5 g/L or 25 mM) despite the fact that cardiomyocytes depend 
primarily upon the oxidation of fatty acids in vivo. This may contribute to the 
observation that iPSC-CM rely primarily upon glycolytic metabolism, rather than 
the more powerful oxidative metabolism of primary cardiomyocytes (Rana et al., 
2012). In consideration of this, culturing iPSC-CM in medium containing fatty acids 
and insulin but no glucose for 3 days resulted in changes associated with 
maturation such as elongation of sarcomeres and enhanced action potential 
upstroke and duration, compared with cells maintained in manufacturers 
maintenance medium (Drawnel et al., 2014). Similarly, in a separate study 20 days 
in medium containing no glucose and supplemented with fatty acid resulted in 
reduced iPSC-CM lactate production and increased oxygen consumption, indicative 
of a shift from glycolytic to oxidative metabolism, underlined by an increase in 
mitochondrial content (Correia et al., 2017). As before this coincided with the 
onset of a host of adaptations that were interpreted as markers of maturation, 
including enhanced myofilament alignment, a decrease in expression of foetal 
genes, and improved excitation contraction coupling. Interestingly, some degree 
of lipotoxicity was observed, and was reduced by including galactose in the 
medium.  
As introduced earlier the thyroid hormone T3 may also have an important role in 
cardiac maturation in vivo, and is a strong regulator of metabolism. Accordingly, 
a week long supplementation of iPSC-CM with T3 invoked structural and 
contractility changes consistent with maturation (Yang et al., 2014). This was 
accompanied by improved calcium handling and enhanced mitochondrial activity 
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(but not content). Together the work discussed thus far suggests that the hormonal 
and metabolic environment of iPSC-CM has a very powerful influence over the 
maturation status of the cells, and that manipulation of one factor can induce 
significant widespread changes across several aspects of the iPSC-CM phenotype. 
Either the initial stimuli have several targets, or the identified metabolic effects 
act as a powerful stimulus/mechanism for maturation. An intervention utilising 
glucose depleted medium supplemented with both T3 and fatty acids 
unsurprisingly resulted in a range of electrophysiological, structural, and genetic 
adaptations indicative of maturity (Lin et al., 2017). However, no relevant 
baseline data for mature cardiomyocytes was provided to assess how much more 
maturation was still required. 
In addition to the metabolic and hormonal environment, the spatial organisation 
and mechanical loading of the heart are important stimuli in promoting cardiac 
maturation in vivo (Yang, et al., 2014). In response to this, a range of research 
has demonstrated the pro-maturation effect of culturing iPSC-CM in a way that 
better represents the in vivo environment than simple culture on a 2D plastic 
culture surface. Specifically, in isolation and/or in combination, culturing iPSC-
CM with substrates designed to mimic the extracellular matrix, in a 3D format, co-
culture with other relevant cell types (e.g. endothelial cells), and mechanical 
loading, have all been reported to enhance the iPSC-CM phenotype towards that 
of adult cardiomyocytes with regards to a range of physiological parameters 
(Tulloch et al., 2011; Chun et al., 2015; Fong et al., 2016). 
Finally, perhaps the most logical and simple stimulus that has been shown to 
enhance iPSC-CM physiology is time. Normal manufacturer’s recommendations for 
use of commercially derived iPSC-CM are typically to perform assays up until 2 
weeks post plating, however research has indicated that longer term culture of 
cells up to and above 6 months duration can promote maturation (Kamakura et 
al., 2013; Guo et al., 2017). This is an important finding that could help to combat 
the criticism of iPSC-CM (and all cultured cells) with regards to disease modelling, 
whereby attempts to replicate complex diseases that develop over years in vivo 
are made over the course of only a week or two in culture.  
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4.1.4 Aims of chapter 
Low levels of GLUT4 protein expression appear to underly the lack of insulin-
stimulated glucose uptake response in iPSC-CM. The critical transcriptional 
elements regulating GLUT4 protein expression in muscle have been identified, and 
might further be supported in vivo by post-transcriptional mechanisms such as the 
action of microRNAs or altered rate of degradation of GLUT4 protein. Several 
interventions have been implemented previously that induced metabolic 
adaptations and more general maturation in iPSC-CM, although the effect on 
GLUT4 expression was never assessed. So far, the most promising interventions 
that directly target metabolic pathways are T3 and MM conditioning. Exercise 
training is also a potent stimulus for adaptation, however this is highly challenging 
to mimic in culture conditions with isolated cells. Similarly, bioengineering 
approaches hold promise for maturation of iPSC-CM, but are out with the scope of 
this project. 
Therefore, the overall aim of this chapter is to identify a protocol (or protocols) 
that can facilitate an increase in expression of GLUT4 in iPSC-CM to the levels 
recorded in mature cardiomyocytes, with an ultimate view to assessing the 
subsequent impact on key physiological outcomes. More specifically, the following 
aims shall be addressed; 
 Quantification of GLUT1/4 expression and functional importance in iPSC-
CM and mature insulin sensitive cells 
 Assessment of the impact of maturation medium upon GLUT1 and GLUT4 
expression in iPSC-CM 
 Assessment of the impact of T3 upon GLUT4 expression in iPSC-CM 
 Development of a Lipofectamine 2000 mediated transfection protocol to 
increase GLUT4 expression in iPSC-CM and subsequent assessment of impact 
on cellular glucose uptake 
 Initial development of lentivirus mediated infection protocol to increase 
GLUT4 expression in iPSC-CM  
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4.2 Results 
4.2.1 Expression and function of GLUT1 and GLUT4 in iPSC-CM  
A key limitation of previous work reporting the effect of various interventions in 
maturing iPSC-CM is that too often the magnitude of adaptations that are desired 
are not explicitly stated. For example, significant increases in APD duration or 
mitochondrial content are reported, but the corresponding reference values of 
adult cardiomyocytes are not. Therefore, prior to attempting to increase GLUT4 
expression in iPSC-CM, the relative and absolute difference in protein expression 
and functional relevance of GLUT1 and GLUT4 between iPSC-CM and mature 
cardiomyocytes was assessed.  
In order to attempt quantification of transporter expression, a reference point of 
a known amount of GLUT1/4 protein was needed. In fully differentiated 3T3-L1 
adipocytes it has previously been published that there are approximately 215 ng 
of GLUT1 protein and 45 ng of GLUT4 protein per 1.5 mg of total protein 
(Calderhead et al., 1990). This corresponds to an estimated 950,000/280,000 
copies of each transporter per cell, however due to variations in size across 
different cell types this number is less useful in this context. Therefore, the 
protein expression of GLUT1 and GLUT4 was assessed in iPSC-CM and primary 
mouse cardiomyocytes relative to 3T3-L1 adipocytes, where a similar amount of 
total protein was loaded as adjudged by GAPDH expression. 
Figure 4-1A and 4-1B provide a clear visual depiction of the stark difference in 
GLUT1 expression between iPSC-CM and adult primary cardiomyocytes when 
assessed against a similar total amount of protein from 3T3-L1 adipocyte lysate. 
The expression of GLUT1 in iPSC-CM is abundant and easy to detect, in contrast 
to the faint (yet still detectable) expression in the primary cardiomyocyte lysates. 
Visually the difference between GLUT4 expression in the 2 sources of 
cardiomyocytes appears equally striking, but in an opposite manner to GLUT1 
(Figure 4-2A and 4-2B). In all blots a range of 3T3-L1 lysates were also loaded to 
provide confidence in this reference signal. 
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In order to quantify the relative difference in transporter expression between 
sources of cardiomyocytes densitometry was performed and the signal from 
technical replicates (different loading volumes) for each lysate on each blot was 
normalised to GAPDH and then averaged. Then the average fold difference in 
expression for the relevant transporter in either iPSC-CM or primary mouse 
cardiomyocytes relative to 3T3-L1 adipocytes was calculated across the 3 
biological replicates shown on each immunoblot. This experiment was performed 
in replicate for each transporter, for each cell type. Quantification depicting the 
relative difference in expression of GLUT1 and GLUT4 is shown in Figures 4-1C and 
4-2C, and key outputs shown in Table 4-1. Because expression was conveyed 
relative to 3T3-L1 adipocytes, the data for iPSC-CM and primary cardiomyocytes 
is shown on the same graph for each transporter, despite being obtained from 
different blots. This analysis revealed that iPSC-CM express approximately 30-fold 
more GLUT1 than primary adult cardiomyocytes, and approximately 10-fold less 
GLUT4. The values obtained between replicate immunoblots was fairly consistent 
in all cases, which provides confidence in this technique. 
iPSC-CM obtained from CDI were also probed for GLUT1 and GLUT4 expression 
relative to 3T3-L1 adipocytes in order to provide information from a second 
commercial source. However, whilst the same general concept was observed (high 
GLUT1/ low GLUT4), the poor GAPDH signal obtained from these cells was not 
representative of total protein loaded and therefore no quantification was 
performed (data not shown). Additionally, a segment of human myocardium was 
kindly donated by Dr. Cherry Alexander. Similar to CDI iPSC-CM, the GAPDH signal 
obtained from lysate of this sample did not suitably represent the total protein 
loaded (Appendix 7.1), however what can be observed is that in primary 
cardiomyocytes from a human origin there is an abundance of GLUT4 protein 
(Figure 4-3). 
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Figure 4-1 GLUT1 expression in iPSC-CM and primary mouse cardiomyocytes 
Protein lysates generated from 3T3-L1 adipocytes, iPSC-CM, and primary mouse 
cardiomyocytes were subjected to SDS-PAGE and immunoblotting probing for the 
expression of GLUT1 and GAPDH (loading control). 3T3-L1 adipocytes acted as a reference 
signal, with either 2 different amounts of 3 technical replicate samples (A) or 3 different 
amounts of 1 sample (B) loaded. For both cardiomyocyte lysates 2 different amounts of 3 
biologically independent samples were loaded. Quantification of relative GLUT1 expression 
is shown in panel C, expressed as the mean (+S.D.) fold difference between cardiomyocyte 
samples (n=3) and 3T3-L1 adipocytes (n=1). Each bar represents data from 1 immunoblot, and 
each immunoblot was performed in replicate. 
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Figure 4-2 GLUT4 expression in iPSC-CM and primary mouse cardiomyocytes 
Protein lysates generated from 3T3-L1 adipocytes, iPSC-CM, and primary mouse 
cardiomyocytes were subjected to SDS-PAGE and immunoblotting probing for the 
expression of GLUT4 and GAPDH (loading control). 3T3-L1 adipocytes acted as a reference 
signal, with either 2 different amounts of 3 technical replicate samples (A) or 3 different 
amounts of 1 sample (B) loaded. For both cardiomyocyte lysates 2 different amounts of 3 
biologically independent samples were loaded. Quantification of relative GLUT4 expression 
is shown in panel C, expressed as the mean (+S.D.) fold difference between cardiomyocyte 
samples (n=3) and 3T3-L1 adipocytes (n=1). Each bar represents data from 1 immunoblot, and 
each immunoblot was performed in replicate. 
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Figure 4-3 GLUT4 expression in primary human myocardial lysate 
Protein lysates were generated from a human myocardial segment and subjected to SDS-
PAGE and immunoblotting, probing for the expression of GLUT4 and GAPDH. 3T3-L1 
adipocyte lysates were also probed to act as a reference and positive control. Several 
amounts of lysate were loaded for each sample (2.5-5 µL 3T3-L1 lysate; 5-10 µL primary 
human cardiac lysate). The immunoblots have been cropped for presentation purposes but 
no raw data has been altered. 
 
Cell Type 
Ave. Fold 
Difference 
GLUT1 
Estimated Amount 
GLUT1 (ng/1.5 mg 
total protein) 
Ave. Fold 
Difference 
GLUT4 
Estimated Amount 
GLUT4 (ng/1.5 mg 
total protein) 
3T3-L1 
Adipocytes 
1 215 1  45 
iPSC-CM 5.1 fold 
higher 
1106 3.1 fold 
lower 
14.6 
Primary Mouse 
CM 
5.7 fold 
lower 
37.5 2.7 fold 
higher 
121.4 
Table 4-1 Quantification of estimated absolute and relative fold difference in GLUT1 and 
GLUT4 between iPSC-CM, primary mouse cardiomyocytes, and 3T3-L1 adipocytes 
Initial findings provided a clear insight and quantification of the difference in 
expression of GLUT1 and GLUT4, between iPSC-CM and the mature cardiomyocytes 
they are designed to represent. However, simply determining the level of 
expression of each transporter in the 2 cell types is not necessarily completely 
explanatory with regards to their functional relevance. From the literature, it has 
been extensively demonstrated that GLUT4 is the predominant transporter in 
mature cardiomyocytes, and that GLUT1 has a limited functional role. However, 
the activity of different transporters can vary based on a number of factors, 
including cellular localisation and substrate specificity. Therefore in order to gain 
further insight into iPSC-CM physiology, basal and insulin stimulated glucose 
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uptake was measured in the presence of GLUT1 inhibition and also a combination 
of GLUT1 and GLUT4 inhibition. The same measurements were also recorded from 
3T3-L1 adipocytes - a mature highly insulin sensitive (GLUT4 dependent) culture 
line – for comparison. 
In order to investigate the stated aim, the novel drug [N4-[1-(4-cyanobenzyl)-5-
methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-fluoroquinoline-2,4-
dicarboxamide] (BAY-876) was used. This has been characterised to inhibit 
different hexose transporters at different concentrations. Specifically, its IC50 for 
GLUT1 is 2 nM, and IC50 for GLUT4 is 290 nM (Siebeneicher et al., 2016). Therefore, 
concentrations of 20 nM and 2 µM were selected for use in this set of experiments. 
As depicted in Figure 4-4, the response of 3T3-L1 adipocytes to the different 
concentrations of BAY-876 are consistent with what would be predicted from 
mature insulin sensitive cells. Key statistical outcomes are listed in detail in 
Appendix 7.2. More briefly, across 3 independent experiments, a robust and 
reproducible statistically significant (P<0.0001) insulin response was observed 
(Figure 4A). When GLUT1 only was inhibited by 20 nM BAY-876 both basal and 
insulin stimulated glucose uptake values decreased significantly (P<0.01) by 
approximately 25% (Figure 4-4B). However when both GLUT1 and GLUT4 were 
inhibited by 2 µM BAY-876, both basal and insulin stimulated uptake were highly 
significantly reduced further (P<0.0001) to almost no detectable signal (Figure 4-
4B). Most importantly, the cells failed to respond to insulin only when GLUT4 was 
inhibited (Appendix 7.2). This suggests that GLUT4 is the predominant transporter 
in these cells. The stock of BAY-876 was originally prepared in DMSO and then 
serial dilutions were prepared prior to the assay. Therefore to ensure that the 
results obtained were not a product of different DMSO concentrations, basal and 
insulin stimulated glucose uptake was recorded in cells incubated with or without 
DMSO, at a final concentration equal to that of cells exposed to 2 µM BAY-876 i.e. 
the highest concentration used. As can be seen in Figure 4-4C, statistical analysis 
revealed that whilst there was a highly significant effect of insulin upon glucose 
transport (P<0.0001), there was no significant difference between basal or insulin 
stimulated [3H]-2DG uptake in the presence and absence of DMSO (P>0.05). 
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Figure 4-4 The effect of GLUT1 and GLUT4 inhibition on [3H]-2DG uptake in 3T3-L1 
adipocytes 
A: Background corrected basal and insulin stimulated glucose uptake in CPM was assayed 
in fully differentiated 3T3-L1 adipocytes. Cells were serum starved (serum free DMEM) for 4 
hours prior to 20 min stimulation with 860 nM insulin +/- 20 nM or 2 µM BAY-876. Cells were 
incubated with [3H]-2DG for 10 min. Each bar represents the mean (+S.E.M.) of 4 replicate 
samples from one experimental day, with 3 independent experiments performed in total. 
Statistical analysis was performed with a 2-way ANOVA where the identified factors were drug 
treatment and experimental day. The level of significance was set at P=0.05. B: The same data 
from panel A is presented, but this time depicted relative to the average of control basal or 
control insulin, as appropriate. C: Background corrected basal and insulin stimulated glucose 
uptake in CPM was assayed in fully differentiated 3T3-L1 adipocytes. Cells were serum 
starved (serum free DMEM) for 4 hours prior to 20 min stimulation with 860 nM insulin +/- 
0.02% DMSO. Cells were incubated with [3H]-2DG for 10 min. Data shown is 4 replicate 
samples for each condition and mean +/- S.E.M. Statistical analysis was performed with a 2-
way ANOVA where the identified factors were DMSO treatment and insulin stimulation. The 
level of significance was set at P=0.05. *** indicates P<0.0001. 
As depicted in Figure 4-5, the response of iPSC-CM to BAY-876 was notably 
different. As has been well established, and is exemplified in Figure 4-5B, iPSC-
CM do not robustly or reproducibly respond to insulin with regards to [3H]-2DG 
uptake. Therefore the effect of 20 nM and 2 µM BAY-876 on basal [3H]-2DG uptake 
only is shown across 3 independent experiments (Figure 4-5A). Statistical analysis 
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revealed that 20 nM BAY-876 significantly (P<0.0001) reduced uptake compared 
to control, however increasing the concentration to 2 µM had no additional effect 
(P>0.05). There was a significant (P<0.0001) interaction effect between 
experimental day and BAY-876 incubation, suggesting that the extent of the 
inhibition of each drug concentration was prone to variation. As before, the drug 
was prepared in DMSO, which has the potential to influence cellular physiology. 
However, in an independent experiment neither insulin nor DMSO (0.02% final 
concentration) significantly (P>0.05) altered [3H]-2DG uptake in iPSC-CM (Figure 
4-5B). 
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Figure 4-5 The effect of GLUT1 and GLUT4 inhibition on [3H]-2DG uptake in iPSC-CM 
A: Background corrected basal [3H]-2DG uptake in CPM was assayed in iPSC-CM incubated 
with 0 / 20 nM / 2 µM BAY-876 for 20 min prior to incubation with the [3H]-2DG for 15 min. Each 
bar represents the mean (+S.E.M) of 3 replicate samples expressed as a percentage of control 
data (0 nM BAY-876) from one experimental day, with 3 independent experiments performed 
in total. Statistical analysis was performed on raw data with a 2-way ANOVA where the 
identified factors were drug treatment and experimental day. The level of significance was set 
at P=0.05. B: Background corrected basal and insulin stimulated [3H]-2DG uptake was 
assayed in iPSC-CM. Cells were incubated with 0 or 860 nM insulin +/- 0.02% DMSO for 20 min 
prior to incubation with [3H]-2DG for 15 min. Data shown is mean of 3 replicate samples 
(+S.E.M.) for each condition. Statistical analysis was performed with a 2-way ANOVA where 
the identified factors were DMSO treatment and insulin stimulation. The level of significance 
was set at P=0.05.  
4.2.2 The effect of maturation medium upon GLUT1 and GLUT4 
protein expression in iPSC-CM 
After initial characterisation of the role of GLUT1 and GLUT4 in iPSC-CM, 
interventions were designed in an attempt to mature the cells. The first approach 
was based upon the MM conditioning approach that was originally devised by 
Drawnel et al., (2014) and was explained in section 4.1.4. The fundamental 
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principle is that forcing iPSC-CM to rely upon the same metabolic fuel (fatty acids) 
that primary cardiomyocytes utilise in vivo could stimulate maturation. Initial 
attempts to enhance insulin stimulated glucose uptake using this protocol (as 
reported in chapter 3) were unsuccessful and indicated that it was toxic to the 
cells. Therefore a range of 8 MM conditions were implemented, as outlined in 
Table 4-2. The overarching principle remained the same, however in addition to 
fatty acids cells were cultured in medium containing a combination of a range of 
insulin concentrations and either 0 or 1 g/L glucose. 1 g/L glucose is equivalent 
to approximately 5.5 mM, which is within the healthy circulating range for 
humans. However, for most cultured cells glucose concentration in medium is 
usually 4.5 g/L, so in this context it is considered ‘low’ glucose. Note that 
condition 1 (MM1) is an exact replication of the originally suggested formula.  Cells 
were cultured in their respective conditions for either 4 or 11 days. Interventions 
were not initiated prior to 48-72 hours after collection from liquid nitrogen storage 
in order to allow sufficient recovery time, therefore cell lysates were generated 
1 or 2 weeks post-plating, as indicated. 
  
 144 
 
Condition Glucose 
Concentration  
Serum 
content 
Insulin 
concentration 
Additional 
components 
MM1 0 mM 1x ITS 
supplement 
860 nM 10 mM HEPES, 2 mM 
Carnitine, 5 mM 
Creatine, 5 mM 
Taurine, 1x NEAA, 1x 
linoleic-oleic acid  
MM2 5.5 mM 1x ITS 
supplement 
860 nM Same as MM1 
MM3 0 mM 10% (v/v) 
FBS 
172 nM Same as MM1 
MM4 5.5 mM 10% (v/v) 
FBS 
172 nM Same as MM1 
MM5 0 mM 10% (v/v) 
FBS 
17.2 nM Same as MM1 
MM6 5.5 mM 10% (v/v) 
FBS 
17.2 nM Same as MM1 
MM7 0 mM 10% (v/v) 
FBS 
0 nM Same as MM1 
MM8 5.5 mM 10% (v/v) 
FBS 
0 nM Same as MM1 
Table 4-2 Details of maturation medium conditions 
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As depicted in Figure 4-6A, the response of iPSC-CM to the different MM conditions 
over 4 days was varied. Quantification across 3 independent experiments revealed 
that there was a statistically significant near 2-fold increase (P<0.05) in GLUT4 
expression (normalised to GAPDH) relative to control in response to MM conditions 
3 and 5, and in general there was a larger response to conditions where no glucose 
was present (conditions with odd numbers). After 11 days of MM conditioning (14 
days post-plating) there was a notable loss of cells in multiple conditions, as 
reflected by differences in GAPDH expression - which was used to indicate total 
protein - despite an equal total loading volume across conditions (Figure 4-6C). At 
this time point it again appeared as though in general conditions with no glucose 
resulted in greater GLUT4 expression than those with low glucose, however no 
fold difference was found to be statistically significant compared to control for 
any condition (P>0.05). 
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Figure 4-6 The effect of maturation medium conditioning upon iPSC-CM GLUT4 expression 
Representative immunoblots depicting GLUT4 and GAPDH expression in iPSC-CM 
maintained for 4 (6A) or 11 (6C) days in a range of ‘maturation medium’ conditions. 
Densitometry was performed and quantification is shown as mean fold difference in GLUT4 
expression normalised to GAPDH (+S.E.M) relative to control cells, across 3 independent 
experiments for each time point (6B and 6D). Statistical analysis was performed with a 2-way 
ANOVA, where the identified factors were experimental day and maturation medium 
conditioning. The level of significance was set at P=0.05. * denotes P<0.05. 
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In contrast to GLUT4, GLUT1 expression responded very clearly to MM conditioning 
regardless of whether cells were incubated for 4 or 11 days (Figure 4-7A and 4-
7C). Across 3 independent experiments statistical analysis confirmed that 
conditions 3 and 5 significantly (P<0.05) increased GLUT1 expression above control 
cells at both time points, whereas condition 7 significantly (P<0.05) increased 
expression after 4 days only. No condition containing 1 g/L glucose significantly 
(P>0.05) increased expression above control levels at any point. 
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Figure 4-7 The effect of maturation medium conditioning upon iPSC-CM GLUT1 expression 
Representative immunoblots depicting GLUT1 and GAPDH expression in iPSC-CM 
maintained for 4 (6A) or 11 (6C) days in a range of ‘maturation medium’ conditions. 
Densitometry was performed and quantification is shown as mean fold difference in GLUT1 
expression normalised to GAPDH (+S.E.M) relative to control cells, across 3 independent 
experiments for each time point (6B and 6D). Statistical analysis was performed with a 2-way 
ANOVA, where the identified factors were experimental day and maturation medium 
conditioning. The level of significance was set at P=0.05. * denotes P<0.05. ** denotes P<0.01. 
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Based upon the response of iPSC-CM (Axiogenesis) to MM conditioning, it was 
concluded that these cells did not tolerate exposure to fatty acids and/or a lack 
of glucose particularly well. Prior MM interventions in the literature had utilised 
iPSC-CM from a different company (CDI). Therefore these measurements were 
repeated with CDI iPSC-CM to assess if these cells from an alternative source would 
respond differently. It was not possible to perform numerous replicates suitable 
for quantification and statistical analysis, however the images displayed in Figure 
4-8 indicate a similar response to the MM conditions as was observed from 
Axiogenesis iPSC-CM. In particular, GLUT1 expression was increased notably in 
conditions where no glucose was present in the medium (conditions 1/3/5/7). 
   
Figure 4-8 The effect of maturation medium conditioning upon CDI iPSC-CM 
Representative immunoblots depicting GLUT1 and GAPDH expression (A) or GLUT4 and 
GAPDH expression (B) in iPSC-CM maintained for 4 (A) or 11 (B) days in a range of ‘maturation 
medium’ conditions. 
Data from 2 separate commercial sources of iPSC-CM indicated that switching their 
primary metabolic fuel from glucose to fatty acids was not sufficient to induce 
metabolic maturation, and indeed it was accompanied by a degree of toxicity with 
longer incubation periods. It was considered possible that iPSC-CM do not possess 
the basic metabolic machinery required to transport and metabolise fatty acids. 
Therefore the expression of the fatty acid transporter CD36 and the mitochondrial 
electron transport chain complexes was assessed in iPSC-CM. Whilst not the only 
proteins with a rate limiting action in fatty acid metabolism, they are essential 
components. When compared with 3T3-L1 adipocytes and HEK 293 cells, it is clear 
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that iPSC-CM express at least 4 out of the 5 mitochondrial complexes required to 
complete the last step of oxidative metabolism (Figure 4-9B). The expression of 
complex I could not be assessed due to its low molecular weight. The expression 
of complex III appeared very weak in comparison to the other complexes, but this 
was also true for the other lysates assessed. In contrast, the expression of CD36 
was undetectable in iPSC-CM lysate, whereas it is abundantly expressed in lysates 
from primary adult cardiomyocytes of murine or human origin (Figure 4-9A). 
 
Figure 4-9 CD36 and OXPHOS expression in iPSC-CM 
Protein lysates were generated from iPSC-CM, primary mouse cardiomyocytes, primary 
human cardiomyocytes, 3T3-L1 adipocytes, and HEK 293 cells. A volume of lysate adjudged 
to give an equal amount of protein between samples (approximately 20 µg) was loaded for 
each sample as necessary into a polyacrylamide gel and subjected to SDS-PAGE and 
immunoblotting, assessing the expression of CD36 (A) or the mitochondrial electron 
transport complexes (OXPHOS) (B). GAPDH was also assessed to act as an indicator of 
relative loading. Lines indicate that the blot has been cropped for presentation purposes, but 
no raw data was altered between segments. 
As introduced, it has previously been reported that both the age of iPSC-CM and 
the physical characteristics of their culture conditions can have a strong influence 
over maturation. Therefore, to conclude this section of work, the expression of 
GLUT1 and GLUT4 was compared between iPSC-CM (from Axiogenesis) that had 
been maintained in normal manufacturer’s maintenance medium for either 1 or 2 
weeks post-plating. Additionally, cells were plated and maintained for 1 week on 
either a 12 or 24 well plate format. 
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As reflected in differences in GAPDH signal in Figures 4-10A and 4-10B, the method 
of lysate generation between conditions meant that different volumes of protein 
were loaded. However, across 2 independent experiments, quantification of 
GLUT1 and GLUT4 expression normalised to GAPDH provided no evidence of 
maturation. If anything, GLUT1 expression in iPSC-CM may slightly increase when 
culture conditions out with the manufacturers recommendations are implemented 
(96-well plate for 1 week), which could be indicative of a stress response. 
Furthermore, no conditions were even close to approaching the levels of GLUT4 
expression recorded from primary adult mouse cardiomyocytes (Figures 4-10C and 
4-10D). 
 
Figure 4-10 GLUT1 and GLUT4 expression in iPSC-CM maintained for different lengths of 
time and on different multi-well plates 
Protein lysates were generated from iPSC-CM that were maintained in Cor4U medium for 1 
week in either a 12, 24, or 96-well plate, or for 2 weeks on a 96-well plate. 20 µL lysate was 
loaded for each sample into a polyacrylamide gel and subjected to SDS-PAGE and 
immunoblotting, probing for the expression of GLUT4 or GLUT1 and GAPDH (loading 
control). Representative images are shown in panels A and B. 2 biologically independent 
experiments were performed and quantification is shown in panels C and D, where values are 
shown relative to the signal in lysates from cells cultured on a 96-well plate for 1 week. Each 
bar represents the value obtained from one immunoblot. Approximately 20 µg primary mouse 
cardiomyocyte lysate was also loaded and quantified for comparison. 
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4.2.3 The effect of triiodothyronine conditioning upon GLUT4 
protein expression in iPSC-CM 
Evidence has been outlined that implicates the thyroid hormone T3 as having a 
vital role in inducing GLUT4 expression during cardiac development in vivo. 
Therefore the effect of incubating iPSC-CM with T3 for 4 days after an initial 
minimum 3 day recovery period post-plating was assessed. It was determined that 
4 concentrations would be used, which covered a range of both physiologically 
relevant values and recommendations based upon relevant literature. Figure 4-
11A shows a representative immunoblot probing for GLUT4 expression in lysates 
from iPSC-CM that have been maintained in normal Cor4U medium supplemented 
with T3. This experiment was performed in triplicate, and quantification revealed 
that there was no significant (P<0.05) difference in GLUT4 expression (normalised 
to GAPDH to control for protein loading) between any experimental group and 
control cells, which were maintained in normal Cor4U medium only.  
 
Figure 4-11 The effect of T3 upon iPSC-CM GLUT4 expression 
A: Axiogenesis iPSC-CM were plated and maintained for 3 days before subsequent addition 
of T3 (0-13.5 nM) to the medium for a further 4 days. Lysates were then generated and 
subjected to SDS-PAGE and immunoblotting in order to assess the expression of GLUT4 and 
GAPDH. Depicted is one representative immunoblot. This experiment was performed with 3 
biologically independent repeats. B: Quantification of fold difference in GLUT4 expression 
(normalised to GAPDH) relative to control cells (0 nM T3). Values displayed are mean (+S.E.M.) 
across 3 independent experiments. Statistical analysis was performed with a 1 way ANOVA, 
where the level of significance was set at P=0.05. 
4.2.4 Transfection of iPSC-CM 
After initial attempts to increase iPSC-CM GLUT4 protein expression had limited 
success, more direct methods were developed. In order to facilitate this a 
commercially produced pcDNA3.1(+)-GLUT4 DNA plasmid containing the GLUT4 
gene sequence was purchased from GenScript. The ultimate aim was to optimise 
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a protocol that facilitated overexpression of GLUT4 protein in iPSC-CM via 
Lipofectamine 2000 mediated transfection. First of all, in order to assess that the 
plasmid was indeed capable of producing GLUT4 protein, it was transfected into 
HeLa cells.  
Figure 4-12A depicts GLUT4 expression in lysates generated from HeLa cells that 
were incubated with a range of volumes of Lipofectamine 2000 and 2.5 µg of 
pcDNA3.1(+)-GLUT4 plasmid DNA per well of a 6-well plate, in addition to lysates 
from untransfected HeLas and also 3T3-L1 adipocytes to act as a positive control. 
GLUT4 protein was detected at 45-55 kDa as anticipated, in addition to a range of 
smaller molecular weight precursor molecules ranging from approximately 30-45 
kDa. HeLa cell lysates were generated via an identical protocol and 30 µL of each 
sample was loaded into the gel. The diminishing GAPDH signal indicates that 
higher volumes of Lipofectamine 2000 may have been toxic. 
 
Figure 4-12 Transfection of HeLa cells with pcDNA3.1(+)-GLUT4 plasmid 
HeLa cells were plated into wells of a 6-well plate and maintained until 90% confluence. Cells 
were then transfected according to the manufacturer’s protocol, as described in methods 
section 2.5.3. Lysates were generated and 30 µL of each sample was subjected to SDS-PAGE 
and immunoblotting in order to assess the expression of GLUT4 and GAPDH (loading 
control). 2 different amounts of 3T3-L1 adipocyte lysate were also loaded in order to act as a 
positive control. 
After initial insight from HeLa cells, it was decided to proceed into iPSC-CM based 
experiments. To begin with, the manufacturer’s protocol was applied without 
modification. Therefore, similar to as just described with the HeLa cells, iPSC-CM 
were maintained for 3 days in normal maintenance medium plus a suggested range 
of volumes of Lipofectamine 2000 and 100 ng of plasmid DNA per well of a 96-well 
plate. Cells were initially incubated for 3 days after plating in normal medium to 
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allow recovery from liquid nitrogen storage. As depicted in Figure 4-13, this 
produced an approximate 2-fold overexpression of GLUT4 protein in iPSC-CM 
exposed to the higher volumes of Lipofectamine 2000, relative to control cells. 
This immunoblot was replicated, with highly similar findings (data not shown).     
 
Figure 4-13 Transfection of iPSC-CM with pcDNA3.1(+)-GLUT4 plasmid 
iPSC-CM were plated at 35,000 cells per well of a 96-well plate and maintained in standard 
Cor.4U medium for 3 days. Thereafter cells were transfected according to the manufacturer’s 
protocol, as described in methods section 2.5.3. The final volume of Lipofectamine 2000 
added to each well is indicated on the immunoblot, and in all cases the final amount of DNA 
per well was 100 ng. 3 days later lysates were generated and 20 µL of each sample was 
subjected to SDS-PAGE and immunoblotting in order to assess the expression of GLUT4 and 
GAPDH (loading control) (A). Quantification of the immunoblot was performed via 
densitometry and shown as the fold difference in GLUT4 expression normalised to GAPDH, 
relative to the average of control values (B).  
The first attempt at increasing iPSC-CM GLUT4 protein expression provided 
confidence that this technique had the potential to realistically enhance GLUT4 
content at least 3-fold to approximate levels recorded in 3T3-L1 adipocytes (Table 
4-1). However, this would require further optimisation of the transfection protocol 
to meet the specific requirements of iPSC-CM. Several variables were altered 
individually over consecutive experiments, most notably the final volume of 
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Lipofectamine 2000 and plasmid DNA added per well, how long cells were 
incubated with the DNA post transfection, and at what point the initial media 
change post transfection occurred. The aim was to identify a protocol that 
maximally increased cellular GLUT4 content, but minimised any loss of cells by 
limiting the inevitable degree of toxicity associated with Lipofectamine and the 
overexpression of exogenous DNA. As depicted in Figures 4-14A and 4-14B, 
increasing the duration post-transfection for which cells were maintained until 
being harvested for lysates by a further 24 hours (96 hours total) appeared to 
enhance the increase in iPSC-CM GLUT4 expression to approximately 4 fold. 
Furthermore, subsequently also performing a media change after approximately 7 
(rather than minimum 24) hours after initial transfection (and therefore reducing 
total exposure to Lipofectamine 2000) appeared to enhance cell survival as 
indicated by GAPDH expression, but still maintained an approximate 3-fold 
overexpression of GLUT4 protein (Figures 4-14 C and 4-14D). In these experiments 
a final volume of 0.4 or 0.5 µL Lipofectamine 2000 and 100 ng DNA per well as 
originally recommended was still utilised because it was found that increasing 
Lipofectamine volume further was ineffective, and increasing the volume of DNA 
did produce further increases in GLUT4 content when normalised to GAPDH, but 
also induced an unacceptable increase in the toxicity of the intervention (data not 
shown). 
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Figure 4-14 Optimisation of iPSC-CM transfection protocol 
A&C: Immunoblots depicting GLUT4 and GAPDH expression in transfected and control iPSC-
CM. Manufacturer’s recommended protocol as described in methods sections 2.5.3. was 
adapted by increasing the time between transfection and generation of lysates from 72 hours 
to 96 hours (A) and then by also decreasing the time between transfection and the initial 
medium change from minimum 24 hours to 7 hours (C). B&D: Quantification of the 
immunoblots depicted in panel A and C was performed via densitometry and is displayed as 
GLUT4 expression normalised to GAPDH, relative to control.  
After this initial optimisation period a protocol was established that elicited a 3-
4 fold increase in GLUT4 content in iPSC-CM. This was still well short of the levels 
recorded from mature primary cardiomyocytes, however was deemed sufficient 
to warrant investigation into any subsequent impact on glucose transport. 
Therefore 3 independent experiments were performed, assessing [3H]-2DG 
transport in transfected and control iPSC-CM. In each case, a sample of cells was 
also harvested for lysate and probed for GLUT4 expression in order to ensure that 
the transfection was successful. A representative image (Figure 4-15A) and 
quantification (Figure 4-15B) of one of these immunoblots shows that – in 
conjunction with Figures 4-14 and 4-15 – that final volumes of 0.5 µL 
Lipofectamine 2000 and 100 ng plasmid DNA was most effective at increasing iPSC-
CM GLUT4 expression. Therefore this condition was taken forwards and performed 
for all transport experiments and is what is referred to when ‘transfected’ cells 
are discussed. Treatment with Lipofectamine 2000 only did increase GLUT4 
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expression slightly, but was still well short of the values obtained in fully 
transfected cells. Later experiments with a final volume of 0.5 µL Lipofectamine 
2000 per well only confirmed the increase in GLUT4 expression is predominantly 
due to the presence of plasmid DNA (Figure 4-17). Regardless, GLUT4 expression 
was confirmed to be increased in all samples accompanying [3H]-2DG uptake 
assays. 
 
Figure 4-15 The effect of Lipofectamine 2000 and plasmid DNA upon iPSC-CM GLUT4 
expression 
A: Representative immunoblot displaying GLUT4 and GAPDH expression in lysates 
generated from transfected and control iPSC-CM. Cells were plated at 35,000 cells per well of 
a 96-well plate and maintained in standard Cor4U medium for 3 days. Thereafter identified 
cells were transfected with a final volume of Lipofectamine 2000 of 0.4 µL per well +/- 100 ng 
GLUT4 plasmid DNA or 0.5 µL + 100 ng GLUT4 plasmid DNA. Lysates were generated 96 hours 
after initial transfection and 15 or 30 µL of each sample was assessed. 3T3-L1 adipocyte lysate 
was also loaded to act as positive control. B: Quantification of immunoblot. Values are 
expressed as fold change in GLUT4 normalised to GAPDH, relative to the appropriate control 
(cells that were not exposed to Lipofectamine or DNA). 
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Figures 4-16A and 4-16B depict basal [3H]-2DG uptake in control and transfected 
iPSC-CM. In one experiment control cells were incubated with Lipofectamine only, 
and in the other two control cells were exposed to neither Lipofectamine nor 
GLUT4 plasmid DNA. It is important to note that a correction factor was applied 
to raw data from transfected cells in order to account for the loss of cells observed 
with the intervention. This was generated by quantifying the fold change in GAPDH 
for the same volume of total lysate via immunoblotting. Across the 3 independent 
experiments there was a clear approximate 2-fold increase in basal uptake in 
transfected cells, and indeed statistical analysis confirmed a highly significant 
effect of transfection upon [3H]-2DG uptake (P<0.0001).  
In the first instance only basal transport is displayed in order to provide a clear 
picture of the effect of GLUT4 transfection, because no insulin response was 
recorded from either basal or transfected iPSC-CM during these experiments (data 
not shown). In one of the experiments, it was assessed if any of a range of drugs 
that are cited in the literature as being capable of increasing cellular glucose 
transport could stimulate an increase in iPSC-CM glucose uptake. However, as 
depicted in Figure 4-16 C, no significant (P<0.05) increase in [3H]-2DG uptake was 
recorded in either control or transfected iPSC-CM in response to AICAR, Ionomycin, 
or indeed insulin. In fact, as can be inferred, [3H]-2DG uptake was actually 
significantly (P<0.05) decreased in several conditions. 
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Figure 4-16 [3H]-2DG uptake in control and transfected iPSC-CM 
A: Background corrected basal [3H]-2DG uptake in CPM was assayed in control and 
transfected iPSC-CM incubated with [3H]-2DG for 15 min. Each bar represents the mean 
(+S.E.M) of 3 replicate samples from one experimental day, with 3 independent experiments 
performed in total. Statistical analysis was performed with a 2-way ANOVA where the 
identified factors were transfection and experimental day. The level of significance was set at 
P=0.05. B: The data presented in panel A was converted to the fold difference in [3H]-2DG 
uptake in transfected iPSC-CM from values obtained in control cells. C: [3H]-2DG uptake was 
recorded in control and transfected iPSC-CM +/- stimulation with 860 nM insulin (45 min), 2 
mM AICAR (45 min), or 0.5-5 µM Ionomycin (15 min) prior to incubation with [3H]-2DG for 15 
min. Data is presented as fold difference in uptake relative to basal values, and depicts mean 
of 3 replicate samples (+S.E.M.) for each condition. Statistical analysis was performed with a 
2-way ANOVA where the identified factors were drug treatment and transfection. The level of 
significance was set at P=0.05. In all cases, ‘transfected’ cells refers to iPSC-CM 4 days after 
initial incubation with 0.5 µL lipofectamine and 100 ng GLUT4 plasmid DNA per well of a 96-
well plate, whereas control cells were incubated with 0 or 0.4 µL lipofectamine only.  
Despite achieving a reliable 3-4 fold increase in iPSC-CM GLUT4 expression, this 
transfection based intervention only increased basal glucose uptake, and did not 
impact the lack of capacity of these cells to exhibit an insulin stimulated glucose 
uptake response. It was considered possible that GLUT4 expression had simply not 
been increased enough to achieve this intended goal. Therefore, before 
investigating alternative techniques, some final adaptations were made to this 
protocol. 
First of all it was assessed if transfection reagents other than Lipofectamine 2000 
were capable of supporting a more robust overexpression of GLUT4. As depicted 
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in Figure 4-17A, lysates from iPSC-CM cultured in Cor.4U maintenance medium 
only, Cor.4U supplemented with one of Lipofectamine 2000, FuGENE HD, or 
Transit TKO transfection reagents, or Cor.4U supplemented with one of the 
transfection reagents in addition to pcDNA3.1(+)-GLUT4 plasmid DNA, were 
probed for GLUT4 and GAPDH expression. As displayed in Figure 4-17B, 
quantification suggests that exposure to any of the transfection reagents alone 
did not alter GLUT4 expression. However, Transit TKO was able to facilitate over 
expression of the GLUT4 DNA plasmid to achieve an increase in GLUT4 protein of 
approximately 2.5 fold, which was similar in margin to that achieved with 
Lipofectamine 2000. FuGENE HD was less effective. A technical replicate of this 
immunoblot was performed with similar outcome, suggesting that Lipofectamine 
2000 was indeed a suitable choice of transfection reagent. This data was 
supported by performing a similar experiment in HeLa cells. As can be seen in 
Figure 4-18, the overexpression of GLUT4 was much weaker when transfected with 
FuGENE HD in comparison to Lipofectamine 2000.  
 
Figure 4-17 iPSC-CM transfection efficiency with different transfection reagents 
A: Representative immunoblot of GLUT4 and GAPDH expression in lysates from iPSC-CM 
cultured in Cor.4U maintenance medium supplemented with one of 3 transfection reagents 
+/- GLUT4 plasmid DNA, or controls. For full transfection protocol details see methods 
section 2.5.3. Lysates were generated 72 hours post transfection, and 35 µL was loaded for 
each sample. B: Quantification of immunoblot. Values are expressed as fold change in GLUT4 
normalised to GAPDH, relative to the appropriate control. 
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Figure 4-18 Comparison of transfection reagents in HeLa cells 
Representative immunoblot of GLUT4 and GAPDH expression in lysates from HeLa cells 
cultured in maintenance medium supplemented with either Lipofectamine 2000 or FuGENE 
HD transfection reagents +/- 1250 ng DNA, or completely untreated cells (controls). Cells were 
maintained on a 12-well plate format. For full transfection protocol details see methods 
section 2.5.3. Lysates were generated 48 hours post transfection, and 40 µL was loaded for 
each sample.  
Finally, from experience with HeLa cells, it was considered possible that 
transfection efficiency and/or the ability to detect transfection could be improved 
by performing the protocol on a larger scale format than a 96-well plate, due to 
an increased volume of cells and therefore also an increased volume of GLUT4 
protein being produced. Therefore, transfection of iPSC-CM was performed on a 
12-well plate format. Although extensive optimisation of the original 
manufacturers protocol was not performed as for on a 96-well plate scale, two 
independent experiments revealed only a similar 3-fold increase in GLUT4 
expression in transfected iPSC-CM (Figure 4-19).  
  
 162 
 
 
Figure 4-19 iPSC-CM transfection efficiency on a 12-well plate format 
A: Representative immunoblot of GLUT4 and GAPDH expression in lysates from iPSC-CM 
cultured in Cor.4U maintenance medium supplemented with Lipofectamine 2000 +/- 1250 ng 
DNA, or untreated cells (control). Cells were maintained on a 12-well plate format. For full 
transfection protocol details see methods section 2.5.3. Lysates were generated 72 hours 
post transfection, and an appropriate amount of each sample was loaded to achieve loading 
of approximately equal amounts of total lysate (10-20 µL). 3T3-L1 adipocyte lysate (~10 µL) 
was also loaded to act as a positive control and reference B: Quantification of 2 independent 
immunoblots. Values are expressed as mean (+S.D.) fold change in GLUT4 normalised to 
GAPDH, relative to control. 
4.2.5 Generation of novel pCDH-GLUT4 lentiviral vector  
Transfection based approaches of the pcDNA3.1(+)-GLUT4 plasmid had yielded a 
promising increase in GLUT4 protein in iPSC-CM, however it was decided that 
pursuing a further increase in the level of overexpression towards values recorded 
from primary cardiomyocytes was the most appropriate next step. Therefore it 
was decided to move towards development of a lentivirus capable of 
overexpressing GLUT4. In order to achieve this, the GLUT4 gene sequence from 
the commercially obtained plasmid would have to be subcloned into a suitable 
lentiviral vector. Prior to attempting this, it was determined if iPSC-CM are indeed 
suitable candidates for lentiviral infection. In the lab there were already 2 active 
lentiviruses in use, one that was produced in-house by Dr. Mohammed Al-Tobi that 
targeted the overexpression of the t-SNARE Syntaxin 4, and another commercially 
obtained virus that targeted the overexpression of GLUT4-GFP (based upon the 
PCDH-CMV-MCS-EF1-HA-GLUT4-GFP plasmid generated by Silke Machauer). 
Figure 4-20 depicts Syntaxin 4 expression in the lysates of Sx4 lentiviral infected 
iPSC-CM, uninfected controls, and 3T3-L1 adipocytes/primary mouse 
cardiomyocytes (positive controls). No Syntaxin 4 signal was obtained from 
uninfected cells, but a highly robust signal was obtained from cells infected with 
fully concentrated virus for 4 and in particular 24 hours. This immunoblot was 
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replicated in order to confirm findings. Similarly, Figure 4-21 displays confocal 
images of iPSC-CM infected with the GLUT4-GFP lentivirus and negative controls. 
The overexpression of this transporter tagged with the fluorescent reporter 
protein is clear, and is supported by corresponding immunoblots of control iPSC-
CM lysates and lysates from cells infected with a range of concentrations of the 
lentivirus. Whether probing with a GLUT4 or GFP primary antibody, a 
characteristic smear at approximately 75 kDa was detected in infected samples 
only. This GLUT4 signal appears higher than the native protein due to being tagged 
with GFP, which is approximately 27 kDa. 
 
Figure 4-20 Lentivirus mediated overexpression of Syntaxin 4 in iPSC-CM 
Representative immunoblot depicting Syntaxin 4 and GAPDH (loading control) expression in 
lysates from iPSC-CM incubated with concentrated (1x) or 1:10 diluted (0.1x) lentivirus 
designed to overexpress Syntaxin 4. iPSC-CM were incubated with the virus for 4 or 24 hours 
with or without 8 µg/mL polybrene as indicated, and lysates were generated 72 hours post 
infection. For full protocol see methods section 2.5.5. Uninfected iPSC-CM, 3T3-L1 
adipoyctes, and primary mouse (Ms) lysates were also probed to act as positive and negative 
controls. For iPSC-CM samples, an equal amount of lysate was loaded across all samples (20 
µL). 
 
Figure 4-21 Confocal image of lentiviral infected GLUT4-GFP iPSC-CM 
Representative confocal images depicting control (A) and lentiviral GLUT4-GFP infected 
iPSC-CM (B). Infected cells were incubated with lentivirus at an MOI of 105 for 24 hours, and 
images were recorded a further 72 hours later. Images were obtained with the same excitation 
intensity settings. For full protocol see methods section 2.5.5. 
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Figure 4-22 Immunoblots of GLUT4-GFP lentiviral infected iPSC-CM 
iPSC-CM were incubated with GLUT4-GFP lentivirus for 24 hours, and then 72 hours later 
lysates were generated and probed via immunoblotting with antibodies for GLUT4 (upper 
blot), GAPDH (middle blot), or GFP (lower blot). 3 different concentrations of lentivirus were 
used, where 1x corresponds to an MOI of 35. For full protocol see methods section 2.5.5. 
Lysates from uninfected control iPSC-CM (con) were also loaded. For all samples an equal 
amount of lysate was loaded (20 µL). 
Initial data confirmed that the expression of exogenous DNA in iPSC-CM is possible 
using this lentivirus based approach. As mentioned, in order to generate a 
lentivirus targeting the overexpression of GLUT4, the first step was to sub-clone 
the GLUT4 gene sequence from the commercially purchased pcDNA3.1(+)-GLUT4 
plasmid into a specialised backbone vector suitable for the development of 
lentivirus, such as pCDH. Therefore, as depicted in Figure 4-23A, after extensive 
optimisation a protocol was established that facilitated highly efficient double 
restriction enzyme digest of the pcDNA3.1(+)-GLUT4 and pCDH-CMV-MCS-EF1-HA-
GLUT4-GFP plasmids in order to excise the GLUT4 and GLUT4-GFP gene sequences 
respectively. The GLUT4-GFP fragment should be approximately 2500 bp, whereas 
the GLUT4 fragment should be approximately 1500 bp. The untagged GLUT4 
sequence was then ligated into the open pCDH backbone to generate a novel 
plasmid - pCDH-CMV-MCS-EF1-GLUT4. In order to confirm that the intended 
products had indeed been successfully ligated, this newly formed plasmid was 
digested according to the original protocol (detailed in section 2.5.4.) and the 
molecular size of the generated fragments were compared to the original 
plasmids. As displayed in Figure 4-23B, after digestion the backbone of this new 
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plasmid was identical in size to that of the original pCDH-CMV-MCS-EF1-HA-GLUT4-
GFP plasmid and the smaller ‘insert’ fragment cleaved was identical in size to the 
fragment from the original pcDNA3.1(+)-GLUT4 plasmid.       
 
Figure 4-23 Generation of pCDH-CMV-MCS-EF1-GLUT4 DNA plasmid 
A: Uncut and double digested (DD) pCDH and GLUT4 plasmids. B: Uncut and DD pCDH, 
GLUT4, and newly generated pCDH-GLUT4 (2 samples from distinct original colonies) 
plasmids. This image has been cropped for presentation purposes, but no raw data was 
altered. For digestion and ligation protocols see section 2.5.4. pCDH = pCDH-CMV-MCS-EF1-
HA-GLUT4-GFP. GLUT4 = pcDNA3.1(+)-GLUT4. pCDH-GLUT4 = pCDH-CMV-MCS-EF1-GLUT4. 
Finally, in order to complete preparation for future development of the intended 
lentivirus, it was important to confirm that the newly developed plasmid was still 
capable of inducing target cells to produce GLUT4 protein. Therefore, the pCDH-
CMV-MCS-EF1-GLUT4 plasmid was transformed into NEB 5-alpha competent E.coli, 
amplified in volume, and then prepped in order to isolate a volume of DNA suitable 
for transfection of mammalian cells in culture. Accordingly, as depicted in Figure 
4-24, despite the presence of nonspecific bands within this immunoblot, only 
lysates from HeLa cells transfected with this plasmid contained clearly detectable 
levels of GLUT4 protein as indicated by the characteristic smear around 45 kDa, 
which was not observed in lysates from untransfected control cells.  
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Figure 4-24 Transfection of HeLa cells with pCDH-GLUT4 plasmid 
HeLa cells were plated into wells of a 12-well plate and maintained until 90% confluence. Cells 
were then transfected according to the manufacturer’s protocol, as described in methods 
section 2.5.3. 4 days later lysates were generated and 35 µL of each sample was subjected to 
SDS-PAGE and immunoblotting in order to assess the expression of GLUT4 and GAPDH 
(loading control). Final volumes of Lipofectamine 2000 added per well are indicated. In all 
cases where DNA was also present, it was at a final volume of 1500 ng. 
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4.3 Discussion 
4.3.1 GLUT1 is the predominant glucose transporter in iPSC-CM 
The data presented in Figures 4-1 and 4-2 provides a clear depiction of the 
difference in glucose transporter isoform expression between iPSC-CM and primary 
insulin sensitive cells. This resolutely consolidates the general conclusions from 
chapter 3 and provides a target to aim for in terms of increasing iPSC-CM GLUT4 
expression. An estimated 3-fold increase would attain levels recorded in insulin 
sensitive 3T3-L1 adipocytes, whereas an approximate 9-fold increase would attain 
levels recorded in primary adult mouse cardiomyocytes. Whilst quantification of 
this nature was not performed, previously published immunoblot data from foetal 
and neonatal rats shows clearly that cardiac GLUT1 and GLUT4 are very 
highly/poorly expressed respectively during early development, and that there is 
a rapid switch in relative expression shortly after birth (Castelló et al., 1994). 
Therefore it can be concluded that iPSC-CM exhibit glucose transporter isoform 
expression consistent with foetal physiology. 
In Figure 4-1B it can be noted that 3T3-L1 adipocytes express far more GLUT1 than 
primary mouse cardiomyocytes, despite being generally more sensitive to insulin 
with regards to glucose uptake (Figures 3-3 and 3-4). This could be partly due to 
the use of troglitazone during the 8 day differentiation period of these cells, as it 
has been shown to enhance the pre-adipocyte fibroblast to mature adipocyte 
transition, but also increases GLUT1 expression (Tafuri, 1996). Additionally, 
similar to other cell types, primary adipocytes show elements of dedifferentiation 
after short periods of in vitro culture, as their insulin sensitivity is typically 
decreased and GLUT1 expression is increased (Ruan et al., 2003). Therefore it is 
perhaps of little surprise that a cell culture model of these cells exhibits relatively 
high levels of GLUT1. The observation that iPSC-CM were found to exhibit 
approximately 5-fold higher levels of expression compared to 3T3-L1 adipocytes 
underlines their physiological immaturity, and that the difference recorded 
between them and primary cardiomyocytes is not simply a function of being 
maintained in culture. Quantification of GLUT1 may be of secondary importance 
compared to GLUT4 in the context of this project, however is still crucial for the 
interpretation of any intervention. If GLUT4 were to be increased and GLUT1 also 
increased, then this could be evidence of general glucose transporter upregulation 
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rather than specific metabolic maturation. In contrast, if GLUT1 levels were 
unchanged or even decreased then this would support the conclusion that 
maturation had occurred.  
Similar results utilising lysates from CDI iPSC-CM and a primary human sample 
support the general conclusions from this first section of work, even if it was 
determined that quantification would have been inappropriate. Ideally human 
cardiomyocyte lysates would be implemented as the gold standard reference for 
iPSC-CM in all experiments within this thesis, however this is not possible for 2 
reasons. First of all, the access to human myocardial sections is extremely limited. 
Secondly, the sections that can be obtained are generally from individuals 
suffering from cardiac disease. In this instance, the donor was undergoing cardiac 
transplant due to prior MI and subsequent progression to cardiomyopathy and 
atrial fibrillation. This sample demonstrated the principle that GLUT4 should be 
readily be detected in cardiomyocytes, however may have actually 
underrepresented true human primary GLUT4 expression due to known 
adaptations post-MI. 
In this first set of experiments there were 2 technical limitations that must be 
acknowledged. First of all, quantification of glucose transporter isoforms 
normalised to GAPDH makes the assumption that GAPDH does indeed adequately 
represent total protein loaded, and that the relationship between GAPDH and 
total protein is similar between different cell types. This was tested, as shown in 
Appendix 1. By comparing ponceau (total protein) and GAPDH signals for 2 
different lysates of each relevant cell type it was concluded that it was 
appropriate to use GAPDH as a loading control for 3T3-L1 adipocytes, Axiogenesis 
iPSC-CM, and primary mouse cardiomyocytes only. The alternative identified 
method for quantification was to generate a GLUT signal to copy number standard 
curve from 3T3-L1 adipocytes and from this work out the number of copies in 
samples from cardiomyocyte samples and then adjust for the equivalent number 
of cells loaded. However, this approach would rely upon several assumptions that 
were essentially impossible to test, such as exact plating density, the percentage 
of cells harvested during the lysis process, the exact loading volumes of each 
sample, etc. Therefore whilst not without limitation, it was decided to simply 
compare signals normalised via GAPDH. 
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The second issue with this approach is a general point that is relevant for much of 
this chapter. That is how to perform densitometry when the target proteins appear 
as smears (due to post-translational modifications) rather than clear and distinct 
bands. When drawing a box around the target protein using Image Studio Lite there 
becomes much larger room for human error as determination of where the signal 
truly starts and ends can be far more subjective. There was no way of totally 
eradicating this problem, however the fairly good reproducibility of results across 
technical and biological replicates indicates that quantification was consistent. 
Additionally, in all cases it supports the initial visual interpretation. 
When assessing the estimated glucose transporter isoform expression data in Table 
4-1, it would be extremely surprising if GLUT1 was not the predominant functional 
transporter in iPSC-CM, due to its overwhelmingly dominant expression over 
GLUT4. However, it was still important to assess this. In order to confirm that the 
selected assay worked as intended it was first of all performed with 3T3-L1 
adipocytes. Although minor, the reduction in insulin stimulated glucose uptake in 
response to GLUT1 inhibition was unexpected, and suggests that this transporter 
may have more of a role in insulin stimulated glucose uptake in this cell type than 
previously thought (Figure 4-4). Whilst it would have been preferable to 
selectively inhibit GLUT4 alone, the near absence of any [3H]-2DG uptake detected 
when both GLUT1 and GLUT4 were inhibited confirmed the predominant role that 
GLUT4 plays in regulating glucose uptake in these cells.  
As anticipated, when only GLUT1 was inhibited in iPSC-CM there was a much larger 
percentage drop in [3H]-2DG uptake (Figure 4-5) compared to 3T3-L1 adipocytes. 
When the concentration of BAY-876 was increased to also inhibit GLUT4 there 
appeared to be only a very minor further decrease in recorded uptake and indeed 
this was not found to be significant. This confirms that the low levels of GLUT4 
that are expressed in iPSC-CM are of limited functional relevance. However, 
intriguingly, inhibition of both of these transporters only inhibited total [3H]-2DG 
uptake by 40-50% (Figure 4-5). What is accounting for this residual uptake is 
unclear. Most likely, there may be an additional glucose transporter(s) present in 
iPSC-CM. Primary candidates would be GLUT3 or GLUT8, which have both been 
demonstrated to be expressed in myocardium (Grover-McKay et al., 1999; Aerni-
Flessner et al., 2012). Attempts were made to assess the expression of these 
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transporters – in addition to GLUT10 and GLUT12 – via immunoblotting, but 
unfortunately these were unsuccessful (data not shown).  
4.3.2 Maturation medium and T3 conditioning did not mature 
iPSC-CM 
There is strong evidence from the literature to suggest that altering the primary 
metabolic substrate that fuels iPSC-CM from glucose to fatty acid can induce 
maturation. Therefore this approach was implemented, with the primary 
outcomes being GLUT1 and GLUT4 expression. Consideration of the effect of 4 
days MM conditioning upon GLUT4 expression (Figure 4-6B) suggests that 
maintenance in medium containing no glucose (conditions 1/3/5/7) in general may 
have matured iPSC-CM GLUT4 content, albeit only 2-fold. However, this conclusion 
is rapidly dismissed when observing the effect of the same intervention upon 
GLUT1 expression (Figure 4-7B). This strongly suggests that what actually occurred 
was a general upregulation of glucose transporters in response to sugar 
deprivation. It is logical that a much greater fold increase would occur in GLUT1, 
as we now understand this to be the predominant transporter in these cells.  
As has been noted previously, MM conditioning can be toxic to cells, and this 
proved to be the case once again. In all experiments lysates were generated in an 
identical manner and an equal volume was probed via immunoblotting. As can be 
seen in the signals for iPSC-CM maintained in MM for 11 days (Figures 4-6C and 4-
7C), there is a general decrease in GAPDH signal relative to untreated cells, which 
reflects the visually observable decrease in viable cell number prior to the 
generation of lysates. Given that GAPDH is a metabolic enzyme it could be 
suggested that this change was reflective of a genuine effect. However, if GAPDH 
expression was to respond then based upon the GLUT data it would be expected 
to both be observable after 4 days conditioning and also to increase, not decrease. 
Interestingly, the cells most affected by the apparent toxicity of MM were those 
maintained in conditions that most closely replicated the originally recommended 
formula (MM1 and MM2). Data from CDI iPSC-CM supported the conclusions drawn 
regarding both the lack of specific maturation and toxic effects of the intervention 
beyond 4 days of conditioning (Figure 4-8).  
 171 
 
Another interesting observation from the data presented is that the effects 
recorded after 4 days of MM conditioning appear to decrease in size when cells 
are maintained for a further 7 days. There are several plausible explanations. First 
of all, it could be that after an initial shock response to the change in conditions, 
cells adapt (perhaps via upregulation of other relevant proteins) and glucose 
transporter expression begins to return to normal. Perhaps more likely is that the 
occurrence of cell death as observed is correlated with the degree of initial 
response. Therefore the cells that do not respond as strongly are more likely to 
survive longer in the new medium, and as these lesser or non-responding cells 
become predominant in the population they more strongly influence the overall 
results for each condition. Finally, Figure 4-10 indicates that GLUT1 expression 
may simply increase with time in iPSC-CM. Elevation of control baseline values 
would reduce the fold impact of any intervention.  
It is not explicitly clear why iPSC-CM did not respond more favourably to MM 
conditioning. Whilst prior studies have reported a degree of toxicity with this 
approach, it has also been accompanied by maturation of a range of parameters, 
including metabolic markers such as lactate production and oxygen consumption 
(Drawnel et al., 2014; Correia et al., 2017). Within the present study, it was 
demonstrated that iPSC-CM express the mitochondrial electron transport 
complexes required to complete oxidative metabolism (Figure 4-9). In contrast, 
there was no detectable expression of the fatty acid transporter CD36 (Figure 4-
9). It may well be that other proteins that are essential for fat oxidation are 
lacking from iPSC-CM, however - similar to the role of GLUT4 for glucose - the first 
step of fat metabolism must be to transport it into the cell, and therefore this 
absence of CD36 is an immediate critically limiting factor. In these experiments 
this alone could account for why medium with no or low glucose was not well 
tolerated. Why this intervention was successful in previous work remains 
unexplained. One possible factor could simply be that the differentiation protocol 
of the cells used was different, and that they had the necessary machinery to 
effectively metabolise the fat. However, the fact that similar results were 
obtained with CDI iPSC-CM (Figure 4-8) in this project casts doubt on that 
explanation. A key challenge when adding fatty acid to medium is the 
unintentional lowering of the pH value of the solution. However, this was 
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monitored using indicator strips in order to ensure that pH did not fall below pH 
7. 
There is a general theme within prior studies indicating that culturing iPSC-CM in 
environments that better replicate relevant features of the in vivo environment 
can induce maturation. Accordingly, it was considered possible that rather than 
plating cells on a 96-well plate format, a larger scale environment could facilitate 
the formation of greater groups of functionally coupled cells capable of 
transducing increased contractile forces. As introduced, mechanical loading is an 
important stimulus for the development of the heart (Tulloch et al., 2011), and 
the rhythmic stretch and contraction of the myocardial wall during every cardiac 
cycle will greatly exceed the spontaneous contractile forces of iPSC-CM cultured 
in small groups within a 96-well plate. However, across 2 independent 
experiments iPSC-CM cultured for 1 week on either a 12 or 24 well format did not 
show any clear adaptation with regards to GLUT1 or GLUT4 expression (Figure 4-
10). 
Similarly, there is robust in vivo evidence that the hormone T3 has a critically 
influencing role in switching the relative expression and contribution of cardiac 
GLUT1 and GLUT4 during foetal to perinatal development (Castelló et al., 1994). 
More specific to iPSC-CM, 2 separate papers identified T3 as capable of inducing 
several phenotypic adaptations consistent with maturation (Yang et al., 2014; Lin 
et al., 2017). However, in this project it was found across 3 independent 
experiments that incubation of iPSC-CM with a range of 4 concentrations of T3 did 
not significantly alter GLUT4 expression.  
There are a couple of possible explanations as to why T3 did not have the intended 
effect. Given that the concentrations selected covered previously implemented 
and physiologically relevant values, this variable is unlikely to have been the 
limiting factor. Rather, prior interventions were sustained for 1 week, whereas in 
this study cells were only incubated for 4 days. This time period was selected in 
order to harvest cells at the same time point as other measurements within this 
project, but may have meant cells were exposed for an insufficient period of time. 
Perhaps of more importance however is that in the prior iPSC-CM based studies 
mentioned, the authors differentiated the iPSC-CM themselves and then exposed 
them to T3 almost immediately. Similarly, in vivo manipulation of circulating T3 
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levels had a markedly diminished impact on cardiac GLUT4 protein expression in 
adult compared to foetal or neonatal rats (Castelló et al., 1994). Together this 
indicates that intervening with T3 may be most effective during or immediately 
after the differentiation of iPSC-CM (or any cardiac model), which was not possible 
to achieve in this project due to obtaining the cells commercially. This approach 
provides a highly reliable phenotype, but prevents the opportunity to intervene 
at the earliest stages of their development. 
4.3.3 iPSC-CM can efficiently over express functional GLUT4 
protein via Lipofectamine 2000 mediated transfection of 
plasmid DNA  
Whilst initial attempts to upregulate iPSC-CM GLUT4 protein expression via 
interventions that were based upon simulation of natural stimuli that are 
physiological regulators of this transporter generated interesting insight into these 
approaches, they were ultimately unsuccessful with regards to the experimental 
aims. The problem with isolating stimuli in this manner is that it prevents 
attainment of any cumulative effect of all factors and removes any possible 
interactions between variables. The majority of physiological mechanisms 
underlying significant processes such as maturation of any given variable are not 
simple individual stimulus – response reactions, but rather involve a complicated 
multifactorial network of factors that may each have different molecular targets, 
varying levels of importance at different time points, and perhaps are even 
dependent upon one another. As outlined in the introduction, cardiac 
development is dependent upon at least an interaction of biomechanical, 
hormonal, and metabolic factors. To accurately recapitulate all of these stimuli 
in vitro would be extremely challenging. Even if maturation were achieved via 
manipulation of one variable based upon elicitation of a certain physiological 
response such as increased GLUT4 expression, it could be argued that it is still not 
physiologically relevant. If taking this ‘physiologically representative’ approach, 
both the intervention and outcome must match the in vivo physiology. 
After consideration, it was determined that a more forceful and direct molecular 
approach could be more effective. Rather than prioritising physiologically relevant 
stimuli, the outcome of enhancing iPSC-CM GLUT4 expression became the sole 
focus. To achieve this a DNA plasmid containing the GLUT4 gene was purchased 
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and initially transfected into HeLa cells in order to ensure that it produced 
detectable levels of protein. There was very clear production of protein in 
transfected HeLa cell lysates compared to controls (Figure 4-12), however rather 
than appearing as one distinct smear multiple additional smaller bands were 
detected. It is common for this protein to run at different molecular weights in 
different species or cell types, and in fact it runs slightly lower than anticipated 
in 3T3-L1 adipocytes, as indicated in this immunoblot. Therefore the upper smear 
in HeLa cell lysates was believed to be fully formed GLUT4 protein. HeLas are 
highly amenable to the introduction of exogenous DNA and the subsequent 
overexpression of the relevant protein. As whole cell lysates were generated it is 
believed that the smaller bands observed were precursors to GLUT4 protein, prior 
to addition of post-translational modifications. 
When adapting this protocol for use in iPSC-CM it was not possible to perform 
extensive replicates for every possible combination of the identified key variables 
that could impact transfection efficiency. Therefore, after initial encouragement 
from following the manufacturer’s recommended protocol for a 96-well plate 
format, several logical adjustments were made in order to maximise the over 
expression of GLUT4. In particular, between Figures 4-13 and 4-14 it can be 
appreciated that utilising volumes of Lipofectamine 2000 within the upper 
recommended range and increasing the time between initial transfection and 
generation of lysates were particularly effective. It is logical that – up to a certain 
point – increased volumes of Lipofectamine 2000 will correlate with increased 
GLUT4 protein expression as there is more reagent available to facilitate the 
uptake of the plasmid DNA. However, data from Figures 4-15 and 4-19 suggests 
that Lipofectamine 2000 itself may induce a small increase in GLUT4 content by 
itself, whereby lysates from cells only treated with this transfection reagent 
showed levels elevated above untreated control lysates. If this were a genuine 
effect then there is no obvious physiological mechanism to account for it. It seems 
highly unlikely that there would be a direct maturation effect. Continual 
disruption of the cell membrane by DNA-lipid complexes could perhaps initiate a 
cellular response, but why GLUT4 would be upregulated is unclear. However, this 
observation was not consistent (e.g. Figure 4-17), and in all cases the increase 
observed was still well short of the increase in GLUT4 expression recorded from 
fully transfected iPSC-CM cell lysates. 
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Final optimisation steps were undertaken to not only ensure that the optimal 
protocol with Lipofectamine 2000 was being implemented, but that Lipofectamine 
2000 was indeed the most suitable transfection reagent to use. Data from Figures 
4-(17-19) confirmed that both FuGENE HD and Transit TKO, or Lipofectamine 2000 
on a 12-well plate format, were not capable of exceeding the 3-4 fold 
overexpression of GLUT4 protein achieved in iPSC-CM achieved with 
Lipofectamine 2000 on a 96-well scale. There are other options that have not been 
explored that could be used to facilitate transfection of the plasmid such as 
electroporation, however based on the available evidence it appears a 4-fold 
increase in GLUT4 protein expression may be the limit that can be expected to be 
achieved using this general approach. 
After optimisation of a protocol that facilitates the overexpression of GLUT4 in 
iPSC-CM to levels observed approximately in 3T3-L1 adipocytes, it was anticipated 
that there would be a clear effect on subsequent measurements of [3H]-2DG 
uptake. This proved to be the case, but ultimately only with regards to basal 
transport, which as depicted in Figure 4-16 increased approximately 2-fold in 
transfected cells. The absolute counts in experiment 3 were decreased because a 
reduced number of cells were plated in each well in an attempt to increase 
transfection efficiency, and as was established in chapter 3 plating density has a 
disproportionately strong impact upon [3H]-2DG uptake in iPSC-CM. However, 
when uptake in transfected cells was expressed as a fold difference from control, 
the data was very consistent across replicate experiments.  
In contrast to the clear impact upon basal transport rates, neither insulin (across 
all 3 experiments) nor AICAR or Ionomycin (in the experiment shown in Figure 4-
16C), could stimulate a significant further increase in [3H]-2DG uptake above basal 
values. If adequate GLUT4 is present, then insulin should stimulate an increase in 
uptake via activation of the GLUT4 trafficking pathway detailed in the 
introduction, whereas AICAR and Ionomycin operate via activation of AMPK and 
calcium dependent mechanisms respectively. Given the effect on basal uptake, it 
can be ruled out that the GLUT4 protein being produced is non-functional. One 
possible explanation is that the protein is not being incorporated into GSVs in 
preparation for rapid trafficking to the membrane in response to the relevant 
stimuli applied. Potentially, the new GLUT4 could be being retained permanently 
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intracellularly and/or being immediately trafficked to the membrane, hence the 
increase in basal uptake. Finally, it could be that now the factor limiting insulin 
stimulated GLUT4 trafficking in iPSC-CM has shifted from a lack of GLUT4 protein, 
to somewhere else in the process. There may be other essential trafficking or 
signalling molecules that are also absent. 
4.3.4 iPSC-CM are amenable to lentiviral mediated infection 
The decision to move towards generation of a lentivirus that induces the 
overexpression of a functional GLUT4 protein was taken because it was concluded 
that the likely achievable limit of overexpression via transfection had been 
attained. Typically transfection is most successfully implemented in sub 
confluent, dividing cells. Given that iPSC-CM are terminally differentiated, and do 
not tolerate being plated at a low density particularly well, it was considered a 
success to achieve a 4-fold overexpression of GLUT4 in these cells using this 
approach. 
Initial proof of concept experiments demonstrated that a highly robust 
overexpression of exogenous genes such as Syntaxin 4 and GLUT4-GFP was possible 
using a lentivirus approach. A relatively low amount of total protein was loaded 
in the Syntaxin 4 immunoblot, which may explain why no signal was obtained from 
control cell lysates (Figure 4-20). However, the key point is that a very strong 
overexpression was detected in infected cell lysates, which seemed to be 
associated with higher concentrations of the virus and incubation durations, and 
also the presence of polybrene, which is designed to improve the absorption of 
the virus (Davis, et al., 2002). Whilst it was not possible to quantify the fold 
difference in expression between conditions due to the lack of signal from control 
cells, a similarly strong overexpression of GLUT4 would likely bring iPSC-CM values 
towards those recorded from primary cardiomyocytes. In the confocal microscopy 
images of infected iPSC-CM, the abundance of GLUT4-GFP is striking (Figure 4-21). 
Unfortunately, when tagged with a reporter GFP protein GLUT4 becomes non-
functional, hence why a novel lentivirus must be generated. From the immunoblot 
presented it appears that with increasing production of exogenous GLUT4 protein, 
the production of native GLUT4 may have decreased (Figure 4-22). However, given 
the poor expression of this protein in iPSC-CM, this should not overly impact the 
efficacy of any intervention. 
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When developing the novel pCDH-CMV-MCS-EF1-GLUT4 plasmid depicted in Figure 
4-23, there were 2 steps that required major optimisation. First of all, the 
restriction digests were required to be of high efficiency, as any contamination 
with even small quantities of undigested DNA, or over digested degraded DNA, 
were unsuitable for subsequent ligation. After extensive manipulation of 
experimental variables, the key optimal conditions were found to be performing 
20 µL total volume reactions for 2 hours. Similarly, successful ligation required 
several trial and error optimisation steps. The key adjustments were increasing 
the volume of each fragment within the ligation, and incubating the reaction at 
16 degrees overnight. The full protocol for all steps is detailed in methods section 
2.5.4. As depicted in Figure 4-24, this novel plasmid was still capable of inducing 
GLUT4 protein production in HeLa cells, therefore the next step must be to 
generate a novel lentivirus with the intention of infecting iPSC-CM. 
4.3.5 Methodological considerations 
Several key methodological issues have already been highlighted and discussed. 
Additionally, when assessing the impact of MM and T3 interventions, it would have 
been useful to validate some of the claimed benefits of these approaches. Despite 
no clear maturation effect, previous adaptations reported could have been 
replicated in order to confirm that the protocols had indeed been implemented 
appropriately. Furthermore, as alluded to, it was not viable to perform extensive 
or exhaustive optimisation of the transfection process in iPSC-CM. This prevented 
robust assessment of the effect of all possible combinations of key variables upon 
transfection efficiency.  
4.3.6 Conclusion and outline of further work required 
In conclusion, quantification of the expression and functional importance of 
GLUT1 and GLUT4 in iPSC-CM revealed that with regards to these parameters this 
cell type exhibits a phenotype highly similar to cardiomyocytes at a foetal stage 
of development in vivo. This also permitted estimation of the magnitude of 
specific adaptations required to mimic primary cardiac physiology. It was 
identified that approximately a 10-fold increase in GLUT4 protein expression was 
required. Initial interventions implementing previously recommended strategies 
such as MM and T3 conditioning were deemed unsuccessful. Transfection of a 
 178 
 
GLUT4 DNA plasmid achieved a reliable maximum 4-fold overexpression of GLUT4 
protein in iPSC-CM, and whilst this increased basal glucose transport it did not 
enhance the lack of insulin stimulated uptake that is characteristic of these cells. 
A novel lentiviral vector has been generated that contains the DNA sequence for 
functional GLUT4 protein. Immediate future aims must be to complete the 
development of this lentivirus and optimise a protocol to achieve an equally robust 
overexpression of GLUT4 in iPSC-CM as what was achieved with a lentivirus 
targeting the overexpression of Syntaxin 4. Longer term aims must focus upon 
studying the physiological impact of enhancing iPSC-CM GLUT4 content to levels 
observed in primary adult cardiomyocytes, and how to use this to induce an insulin 
stimulate glucose uptake response, if this does not happen spontaneously.  
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5 The regulation of glucose uptake in models of 
cardiac disease 
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5.1 Introduction 
Previous chapters have reported investigation into the regulation of glucose 
uptake in iPSC-CM. This is with an ultimate aim of developing a clinically relevant 
model of DCM. However, when examining the regulation of glucose uptake into 
the primary adult cardiomyocytes that iPSC-CM are designed to represent, 
surprisingly little is known. Given both the pathological consequences when this 
regulation becomes dysfunctional in IR and the need to validate iPSC-CM 
physiology, this is a limitation that must be addressed. 
5.1.1 The importance of SNARE proteins in cardiac physiology 
When considering the process of GLUT4 trafficking, as outlined in section 1.2, 
extensive study of relevant experimental models such as 3T3-L1 adipocytes leads 
us to understand that there is a significant contribution from dozens of proteins, 
ranging from insulin signalling intermediates and effector proteins to the glucose 
transporter itself. Together these facilitate an increase in glucose disposal into 
insulin sensitive cells in response to insulin stimulation through an increased 
availability of GLUT4 at the cell surface. However, aside from determining that 
insulin does increase glucose uptake into cardiomyocytes, many of the key details 
of the underlying physiological processes have not been conclusively validated in 
cardiomyocytes. It would seem likely that highly similar mechanisms are present 
across all insulin sensitive cell types, however this cannot be assumed and even 
apparently minor intercellular and interspecies differences may be of vital 
importance when considering disease phenotypes. 
Understanding the regulation of the subcellular localisation of the GLUT4 
containing GSVs is initially the most obvious immediate aim, however it could be 
argued that of even greater importance is detailing the final step of GLUT4 
trafficking whereby the GSV and plasma membranes fuse. Membrane fusion is a 
common physiological action in a range of biological contexts that is largely 
dependent upon the interaction of SNARE proteins. Extensive characterisation of 
the experimental model 3T3-L1 adipocytes indicates that in the context of GLUT4 
trafficking the formation of a stable complex between the GSV associated SNARE 
protein VAMP2 and the plasma membrane bound SNARE proteins Sx4 and SNAP23 
is integral to catalyse the fusion of these membranes (Kawanishi et al., 2000). 
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Within the context of this project, characterisation of SNARE protein expression 
in cardiomyocytes is of importance for two reasons. First of all, fatty acid induced 
IR in the HL-1 mouse atrial cardiac cell line was associated with redistribution of 
SNAP23 from the cell membrane to developing cytosolic lipid droplets (Boström et 
al., 2007). Subsequent transfection of SNAP23 reinstated the insulin stimulated 
glucose uptake response by facilitating an increase in insulin induced GLUT4 
plasma membrane expression back to levels recorded prior to the induction of IR. 
A similar phenotype was observed in human diabetic skeletal muscle samples, 
whereby SNAP23 was redistributed away from the cell surface relative to healthy 
control samples (Boström et al., 2010). In these samples the expression of the 
accessory protein Munc18 that regulates the interaction of SNAP23, Syntaxin 4 and 
VAMP2 was increased, however the exact action of this protein is still debated 
(Laidlaw et al., 2017) therefore the importance of this observation is challenging 
to interpret. This evidence from both a human muscle and cardiac model confirms 
the powerful potential of SNARE proteins to regulate insulin stimulated glucose 
uptake. Secondly, functional coupling between SNAP25 and cardiac potassium 
channels has been uncovered that opens up the possibility of a direct link between 
SNAREs and ion channel function, which are an integral regulator of cardiac 
excitability and therefore contractility (Chao et al., 2011). This would give SNARE 
proteins an influence over both glucose uptake and contractility in the heart, both 
of which are perturbed in several cardiac diseases, including DCM. 
5.1.2 Which SNARE proteins are expressed in the heart?  
Where previous literature has investigated SNARE expression in the heart, it is 
mostly focussed upon the specific expression of one or two isoforms of each 
category (VAMP, SNAP or Syntaxin), not always within the context of a specific 
physiological process. For example, generic assessment of SNAP47 distribution in 
mouse tissues found detectable levels of mRNA in cardiac lysate (Holt et al., 
2006). Similarly, VAMP1 and VAMP2 mRNA was detected in rat cardiac samples 
(Rossetto et al., 1996). Finally, investigation into the machinery that regulates 
atrial natriuretic hormone release from the heart reported protein expression of 
SNAP23, Syntaxin 4, and VAMPs 1-3 (but not SNAP25 or Syntaxin 1) in samples of 
neonatal rat heart (Ferlito et al., 2010). Interestingly, the expression of these 
proteins varied between atrial and ventricular samples. 
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On the basis of these highly selectively targeted studies, the expression of the 
majority of the multiple existing SNARE protein isoforms in cardiomyocytes is 
ambiguous. However, there is some work that has attempted to detail the 
expression and interactions of a greater number of SNAREs in cardiac models at 
one time. First of all, mRNA encoding a wide range of SNAREs was detected in 
both neonatal and adult rat cardiomyocytes, including all of the known VAMP 
isoforms except from VAMP 7 (Peters, et al., 2006). A range of Syntaxin isoforms 
were also identified, however the expression of Syntaxin 16 – which has been 
previously cited as important in the intracellular sorting of GLUT4 during its 
trafficking (Proctor et al., 2006) – was not assessed. Nonetheless, 
immunoprecipitation analysis did identify the presence of 2 complexes, involving 
VAMP2/SNAP23/Syntaxin4 and VAMP2/Syntaxin1/SNAP25. This does not confirm 
beyond doubt that this first complex is indeed responsible for mediating GSV-PM 
membrane fusion in the heart, but does support that theory. 
The most insightful prior analysis regarding this topic was performed using the 
mouse atrial HL-1 cardiomyocyte model. The expression of VAMPs 2-7 (VAMP6 is 
not recognised and VAMP8 was not detected) was identified and then subsequently 
each isoform was knocked down and the impact on insulin stimulated GLUT4 
delivery to the cell surface and glucose uptake was assessed (Schwenk et al., 
2010). This revealed an important role for both VAMP2, but also VAMP5, in insulin 
stimulated GLUT4 trafficking in this cardiomyocyte model. 
In combination, these studies provide considerable evidence that the SNARE 
complex previously identified as facilitating the GSV-PM interaction in other cell 
types may also be predominant in the heart. However, there are several important 
limitations in this previous work. First of all, in several studies only mRNA 
expression was reported for target SNAREs. It cannot automatically be assumed 
that this data is also reflective of protein expression, given the possibility of pre 
and/or post translational regulation. Secondly, where protein expression is 
reported, it would be more meaningful if the absolute amount of protein detected 
was reported, rather than a binary system of present or absent. Thirdly, the roles 
of different SNARE proteins may be interchangeable to at least some degree. 
Having a narrow focus on a restricted number of SNAREs may prevent full 
appreciation of the networks and interactions underlying insulin stimulated 
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glucose uptake. Additionally, within the described literature there was conflicting 
data. For example, it is not clear whether VAMPs 7 and 8 are expressed in 
cardiomyocytes, or not. Finally, the work mentioned was performed primarily with 
atrial cardiomyocytes. In vivo, these are outnumbered considerably by ventricular 
cardiomyocytes, and it is conceivable that the metabolic requirements and 
regulation of these subpopulations could differ due to their different contractile 
requirements.  
Therefore, a broad characterisation of SNARE protein expression in a more 
representative cardiac sample would both complement previous literature and act 
as a guide for future studies. Analysis of changes in expression from diabetic 
samples could then be undertaken to assess the role of SNAREs in cardiac IR and 
potentially DCM. Subsequently, more specific factors such as SNARE localisation, 
interactions (with each other and other proteins), and their roles in various 
physiological processes could be fully elucidated. 
5.1.3 The importance of glycemic control post-MI 
When considering cardiac IR in a pathophysiological setting, the majority of 
individuals presenting with this phenotype will be suffering from diabetes already, 
or will eventually develop this condition. There are multiple causes and 
manifestations of diabetes, as outlined in chapter 1. In the context of SNARE 
protein expression, it would be of significant interest to investigate how this 
expression may change in a relevant model of diabetes. However, this is not the 
only context within which glycemic control (or a lack thereof) is of importance. 
There is an established – although not entirely understood – relationship between 
IR and MI. 
An MI is defined by an occlusion of a coronary artery, which therefore starves the 
downstream myocardium of oxygen and nutrients. If small and/or transient, 
individuals confronted with this ischemic event can make a full recovery. 
However, a prolonged MI that blocks a major vessel supplying a large region of the 
heart can either cause instant death, or significantly reduce life expectancy. The 
regeneration capacity of the heart is limited, therefore surviving myocardium 
must compensate for the loss of pump capacity. This promotes a remodelling 
process that often leads to progressive heart failure and disruption of the tight 
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electrical coupling across regions of the heart as the walls of the hearts chambers 
become thinner, fibrotic, and ultimately less powerful. 
There is a body of literature that describes an increased risk/incidence of MI in 
individuals diagnosed with diabetes (e.g. Laakso et al., 1995). Within a separate 
diabetic population, an 11 year prospective study found that post-prandial 
systemic glucose concentration was a significant predictor of MI incidence and all-
cause mortality (Hanefeld et al., 1996). This association between glycemic control 
and risk of MI was further strengthened by the observation in a South Asian 
population that both fasting and post-prandial blood glucose values were 
significantly higher relative to appropriate controls in patients admitted to 
hospital for treatment of an MI, even though they were not diabetic and many of 
their values were well below the normal thresholds associated with diabetes 
(Gerstein et al., 1999). This principle established is supported by evidence that 
uncovered a significant relationship between the presence of systemic IR and 
incidence of MI in a separate population at less risk of cardiometabolic disease 
than South Asians (Hedblad et al., 2002). 
It could be proposed that this phenomenon is merely observed because of an 
association of hyperglycemia with other factors more likely to lead to an MI, such 
as hyperlipidemia or hypertension. This is countered by the fact that in several of 
the studies mentioned above, these and other relevant variables were accounted 
for in the statistical analysis employed. 
Characterisation of non-diabetic acute MI patients revealed a high proportion of 
previously undiagnosed diabetes or impaired glucose tolerance (Norhammar et al., 
2002). This could be used to just restate the established link between insulin 
sensitivity and risk of MI, however this relationship has an additional layer of 
complexity. For example, long term (5 year) survival post-MI is significantly worse 
in diabetic individuals relative to controls (Koek et al., 2007). In this study it was 
established that short term (approx. 1 month) survival was not significantly 
different between groups, indicating that it was unlikely to be simply explained 
by diabetic individuals being at greater risk of a more severe initial cardiac injury. 
Rather, it appears that glycemic control may influence the subsequent long term 
remodelling process post-MI, which is fundamental in determining prognostic 
outcomes. In accordance with this, intensive insulin therapy improved 1 year post-
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MI survival rates in diabetic patients, and was at least in part mediated by 
improved metabolic regulation as indicated by reduced levels of glycated 
haemoglobin (Malmberg et al., 1996). However, conflicting research also indicates 
that regardless of the presence of diagnosed diabetes or not, an MI can induce an 
elevation of blood glucose concentration (stress hyperglycemia), which 
significantly increases short term mortality rates post-MI (Capes et al., 2000). An 
intervention that improved metabolic control immediately post-MI in non-diabetic 
patients significantly improved functional outcomes, in part linked to reduced 
inflammation driven remodelling (Marfella et al., 2009). 
Overall, it is clear that the ability to regulate blood glucose concentration is 
important in determining the success of the recovery process post-MI. What is not 
clear however is whether this is due to alterations in circulating blood glucose 
levels directly impacting cardiac physiology, or if blood glucose concentration is 
just an indirect marker that indicates – but does not primarily cause – independent 
cardiac maladaptation. For example, it could be that systemic elevations in 
circulating blood glucose concentration correlate with the onset of myocardial IR, 
and that is what is driving the pathological remodelling process post-MI. Indeed, 
there is evidence from a rat model that insulin signalling is cardioprotective in 
ischemic myocardium and reduces cell death (Gao et al., 2002). Changes in 
substrate availability or utilisation may also be critical under conditions of 
ischemic stress. It would be impractical (and possibly unethical) to record cardiac 
glucose uptake post-MI in human patients, however data from an animal model 
provides a degree of insight. Once again in a rat model, progressive myocardial IR 
- as indicated by impaired insulin stimulated cardiac fluoro-deoxyglucose uptake 
and Akt phosphorylation - was detected after only 1 week post-MI (Fu et al., 2015). 
This myocardial IR was surprisingly not reflected in systemic glycemic control, and 
treatment or exacerbation of this phenotype lead to improvement or deterioration 
of cardiac remodelling/function respectively. 
This work suggests that cardiac IR may directly influence outcomes post-MI. 
However, it would be beneficial to replicate these initial findings in a more 
clinically relevant and translatable model, for example a larger organism. 
Additionally, this study only recorded myocardial insulin sensitivity up to 2 weeks 
post-MI. Given that the importance of glycemic control has been implicated in 
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long term survival, it is necessary to assess if this identified cardiac phenotype 
extends beyond this initial acute phase. Finally, Fu et al. (2015) identified that 
TNF-α released from the ischemic myocardium and its subsequent inhibition of 
intracellular insulin signalling may be the mechanism by which cardiac IR occurred 
post-MI. However, much more work needs to be completed in order to fully detail 
this mechanism. In the context of this project it would be valuable to assess if 
cardiac SNARE protein expression changes post-MI, because as outlined before 
they have a unique link to the regulation of both insulin stimulated glucose uptake 
and cardiac contractility. 
5.1.4 Aims of chapter 
Overall, it is clear that there is a severe deficit in knowledge regarding the 
expression of SNARE proteins in healthy cardiomyocytes, let alone the role they 
may have in different physiological processes and cardiac disease states. 
Therefore, in accordance with the previous literature discussed, the following 
aims will be addressed; 
 Identification of SNARE proteins expressed in primary cardiac tissue 
 Assessment of changes in cardiac SNARE expression in diabetic models 
 Assessment of insulin sensitivity in post-MI primary rabbit model 
 Assessment of SNARE protein expression in post-MI rat model  
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5.2 Results 
5.2.1 Quantification of SNARE proteins in primary cardiac tissue 
As outlined in section 5.1.2., the expression of many of the known SNARE protein 
isoforms in cardiac tissue is ambiguous. It is the aim of this project to better 
characterise this expression in a general way in both health and disease, in order 
to act as a platform for future more detailed and specific analysis. However, based 
upon the prior literature there is a specific interest in SNAP23, Syntaxin 4, and 
VAMP2, based upon their proposed involvement in the fusion of the GSV and 
plasma membrane during the final step of insulin stimulated GLUT4 trafficking. 
Therefore, attempts were made to not only confirm the expression of these 
proteins in primary cardiac samples, but also to attempt quantification of absolute 
expression in order to allow more powerful interpretation of future work. 
In order to quantify the expression of the identified SNAREs in primary cardiac 
tissue, first of all purified recombinant protein had to be produced in order to 
generate standards against which signals from known amounts of cell lysate could 
be compared. This production process is detailed in methods section 2.5.1. At 
several stages of this process samples were collected in order to assess the 
efficacy of recombinant protein production and elution. These samples were then 
subjected to SDS-PAGE and Coomassie staining. Figure 5-1 depicts a typical gel 
showing the presence of total protein in each of the identified samples. In this 
case the recombinant protein being produced was Syntaxin 16 (tagged with GST). 
This protein was produced within this project but not with the intention for use 
in this section, however it is displayed for presentation purposes because 
recombinant VAMP2, Syntaxin 4, and SNAP23 were previously produced by Dr. 
Jessica Sadler. As displayed in Figure 5-1, initial cell lysates contain numerous 
different proteins as would be expected from complex bacterial cells. However, 
after purification and elution (E1/E2), only one clear distinct band is visible in the 
loaded sample, which corresponds to the purified protein at the anticipated 
molecular weight. 
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Figure 5-1 Production and purification of recombinant fusion protein 
Recombinant fusion protein Syntaxin16-GST was generated according to the method 
described in section 2.5.1. After each of the following stages a sample was collected and then 
subsequently subjected to SDS-PAGE and Coomassie staining; lysate generation (Lysate), 
lysate after incubation with beads (Beads), 3 washes of beads (Wash1-3), 2 rounds of elution 
of beads (E1-2). 
After obtaining recombinant purified protein samples, it was then necessary to 
quantify their protein concentration. This was achieved by loading several 
different amounts of each sample against a range of known amounts of BSA. These 
were once again subjected to SDS-PAGE and Coomassie staining. A representative 
gel is displayed in Figure 5-2, in this case depicting quantification of Syntaxin 4. 
Densitometry was performed and a line of best fit was produced from the BSA 
standard samples, plotting protein concentration against Coomassie signal 
intensity. The equation of this line was then used to calculate the amount of 
protein (and therefore concentration) of the unknown samples. Note that prior to 
use in this study, recombinant proteins had been cleaved of their GST tag. 
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Figure 5-2 Representative quantification of purified protein 
Different amounts of purified protein sample of unknown concentration were loaded against 
a range of known amounts of BSA and subjected to SDS-PAGE and Coomassie staining. 
The final preparation step required prior to performing the ultimately intended 
quantification was to optimise the process of extracting protein from cardiac 
lysates. When considering this protocol, as described in its full final form in 
methods section 2.3.3.1, the step where it was most unclear from the literature 
and personal communications what would provide optimal results was in the 
process of mechanically homogenising the tissue. This step is required to expose 
the cardiomyocytes to physical stress in order to fully lyse these cells and liberate 
the intracellular proteins. Mechanical lysis was used in addition to chemical lysis 
(cells were also incubated with RIPA buffer) due to the highly fibrous nature of 
cardiac tissue and the abundance of myofilaments in each myocyte. Therefore, 2 
separate homogenisation methods were used to generate 3 lysates from a total of 
6 independent mouse hearts. One set of lysates was generated using the manual 
homogeniser method described in section 2.3.3.1., whereas the other set was 
generated via 2 x 1 min incubations of cardiac segments in RIPA buffer with 
stainless steel micro beads within a rapidly shaking plastic vial (25 Hz). All other 
aspects of the protocols prior and subsequent to this mechanical homogenisation 
step remained the same. Then protein concentration was estimated via a micro 
BCA assay and an equal amount of total protein was loaded for each sample. These 
were then subjected to SDS-PAGE and immunoblotting for different SNARE 
proteins.  
 190 
 
As can be seen in Figure 5-3, there was not a striking difference in the signals 
obtained between lysates generated via the different methods for either Syntaxin 
4 or Syntaxin 8. Both techniques were efficient at extracting protein and 
facilitating the detection of a clear, clean signal. However, the total amount of 
protein harvested from the manual homogeniser was much greater than that 
generated using the micro beads. Therefore, in order to maximise the potential 
to generate insight into the physiology of cardiomyocytes, this method was 
selected for future lysate generation and was employed throughout this project. 
 
Figure 5-3 Comparison of mechanical homogenisation methods with primary cardiac tissue 
6 independent mouse hearts were lysed via 2 separate homogenisation methods and 
subjected to SDS-PAGE and immunoblotting in order to assess the expression of Syntaxin 4 
and Syntaxin 8. Manual homogenisation refers to lysates generated using a manual 
homogeniser apparatus, whereas mechanical homogenisation refers to lysates generated 
using beads within a rapidly shaking vial. In all cases, 40 µg of cardiac lysate was loaded. Rat 
brain lysate (RB) was also loaded in order to act as a positive control. Ponceau stain is 
displayed in order to indicate relative loading. 
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In order to quantify the expression of VAMP2, SNAP 23 and Syntaxin 4 in primary 
rodent cardiomyocytes, known amounts of each lysate were loaded against known 
amounts of each purified recombinant protein. For primary mouse samples, 
lysates from 3 independent hearts were analysed individually, whereas the 
primary rat samples are the product of 3 independent hearts that have been 
pooled and therefore were analysed together. For the purposes of quantification, 
immunoblots were subjected to densitometry and then the signal from the purified 
protein samples was plotted against the amount of protein loaded. A line of best 
fit was plotted and the equation was used to estimate the amount of the target 
protein present in each of the cardiac lysates. This number was then converted 
into number of molecules (copy number) normalised relative to the estimated 
total amount of protein loaded for each lysate. Where more than one amount of 
any given lysate was loaded, the average amount of protein detected was 
calculated. Finally, the average expression for each source of cardiac lysate 
(mouse/rat) was calculated across all samples on the immunoblot. This procedure 
was performed several times in an attempt to obtain signals from the cardiac 
lysates and purified protein within a similar range. This was successfully achieved 
for SNAP23 and Syntaxin 4. However, for VAMP2 the signals obtained from cardiac 
samples were slightly out with the range of signals obtained from the standard 
purified protein. 
Figure 5-4 shows a representative immunoblot probing for the expression of 
Syntaxin 4 in both mouse and rat cardiac lysates, and samples of purified 
recombinant Syntaxin 4. GAPDH is also displayed in order to indicate relative 
loading between cardiac samples only. This protein (and any others except from 
Syntaxin 4) should not be detected in this purified protein sample. Table 5-1 shows 
the output of quantification of each SNARE protein in both mouse and rat cardiac 
samples.  
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Figure 5-4 Quantification of SNARE proteins in lysates from primary rodent cardiac tissue 
Cell lysates were generated from 3 individual primary mouse (M1-3) and 3 pooled rat hearts 
(Rat), and then subjected to SDS-PAGE and immunoblotting alongside purified recombinant 
Syntaxin 4 samples, probing for the expression of Syntaxin 4 and GAPDH. 10 and 20 µg of 
each cardiac sample was loaded, whereas 0.5-1.5 ng of purified Syntaxin 4 was loaded.  
Species SNAP23      
Copies / mg 
Syntaxin 4  
Copies / mg 
VAMP2       
Copies / mg 
Mouse 2.07 x 1012 7.26 x 1011 9.72 x 1011 
Rat 1.45 x 1012 6.82 x 1011 9.15 x 1011 
3T3-L1 Adipocytes 5.28 x 1012 1.72 x 1012 2.28 x 1012 
Table 5-1 Estimated absolute expression of key SNARE proteins in rodent cardiac lysates 
Reported values are mean of signals obtained from 3 independent hearts for each species, 
and are expressed as copy number of each protein per mg of total protein lysate. Values for 
3T3-L1 adipocytes were obtained from Hickson et al., (2000). 
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5.2.2 Cardiac SNARE protein expression in diabetic mouse 
models 
As outlined in section 5.1.1., SNARE proteins are vital in facilitating membrane 
fusion, which is a common requirement of general intracellular trafficking, 
including that of GLUT4. Within the context of diabetes, impaired expression of 
GLUT4 at the cell surface of cardiomyocytes in response to insulin is believed to 
have a potentially important role in the development of cardiomyopathy. 
Therefore, considerable work has investigated the role of deficits in insulin 
signalling within the context of progressive IR. However, there is a lack of research 
into the expression and possible roles of SNAREs in cardiomyocytes, both in a 
normal baseline state and within a diabetic phenotype. Therefore, in this project 
the protein expression of a wide range of SNAREs was probed in cardiac lysates 
generated from 2 well characterised diabetic mouse models, and relevant 
controls. 
First of all, the db/db mouse model was investigated. This is a model with a 
mutation in the leptin receptor gene, which leads to the rapid development of 
obesity and changes in blood chemistry characteristic of diabetes – including 
hyperglycemia, hyperlipidemia, and hyperinsulinemia – within the first 6 weeks 
after birth (Kobayashi et al., 2000). Presently, the multiple physiological changes 
observed in this model make it the most relevant for studying type 2 diabetes 
(Burke et al., 2017). Of utmost importance for use within this project is the 
previous characterisation that hearts from db/db mice exhibit both impaired 
contractility and impaired insulin stimulated glucose uptake (Carroll et al., 2005; 
Panagia et al., 2007). Therefore, cardiac samples from these mice provide an ideal 
opportunity to study how SNARE protein expression may change in a DCM 
phenotype. 
Figure 5-5 shows a selection of representative images generated from 6 individual 
db/db and db/m (relevant control group) hearts. On each immunoblot a lysate 
generated from a mouse brain and in some cases where appropriate also a 3T3-L1 
adipocyte lysate were loaded in order to act as positive controls. However, for 
presentation purposes immunoblots have been cropped in order to display 
expression of the identified SNARE proteins (and GLUT4) only. Borders on the 
images indicate where cropping has occurred, but no raw data has been altered 
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between panels. As displayed, the expression of SNAP23 and Syntaxin 4 were 
clearly detectable, and did not differ between experimental groups. The 
expression of VAMP2 and VAMP5 appeared to increase/decrease in lysates 
generated from db/db hearts respectively, however when attempting to replicate 
these findings across independent immunoblots with the same samples, they were 
not reproducible. In contrast, the expression of GLUT4 was significantly (P<0.05) 
decreased in samples from db/db hearts, and this finding was reproducible. Only 
5 db/m samples were assessed in this immunoblot due to sample availability. The 
expression of a wide range of additional SNAREs was assessed and is indicated in 
Table 5-2. Quantification of any potential difference in expression between groups 
was only undertaken when a clear, reproducible signal was visually observed, and 
was performed via densitometry. Signals were normalised to Ponceau to account 
for variations in protein loading, and where appropriate the mean percentage 
difference in expression is reported in Table 5-2. 
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Figure 5-5 SNARE and GLUT4 protein expression in db/db and db/m cardiac lysates 
Lysates were generated from myocardial segments from db/db and db/m mice and subjected 
to SDS-PAGE and immunoblotting, assessing the expression of a range of SNARE proteins 
and GLUT4. In all cases 40 µg of total protein was loaded for each lysate, and variations in 
loading were assessed by Ponceau staining, as displayed. 
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Protein Detected? Difference? Protein Detected? Difference? 
SNAP23 Yes No Syntaxin 
16 
Yes No 
SNAP29 Yes No VAMP1 No N/A 
SNAP47 Yes No VAMP2 Yes No 
Syntaxin 
2 
Yes No VAMP3 Yes No 
Syntaxin 
3 
Yes No VAMP4 Yes No 
Syntaxin 
4 
Yes No VAMP5 Yes No 
Syntaxin 
5 
Yes No VAMP7 No N/A 
Syntaxin 
8 
Yes No VAMP8 Yes No 
GLUT4 Yes Yes, significantly 
(P<0.05) decreased in 
db/db lysates by 35% 
   
Table 5-2 SNARE protein expression in cardiac lysates from db/db and db/m mice 
Where appropriate, the mean percentage difference between groups is reported. Statistical 
analysis was performed with a 2-tailed unpaired t-test on raw data, with the level of 
significance set at P=0.05. 
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It is a common approach to use genetically modified animal models in order to 
induce a desired phenotype and/or investigate the physiological action of target 
genes/proteins. However, this approach is open to the criticism that the data 
generated may have limited translational capacity when considering human 
disease that is primarily induced by environmental factors. In the context of 
diabetes research, this criticism is partly overcome by the use of high fat feeding 
(HFD) of rodents in order to induce obesity and a subsequent phenotype 
characteristic of the early stages of diabetes (Burke et al., 2017). For example, in 
rats systemic IR was observed after only 3 weeks on a HFD, whereby 60% of total 
calories were obtained from fat (Kraegen et al., 1991). Similar to db/db mice, in 
a rat HFD model impairment of both cardiac insulin signalling and contractile 
function were observed (Ouwens et al., 2005). Therefore, HFD rodents provide a 
second, arguably more clinically relevant model, through which SNARE protein 
expression can be studied in a (pre) diabetic-like cardiac phenotype. 
In accordance with this, the expression of a broad range of SNARE proteins was 
assessed in lysates generated from myocardial segments from HFD mice and 
appropriate controls (mice on a standard CHOW diet). Data obtained from Dr. 
Anna White indicated that these HFD mice exhibited significantly greater weight 
gain relative to controls and also delayed systemic glucose clearance upon 
challenge via a glucose tolerance test, although this latter difference was not 
significant between groups (data not shown). As displayed in Figure 5-6 and Table 
5-3, once again a range of SNARE proteins were detected from these mouse hearts, 
regardless of experimental group. CHOW group 2 and HFD group 1 were lysates 
generated from 3 individual hearts, whereas CHOW group 1 and HFD group 2 were 
generated from 2 and 4 individual hearts, respectively. Where appropriate, 
quantification was performed in accordance with the approach detailed above for 
db/db mice. In lysates from HFD fed mice VAMP2 (in at least one sample) 
expression appeared to decrease, whereas VAMP5, SNAP23 (in one sample) and 
SNAP29 expression appeared to increase. Of these differences, only the increases 
in SNAP29 and VAMP5 were found to be statistically significant (P<0.05). GLUT4 
expression was not reduced in this model. 
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Figure 5-6 SNARE and GLUT4 expression in cardiac lysates from HFD and CHOW mice 
A: Lysates were generated from myocardial segments from HFD and CHOW fed mice and 
subjected to SDS-PAGE and immunoblotting, assessing the expression of a range of SNARE 
proteins and GLUT4. In all cases 2 distinct samples were loaded for each experimental group, 
composed of lysates generated from 2-4 individual hearts. For blots displaying SNAP23, 
Syntaxin 4 and GLUT4, either 20 (a) or 40 (b) µg of total protein was loaded for each lysate. In 
all other blots only 40 µg of total protein was loaded for each lysate. Variations in loading 
were assessed by Ponceau staining, and a representative image is displayed. 
B: Quantification of the immunoblots displayed for VAMP5 and SNAP29 in panel A. Values 
are expressed as mean (+S.D.) fold change of each protein normalised to Ponceau staining, 
relative to control. Statistical analysis was performed with a 2-tailed unpaired t-test on raw 
data, with the level of significance set at P=0.05. * denotes P<0.05. 
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Protein Detected? Difference? Protein Detected? Difference? 
SNAP23 Yes 15% higher expression 
in HFD lysates, 
difference was not 
significant (P>0.05)  
Syntaxin 
16 
Yes No 
SNAP29 Yes Yes, significantly 
(P<0.05) increased in 
HFD lysates by 73% 
GLUT4 Yes No 
SNAP47 Yes No VAMP1 No N/A 
Syntaxin 2 Yes No VAMP2 Yes 23% lower expression 
in HFD lysates, 
difference was not 
significant (P>0.05) 
Syntaxin 3 Yes No VAMP3 Yes No 
Syntaxin 4 Yes No VAMP4 Yes No 
Syntaxin 5 Yes No VAMP5 Yes Yes, significantly 
(P<0.05) increased in 
HFD lysates by 100% 
Syntaxin 6 Yes No VAMP7 No N/A 
Syntaxin 7 No N/A VAMP8 Yes No 
Syntaxin 8 Yes No    
Table 5-3 SNARE protein expression in cardiac lysates from HFD and CHOW mice 
Where appropriate, the mean percentage difference between groups is reported. Where 2 
different amounts of the same sample were loaded, signals were averaged to provide 1 value 
per sample. Statistical analysis was performed with a 2-tailed unpaired t-test on raw data from 
the corresponding immunoblots displayed in Figure 5-6, with the level of significance set at 
P=0.05. 
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5.2.3 Cardiac insulin sensitivity and SNARE expression post-MI 
There is strong evidence that glycemic control impacts both the risk of, and 
recovery from, MI (Laakso et al., 1995; Koek et al., 2007). However, the 
physiological mechanisms underlying these associations are yet to be fully 
detailed. A post-MI rat model (Fu et al., 2015) indicated that the development of 
cardiac IR may be central to pathological outcomes. However, it has not been 
reproducibly reported in a longer term, more translatable experimental model 
that cardiac IR actually occurs post-MI, let alone its clinical significance when 
compared to other variables. Therefore, insulin stimulated glucose uptake and 
insulin stimulated phosphorylation of Akt was assessed in an 8-12 week post-MI 
rabbit model. 
Prior to assessing the intended outcomes in the experimental and relevant control 
groups, optimisation of the [3H]-2DG uptake assay that acts as a surrogate for 
glucose uptake was performed. As reported in chapter 3, extensive optimisation 
of this technique was performed with iPSC-CM, which facilitated the development 
of a suitable protocol for measuring uptake on a 96-well plate scale. However, 
primary cardiomyocytes also have unique challenges. Unlike cells that are 
maintained in culture prior to the day of the assay, the isolation procedure results 
in many cells dying or being critically damaged. Whilst there are several washing 
steps prior to performing the main [3H]-2DG assay, a significant number of dead 
cells will inevitably be retained throughout the experiment, and may impact the 
data obtained. Of greatest concern is the potential for these cells to trap residual 
glucose within the wells or conversely to detach and also remove viable 
cardiomyocytes. Either of these events would increase the noise of this assay. 
Therefore, it is desirable to reduce the number of dead cells upon initial plating 
as much as possible. 
Several factors can influence the ratio of living: dead cardiomyocytes upon plating 
these cells. First of all, the ‘quality’ of the isolation procedure is critical. If 
incubated with collagenase for too long (over digested) the chances of excessive 
membrane damage is high, which will greatly increase the number of cells that 
die. The likelihood of this being a significant problem in this project was minimal, 
as the isolation was performed by experienced technicians. A second important 
factor determining the viability of the isolated cells is the time allowed for the 
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cells to adapt to each level of calcium in the KRP during the stepwise progression 
from total absence to physiological values, as described in section 2.2.9. Rushing 
through these steps can lead to calcium induced overload and associated death of 
cells, but this was accounted for and performed appropriately. Finally, the last 
factor thought to be critical was which section of the heart the cells were obtained 
from. Due to the physical dimensions of the heart and associated blood vessels 
through which collagenase is perfused during the isolation procedure, it is possible 
that the viability of cells may vary between anatomical regions. Anecdotally, with 
the protocol employed in the lab, the percentage of living cells obtained seemed 
to be greater in the septum compared to the left ventricle, and certainly more so 
than from the atria. Within initial optimisation steps across separate experiments, 
the variability of glucose uptake between samples from the same heart and 
associated insulin response of septal cardiomyocytes appeared more robust in 
comparison to left ventricular cardiomyocytes. Therefore, these fundamental 
glucose uptake measurements were directly compared between cells from these 
regions. Atrial cardiomyocytes were never assayed. 
Figure 5-7 depicts basal and insulin stimulated glucose uptake in ventricular and 
septal cardiomyocytes. Importantly, these cells were obtained from the same 
heart and assayed under identical conditions, therefore facilitating a direct 
comparison. Statistical analysis revealed that insulin significantly (P<0.05) 
increased [3H]-2DG uptake in both groups, and that there was no significant 
difference (P>0.05) between basal or insulin stimulated values between the 
conditions. However, the presence of an (assumed) outlier in the left ventricular 
group was not an uncommon observation across all experiments with these cells 
(data not shown), and the extremely tight septal basal values meant that for the 
rest of this project it was decided to use septal cardiomyocytes. 
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Figure 5-7 Measurement of glucose uptake in LV and septal rabbit cardiomyocytes 
Background corrected basal and insulin stimulated [3H]-2DG uptake was assayed in isolated 
primary rabbit left ventricular (LV) and septal (Sep) cardiomyocytes. Cells were plated at 
approximately 20,000 viable cells per well, and were incubated with 860 nM insulin for 20 min 
prior to a 20 min incubation with [3H]-2DG. Each data point represents the value obtained from 
a single well, in addition to the mean +/- S.D. for each condition. Statistical analysis was 
performed with a 1 way ANOVA, and the level of significance was set at P=0.05. * denotes 
P<0.05. 
After initial development of an appropriate method for measuring glucose uptake, 
measurements were obtained from 8-12 week post-MI rabbits and controls. Data 
was provided by the donors of the tissue that clearly showed that ejection fraction 
was impaired at 8 weeks post-MI in the experimental group, which indicated 
successful induction of the intended MI and subsequent heart failure phenotype 
(data not shown). When performing these [3H]-2DG uptake assays, on each 
experimental day cells were plated into several wells of a 96-well plate. The 
number of replicate wells plated varied, but was typically 6 for each condition. 
This was in order to increase confidence in the responses recorded. However, for 
the purpose of analysis of the primary intended outcomes, the mean basal and 
insulin stimulated uptake value for each independent experiment was calculated. 
Therefore, each independent experiment carried equal weighting in this analysis 
process. In Figure 5-8, both individual data points (A) and summaries of each 
condition (B) are presented in order to provide optimal insight into the data 
generated. Statistical analysis revealed that there was a significant effect of MI 
upon the recorded uptake values (P<0.05). Post-test multiple comparisons found 
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that the effect of insulin upon uptake values in control cells strongly trended 
towards significance (P<0.10), however there was no significant effect (P>0.10) in 
post-MI cells.  
 
Figure 5-8 Basal and insulin stimulated [3H]-2DG uptake in post-MI rabbit cardiomyocytes 
Background corrected basal and insulin stimulated [3H]-2DG uptake was assayed in isolated 
primary rabbit septal cardiomyocytes. Cells were plated at approximately 15,000 viable cells 
per well, and were incubated with 860 nM insulin for 20-30 min prior to a 20 min incubation 
with [3H]-2DG. Data is presented as both individual data points and mean +/- S.E.M. for each 
condition (A) or only as summaries of each condition presented as mean + S.E.M. (B). Each 
data point represents the value obtained from a single animal. Statistical analysis was 
performed with a 2 way ANOVA, where the identified factors were insulin stimulation and MI. 
The level of significance was set at P=0.05. 
In addition to assessing the impact of MI upon insulin stimulated glucose uptake, 
the effect upon a primary intracellular signalling target of insulin was also 
investigated. In total, replicate samples from a minimum of 4 independent hearts 
from each experimental group was assessed for phosphorylation of Akt in a basal 
and insulin stimulated state. As displayed in the representative images in Figure 
5-9, both groups displayed a strong activation of Akt in response to insulin. 
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Quantification was not performed because of technical difficulties in attempts to 
assess the expression of total Akt, and therefore in some cases (as displayed) 
GAPDH was used as a loading control instead. It would not be appropriate to 
compare phosphorylation values obtained from normalisation against different 
loading controls. 
 
Figure 5-9 Insulin stimulated Akt phosphorylation in post-MI rabbit cardiomyocytes 
Representative images depicting the expression of phosphorylated Akt (ser473) and GAPDH 
in lysates generated from post-MI and control isolated primary rabbit cardiomyocytes that 
were stimulated with 0 (Basal -Bas) or 860 (Ins) nM insulin for 20-30 min, and then subjected 
to SDS-PAGE and immunoblotting. These are representative immunoblots showing 3 
replicate samples for each condition within one experimental day, and in total a minimum of 
4 independent experiments were performed with samples obtained from separate animals. In 
all cases, an equal amount of total protein was loaded across samples contained within each 
immunoblot. 
After assessing parameters related to insulin sensitivity, the impact of MI upon 
GLUT4 expression was assessed. For each experimental group, enough material 
was available to provide insight from 5 biologically independent samples. Some of 
these lysates were generated after plating, whereas others were generated 
directly after isolation, hence why there is variability in the amount of protein 
loaded for each sample as indicated by GAPDH. However, as depicted in Figure 5-
10, there was considerable variation in the levels of expression recorded. Whilst 
in several post-MI samples it appeared as though expression was reduced, 
statistical analysis revealed no significant (P>0.05) difference between groups 
overall. 
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Figure 5-10 GLUT4 protein expression in post-MI rabbit cardiomyocytes 
Lysates were generated from post-MI and control rabbit cardiomyocytes and subjected to 
SDS-PAGE and immunoblotting, in order to assess the expression of GLUT4 and GAPDH. 
Quantification of GLUT4 normalised to GAPDH is presented, displaying both individual data 
points and the mean +/- S.E.M. for each group. Statistical analysis was performed with an 
unpaired t-test, and the level of significance was set at P=0.05. 
Finally, it was a key experimental aim to also assess the impact of MI upon SNARE 
protein expression. However, sample availability meant that this could not be 
achieved with the rabbit cells used to generate the data presented in Figures 5-7 
to 5-10. Alternatively, access was provided to myocardial samples from post-MI 
and control Wistar rats. The induction of MI was performed according to a highly 
similar protocol to that of the rabbit model. Analysis of lysates generated from 
these rat samples was focussed upon SNARE proteins cited as being relevant to 
GLUT4 trafficking. As displayed in Figure 5-11, all of the target proteins were 
identified. However, across replicate immunoblots no clear or consistent 
differences were noted between groups, therefore quantification is not 
presented.   
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Figure 5-11 SNARE and GLUT1/4 protein expression in post-MI and control rat 
cardiomyocytes 
Lysates were generated from post-MI and control rat cardiac segments and subjected to SDS-
PAGE and immunoblotting, in order to assess the expression of a range of proteins involved 
in GLUT4 trafficking. GAPDH expression was also assessed to act as a loading control. Each 
sample number refers to lysate generated from an independent heart. 
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5.3 Discussion 
5.3.1 Syntaxin 4, SNAP 23 and VAMP 2 are expressed to varying 
degrees in primary cardiac tissue 
When considering the expression of the SNARE proteins Syntaxin 4, SNAP23 and 
VAMP2 in cardiac tissue, it would be highly valuable to not only confirm that they 
are present, but also to estimate their relative and absolute abundance in order 
to aid the interpretation of future work. As displayed in Figures 5-1 – 5-4 this was 
attempted in this project via the use of immunoblotting to compare signals from 
known amounts of purified protein against known amounts of cardiac lysate. 
Before consideration of the generated results, several assumptions inherent to 
this approach must be acknowledged. This quantification protocol involved a two-
step process whereby first BSA was used as a protein standard to estimate the 
concentration of the generated purified protein samples, and then these samples 
were in turn used as standards for the cardiac lysates. Both of these processes 
rely on the assumption that antibody/coomassie binding and the corresponding 
detected signal was linear across the ranges loaded, and that the reported amount 
of all samples loaded was accurate. Additionally, there was an assumption that 
each of the 3 proteins targeted were extracted via the cell lysis procedure with 
high efficiency, as expression was normalised against total protein loaded. For the 
membrane bound SNAP23 and Syntaxin 4, this is a reasonable assumption. 
However, the smaller GSV bound VAMP2 is notoriously difficult to extract and 
detect, therefore there is a risk of underestimation of the expression of this 
protein. 
After consideration of the noted potential limitations, there are several findings 
of interest. First of all, quantification of this nature has been performed previously 
using 3T3-L1 adipocytes (Hickson et al., 2000), as displayed in Table 5-1. In these 
insulin sensitive cells there was similar expression levels of VAMP2 and Syntaxin 
4, and 2-3 times more SNAP23. As reported in Table 5-1, the relative expression 
of these proteins was highly similar in primary cardiac lysates. There was very 
close agreement in the generated numbers between the mouse and rat samples 
for Syntaxin 4 and VAMP2, with a more substantial discrepancy for SNAP23. It is 
not clear why this was the case, however expression still exceeded that of the 
other 2 SNARE proteins in both species. There are several possible reasons why 
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SNAP23 is expressed to a considerably greater extent than Syntaxin 4 and VAMP2. 
For example, it may be involved in other trafficking events in addition to that of 
GLUT4. This would mimic the multiple roles of Syntaxin 6, which is known to 
interact with many other SNARE proteins (not restricted to one SNAP isoform and 
one VAMP isoform) and therefore contributes to the regulation of several different 
cellular trafficking events, in a cell type specific manner (Wendler and Tooze, 
2001). 
The quantification values displayed in Table 5-1 also compare favourably to the 
estimated quantification of GLUT4 in primary cardiomyocytes. Conversion of the 
value reported in Table 4-1 produced an estimated expression of 8.76 x 1011 copies 
of GLUT4 per mg of total protein lysate. This corresponds almost exactly to the 
number obtained for Syntaxin 4 and VAMP2, which is to be expected if we assume 
that their joint physiological role in GLUT4 trafficking in other cell types also 
applies to cardiomyocytes. Hickson et al., (2000) reported that the total levels of 
GLUT4 per 3T3-L1 adipocyte were approximately 50-100% below that of these 
proteins. When considering the ratio of expression of each of these 3 SNARE 
proteins to GLUT4 transporters, it can be appreciated that this relationship will 
be more in favour of the SNARE proteins in 3T3-L1 adipocytes in comparison to 
primary cardiomyocytes. Additionally, the absolute expression of SNARE proteins 
was higher in 3T3-L1 adipocytes (Table 5-1). This suggests that there would be 
more fusion machinery available to complete the final step of GLUT4 trafficking 
in these cells. This could offer a potential explanation as to why 3T3-L1 adipocytes 
exhibit such a greater fold insulin stimulated glucose uptake response than 
primary cardiomyocytes (Figures 3-3 and 3-4), despite expressing less GLUT4. 
5.3.2 Alterations in SNARE and GLUT4 protein expression may 
contribute towards diabetic myocardial IR 
In order to assess the possible role of SNAREs in the insulin resistant heart, cardiac 
lysates from 2 different diabetic mouse models were probed for a wide range of 
SNARE proteins. It must be acknowledged that whilst the literature and provided 
supporting evidence strongly suggests that these samples are most likely to have 
been obtained from animals exhibiting cardiac IR induced by genetic or dietary 
interventions, this was not measured directly. Additionally, if we (reasonably) 
assume that these hearts were insulin resistant, any limitation in contractile 
 209 
 
function and the presence of corresponding vascular disease was not assessed. 
Therefore, care must be taken when stating the physiological context of any 
findings. It is highly likely that the samples from the 2 models exhibited IR, but it 
cannot be stated with confidence that they exhibited a complete DCM phenotype, 
although it also cannot be totally discounted. 
Before considering any difference between groups, it is important to first of all 
consider the wide range of SNARE proteins detected in these primary mouse 
cardiac lysates, which has been detailed in this general manner for the first time. 
Previous literature had reported the expression of selective SNAREs in cardiac 
tissue, often in non-primary models. However, as reported in Tables 5-2 and 5-3, 
there is in fact a wide range of SNARE machinery present in these cells. Both sets 
of lysates produced identical results regarding the expression of each target 
protein, with only Syntaxin 7, VAMP1 and VAMP7 being identified as absent in the 
lysates. The next logical step in a general sense must be to identify interactions 
between these proteins in vivo, before then identifying the physiological role of 
each complex. 
As has been inferred, evidence of the expression of SNARE proteins in 
cardiomyocytes previously cited as important in GLUT4 trafficking – both in the 
internal sorting processes and GSV-PM fusion – cannot be taken as evidence that 
they are also exclusively responsible for regulating this process in cardiomyocytes. 
However, it is of particular interest that of the broad range of 19 relevant proteins 
assessed, the only ones that appeared to differ between diabetic samples and 
controls are those that were previously identified as relevant to GLUT4 trafficking 
(in addition to SNAP29). 
When designing experiments with HFD and CHOW samples it was initially thought 
that pooling samples from independent hearts would be necessary in order to 
generate enough lysate to obtain strong signals from the target proteins. However, 
this was in fact unnecessary and unfortunately only served to reduce the statistical 
power of quantitative analysis. Whilst subjectively it appeared as though VAMP2 
and SNAP23 expression may have been altered, these differences were not found 
to be statistically significant. In contrast, VAMP5 and SNAP29 expression were 
found to significantly increase in lysates from HFD mice. This is of interest as these 
proteins have not been previously cited (SNAP29) or conclusively demonstrated 
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(VAMP5) to be of significant relevance to GLUT4 trafficking. SNAP29 has been 
described as displaying fairly indiscriminate binding to Syntaxin isoforms and is 
yet to be associated predominantly with any one physiological process (Hohenstein 
and Roche, 2001), therefore the interpretation of these findings is dependent 
upon future investigation. 
In cardiac lysates from db/db and db/m mice, no reproducible differences in 
expression of any SNARE protein was noted between experimental groups. 
However, a significant decrease in GLUT4 protein expression was detected in 
db/db lysates. This is of significance for the regulation of glucose uptake, and 
could largely account for the deficit in cardiac insulin stimulated glucose uptake 
reported in the literature from these mice (Carroll et al., 2005). The observation 
that there was no notable difference in GLUT4 between HFD and CHOW fed mice 
also supports a previously introduced theory. It has been stated that HFD mice 
represent an early diabetic phenotype, whereas db/db mice are more similar in 
many aspects to a more established manifestation of this condition (Burke et al., 
2017). Accordingly, relatively subtle alterations in insulin signalling networks – and 
therefore perhaps also in SNARE expression/interaction/localisation – are likely to 
drive initial development of IR, whereas a reduction in GLUT4 protein content is 
a more permanent change that indicates progression to a more severe state of 
diabetes. Therefore, the changes in cardiac GLUT4 content observed within this 
study are consistent with the initial theory regarding the characterisation of the 
two employed models. Often when identified disease phenotypes are discussed 
and characterised we look for one explanation and mechanism, but the probability 
is that the different factors underlying an overall pathophysiological outcome will 
likely vary at different stages of disease progression. 
5.3.3 Glucose transport is impaired in a post-MI rabbit model 
The link between glycemic control and MI is multifaceted and complex. Of 
particular interest within this project is whether or not previously non-diabetic 
rabbits show signs of cardiac IR 8-12 weeks post-MI. This model has several 
benefits that make it an attractive alternative to a previously employed short term 
rat model. Most importantly, the size of the animal (and associated characterised 
cardiac physiology) and increased duration post-MI prior to obtaining 
measurements increase the clinical relevance.   
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After initial optimisation (Figure 5-7), analysis of recorded [3H]-2DG uptake under 
identical conditions revealed a significant effect of MI upon the recorded signal. 
Therefore it can be concluded that MI induces a reduction in cardiac glucose 
uptake. An immediate concern could be that this simply reflects measurements 
obtained from less cells. MI would without question induce a considerable degree 
of cell death. However, as a reminder, these cells were plated based upon number 
of viable cells per well, not total number of cells. In fact based upon this it could 
be predicted that an increase in recorded signal may be recorded from post-MI 
cells due to there likely being a greater number of dead cells per well that could 
trap residual glucose during the course of the assay. A second concern is that 
cardiomyocyte isolation is itself a stressful procedure for the cells. Post-MI cells 
may already be in a heightened state of vulnerability, therefore subsequent 
exposure to this isolation procedure, in addition to radioactivity, could induce a 
stress response. What appears to be a reduction in glucose uptake post-MI could 
actually just be an enhanced stress response post-isolation. However, this is also 
countered by the observation that in a state of stress (e.g. ischemia) glucose 
uptake often increases, not decreases (Russell et al., 2004). Therefore, after 
consideration, it can be concluded that the reduction in glucose uptake post-MI is 
likely a reflection of a genuine physiological adaptation. 
This observation and possible explanation becomes much clearer when considering 
statistical post-test multiple comparisons. Although subjectively there appears to 
be a difference between both basal and insulin stimulated glucose uptake when 
comparing control and post-MI cells, these differences were not found to be 
significant. This may be partly linked to the variation and lower number of 
replicates performed in the post-MI condition, on account of sample availability. 
Additionally, insulin increased the recorded glucose uptake signal by a mean of 
597 CPM in post-MI cells from 845 to 1443 CPM, which was not found to be a 
significant increase (P=0.64). In contrast, insulin increased the recorded glucose 
uptake by a mean of 1073 CPM in control cells from 1311 to 2383 CPM. Although 
this was not found to be significant (P=0.06), it can be taken as evidence that 
there was a considerably stronger insulin response in control cells compared to 
post-MI cells. Therefore it is reasonable to conclude that the overall significant 
effect of MI upon recorded uptake values is largely attributable to a reduction in 
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absolute insulin response, indicative of reduced cardiac insulin sensitivity induced 
by MI. 
An important point to consider is that the process of recording glucose uptake 
from isolated cells of rabbits 8-12 weeks post-MI could create a 2-step unintended 
selection process that may bias results. First of all, it has been demonstrated that 
glycemic control in the immediate period post-MI is important for survival 
outcomes (Capes et al., 2000). Therefore, the animals that survive to 8-12 weeks 
post-MI (<100%) may be less likely to have suffered from the onset of cardiac IR. 
However, it must be acknowledged that the predominant reason for survival or 
otherwise is likely to be the severity of the initial cardiac injury. 
Secondly, the process of cardiomyocyte isolation is physiologically stressful, and 
a large number of cells will always die. It is logical that the cells that survive may 
be in a superior physiological condition to those that do not. Additionally, even if 
a heart is characterised as insulin resistant, significant heterogeneity in phenotype 
will still exist on the cellular level. It is entirely possible that cells that are not 
fully representative of the overall phenotype of the heart from which they were 
derived will predominate the population of isolated cells. Therefore, combined 
there is an overall risk of selecting the ‘healthiest’ cells from ‘healthiest’ hearts 
within the post-MI rabbit population, whereby in this instance ‘healthiest’ refers 
to least insulin resistant. In order to counter this risk, it would be beneficial to 
record whole heart basal and insulin stimulated glucose uptake in both populations 
at several points before and after the induction of MI. 
With these limitations in mind, it can still be argued that reduced insulin 
sensitivity was observed in post-MI cardiomyocytes. Therefore, the underlying 
mechanism must be considered. The data presented in Figure 5-9 strongly suggests 
that an impairment of insulin stimulated Akt phosphorylation is not the issue. In 
isolated cardiomyocytes from both control and post-MI rabbits, a weak phospho-
Akt signal was obtained in unstimulated cells. However, insulin stimulation 
strongly and reproducibly increased this signal several fold, in samples from all 
hearts assessed. It is a possibility that insulin signalling downstream of Akt may be 
impaired, but more often in insulin resistant myocytes deficits originate at or 
proximal to Akt and therefore would be expected to also impact the activation of 
this protein. Similarly, overall there was no statistically significant reduction in 
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GLUT4 protein content post-MI. Therefore this cannot be used as a general 
explanation for the reduced insulin stimulated glucose uptake in this group. 
However, when looking at individual data points, it is reasonable to suggest that 
this may have been a strong influencing factor in some cases. 
Finally, immunoblot analysis revealed no difference in expression of the SNARE 
proteins primarily associated with GLUT4 trafficking in cardiac lysates obtained 
from post-MI and control rats. These samples were kindly donated from long term 
storage, as opposed to freshly isolated tissue, therefore it was not possible to 
assay glucose uptake and assess if they were insulin resistant or not. Based upon 
prior literature employing a similar protocol, it was anticipated that they would 
be. This analysis is particularly valuable because it confirms the data obtained 
from mice regarding the expression of this range of proteins in primary cardiac 
tissue in a second species. However, at this point the mechanism underlying IR in 
the heart post-MI remains unclear. 
5.3.4 Methodological considerations 
There are 2 additional issues to consider regarding the work discussed in this 
chapter. First of all, as alluded to throughout section 5.3, many assumptions had 
to be made regarding the phenotype of the animal models studied. Whilst prior 
literature and data was used to guide the interpretation of results generated 
within this study, it would have been preferable to confirm disease phenotypes 
directly through independent measurements. However, given the number of 
disease models (HFD mice, db/db mice, post-MI rabbit, post-MI rat) access was 
generously provided to, this would have required resources out with the scope of 
this project. Secondly, the use of Ponceau staining to solely account for 
normalisation of protein loading is unique to this section of the thesis. In chapters 
3 and 4, when reporting data from iPSC-CM, Ponceau staining was always used 
during the immunoblotting procedure in order to act as a guide and ensure 
successful transfer. However, in almost all cases a housekeeping protein such as 
GAPDH was also probed for via immunoblotting in order to provide a well-
recognised quantifiable loading control. The reason only Ponceau staining was 
used during the work described within this chapter is that at the time of study, 
guidelines from reputable journals were indicating that this was preferable to the 
use of GAPDH. However, through experience it was determined that this approach 
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also has many limitations. Primarily, it is challenging to image with the same 
quality and resolution as an immunoblot for a housekeeping gene, and staining 
across lanes can become uneven when washing to reduce background. 
5.3.5 Conclusion and outline of further work required 
In conclusion, this body of work has demonstrated that the key SNARE proteins 
involved in various steps in GLUT4 trafficking are present in several primary rodent 
cardiac models. The members of the complex believed to initiate GSV-PM fusion – 
SNAP23, Syntaxin 4, and VAMP2 – were found to be expressed in absolute terms at 
a similar ratio as previously identified in 3T3-L1 adipocytes. However, a range of 
additional SNAREs were also shown to be present in cardiomyocytes, therefore 
future work must fully elucidate the functional interactions and roles of each of 
these. Work using db/db and HFD mice demonstrated that cardiac GLUT4 content 
may be reduced only once a more severe diabetic phenotype has been attained. 
Alterations in SNARE protein expression do not seem to play an important role in 
the development of cardiac IR, however the functions of SNAP29 and VAMP5 
require further study. Finally, cardiac insulin stimulated glucose uptake appears 
to be reduced in a clinically relevant post-MI model. Initial investigation did not 
indicate that any of the most obvious physiological adaptations (reduction in 
GLUT4 content, impaired insulin signalling) were present in these post-MI cells. 
Therefore, further characterisation of this model is required in order to generate 
novel hypotheses and molecular targets for future interventions. 
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6 Discussion 
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6.1 Key findings from this study 
iPSC-CM have previously been demonstrated to exhibit cardiomyocyte like 
features with regards to the expression of critical genes and proteins, and also 
their function. However, from the various perspectives from which they have been 
studied, there is a strong general consensus that these cells represent 
cardiomyocyte physiology at a foetal or at best neonatal stage of development. 
This is particularly true when considering their spontaneous contractile activity 
on account of an unstable membrane potential, and disordered arrangement of 
myofilaments.  
The primary aim of this thesis was to examine the potential of these cells to form 
the basis of a novel cellular model of DCM. In order to be suitable candidates they 
must meet several criteria, but of critical importance is that they exhibit an 
insulin stimulated glucose uptake response. Despite extensive investigation and 
several attempts to intervene, no robust or reproducible response was detected 
at any point. Several parts of the GLUT4 trafficking machinery required to elicit 
this response were present and activated by insulin (to at least some degree), 
however the critically limiting factor appeared to be a fundamental lack of GLUT4 
expression. Whilst there are detectable levels of this protein in iPSC-CM lysate, it 
is approximately 10-fold less than what was recorded from the primary mature 
cardiomyocytes they are designed to mimic. Functional studies inhibiting the 
action of glucose transporters confirmed that the GLUT4 that is present in iPSC-
CM is of limited importance to overall glucose uptake, and instead GLUT1 is 
predominant. GLUT1 is primarily responsible for regulating glucose uptake in 
foetal cardiomyocytes, therefore this data is consistent with the general 
characterisation of the developmental stage of iPSC-CM in the field. Of the 
interventions applied in this study in an attempt to increase GLUT4 content, only 
Lipofectamine 2000 mediated transfection was successful (3-4 fold), and yet this 
still did not induce an insulin response. 
Through undertaking research in order to detail the in vivo human cardiac 
standard against which iPSC-CM must be compared, it became evident that there 
is a large deficit in the current literature regarding the understanding of the 
regulation of cardiac glucose uptake under baseline conditions. Within the context 
of DCM research, this is a serious issue. In order to counteract cardiac IR, the 
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mechanisms underpinning the action of insulin – in this case translocation of GLUT4 
to the PM – must be fully understood. Even if a DCM model was generated via iPSC-
CM, if the underlying physiology was not understood then it would not be efficient 
or effective to simply apply different compounds and observe their effect in the 
hope of increasing insulin sensitivity. Rather, it is necessary to design 
interventions based upon identified pathophysiological alterations, in order to 
enhance both the chances of success and safety of the applied intervention. 
Within this project, for the first time, a wide range of SNARE proteins were 
demonstrated to be present in cardiac lysates generated from several rodent 
models. In addition to those previously cited as important in GLUT4 trafficking, 
several other VAMP, Syntaxin, and SNAP isoforms were identified. This is the first 
step of a full characterisation that is required in order to better detail intracellular 
trafficking within cardiomyocytes, in particular that of GLUT4. Additionally, 
insulin sensitivity was found to be reduced in cardiomyocytes isolated from a post-
MI rabbit model. Therefore, this provides a clinically relevant model through 
which the complex relationship between glycemic control and MI physiology can 
be studied in an experimental setting. The expression of key SNARE proteins did 
not vary between either post-MI or diabetic (db/db and HFD) animal 
cardiomyocyte models and controls, however GLUT4 protein expression was 
reduced in the most severe (db/db) diabetic model.  
6.2 Implications for previous literature 
With regards to previous literature, the work most relevant to the data presented 
in this project was performed by Drawnel et al., (2014). They claimed to not only 
have successfully matured iPSC-CM physiology through culturing the cells in 
medium depleted of glucose and instead supplemented with fatty acids, but also 
to have induced a DCM phenotype through subsequent addition of ‘pro-diabetic’ 
factors to the culture conditions. When diagnosing any disease, or in this case 
assessing whether an experimental model matches a disease phenotype, there are 
usually several criteria that have to be met. This is also true for diabetes, however 
there is one factor that is crucial and non-negotiably essential. Without the 
presence of IR, it is not possible to state that a diabetic phenotype is present. As 
discovered within this project, iPSC-CM do not increase glucose uptake in response 
to insulin stimulation. Therefore, it cannot be concluded from the study 
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introduced that a true DCM phenotype was indeed induced in iPSC-CM. If the range 
of other adaptations reported in response to diabetic conditioning (cellular 
hypertrophy, impaired intracellular calcium cycling, arrhythmic contraction) were 
accompanied by IR, then this model would be of utmost importance and value.   
The work reported in this thesis serves to build upon extensive prior 
characterisation of iPSC-CM, and improve our understanding of the metabolic 
profile of these cells. Whilst previous study of iPSC-CM metabolism is limited, the 
findings from this study are complimentary. For example, iPSC-CM primarily rely 
upon glycolytic metabolism of glucose to generate ATP (Rana et al., 2012), which 
is a far less productive and sustainable mechanism than the aerobic metabolism 
of fatty acids that predominates in the mitochondria of primary cardiomyocytes. 
This aspect of the iPSC-CM phenotype closely mimics foetal physiology (Werner et 
al., 1983). The only situation in which primary cardiomyocytes would typically 
depend upon glucose is in a state of acute or chronic stress, such as ischemia or 
cardiomyopathy (Montessuit et al., 1998; Dávila-Román et al., 2002). Therefore, 
findings within this study that iPSC-CM express very high levels of the glucose 
transporter isoform GLUT1 and low levels of expression of GLUT4 and the fatty 
acid transporter CD36 are consistent with the dependence of iPSC-CM upon 
glucose as the primary metabolic substrate.  
In general, there are two possible approaches that can be employed when 
developing disease models with iPSC-CM. First of all, if iPSC-CM are generated in 
a healthy baseline condition, then an external stimulus (or stimuli) of an 
appropriate nature can be applied in order to induce the desired phenotype. This 
is the approach employed by Drawnel et al., (2014) when attempting to induce a 
DCM phenotype. At present, with the metabolic characteristics of iPSC-CM as 
described, any model of this type is of questionable relevance, regardless of the 
condition attempting to be replicated. Even if the primary physiological 
characteristic of a cardiac disease is not related to metabolism, when considering 
the vital role of metabolism in general cellular physiology, let alone in the 
adaptive process in response to disease (e.g. post-MI), if the metabolic profile of 
iPSC-CM is at an immature stage of development then the interpretation of data 
generated from any disease model with these cells becomes highly complicated. 
There are already several issues to address when inducing phenotypes in a cell 
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type over the course of a few days or weeks and claiming that they are 
representative of conditions that develop over a series of months or years, as is 
normally the case in cell culture disease models. However, if that cell type is also 
well characterised to be of foetal physiology, then that limitation must be 
overcome before any models are developed. 
In contrast, disease phenotypes have also (more commonly) been studied with 
iPSC-CM generated from patients already suffering from certain conditions. In this 
instance, cells can spontaneously display a physiological deficit corresponding to 
the appropriate disease. For example, hypertrophy and prolonged action potential 
durations were recorded in iPSC-CM from individuals suffering from LEOPARD and 
long QT syndrome respectively, relative to controls (Carvajal-Vergara et al., 
2010b; Itzhaki, Maizels, et al., 2011). Where the phenotype in question is believed 
to have a defined genetic origin and relatively non-complex physiological 
mechanism, the strict correspondence of all aspects of iPSC-CM to an adult 
phenotype is less critical. In this case, what is of more importance is that results 
regarding the efficacy and safety of any applied interventions translate accurately 
to an in vivo human setting. Currently, iPSC-CM are widely used to assess the 
cardiotoxic potential of novel drugs in development, however the reverse case of 
whether drugs identified as potentially effective via iPSC-CM research exhibit a 
high degree of off-target effects also requires assessment. Overall, the findings 
reported in this study enhance the interpretation of data generated via this 
approach, but does not necessarily impact its translational capacity. 
With regards to the reported data generated with primary cardiomyocytes 
(chapter 5), the biggest implication regarding previous literature is to clear up 
ambiguities regarding the expression of certain SNARE proteins and provide a 
platform of characterisation that can inform a range of future research questions. 
Of particular note is the finding that VAMP7 protein was not detected, whereas 
VAMP8 was indeed found to be expressed (Table 5-2 and Table 5-3). Prior work 
with mouse cell lines had produced contradictory findings (Peters et al., 2006; 
Schwenk et al., 2010). Similarly, the detection of reduced cardiac insulin 
stimulated glucose uptake in 8-12 weeks post-MI rabbits confirms that the 
previously identified cardiac IR detected in rats 2 weeks post-MI (Fu et al., 2015) 
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extends to this more clinically relevant model, and provides a suitable model upon 
which further theories can be tested. 
6.3 What next for iPSC-CM? 
Overall, the biggest contribution of this body of work for the field of iPSC-CM 
research has been to provide novel characterisation of the regulation of glucose 
uptake in these cells, and indicate initial steps towards developing techniques 
that may increase cellular GLUT4 content and thereby possibly also induce an 
insulin response. Based upon this and an abundance of prior data considering other 
aspects of iPSC-CM physiology, the most pressing requirement for the future of 
research with these cells is the development of effective maturation strategies. 
The term maturation can be interpreted in many different ways. The physiological 
maturity of a cell is not defined by any single parameter, but rather by the 
combination of all aspects of its gene/protein expression, structure, and function. 
An argument could be made that maturation of the metabolic phenotype is of 
primary importance, due to the critical role metabolism plays in numerous 
processes in every cell. Specifically, enhancing GLUT4 protein content could have 
knock on effects for iPSC-CM substrate utilisation and ATP generation, which in 
turn could enhance calcium cycling and contractility and therefore generate an 
increased demand for improved efficiency of myofilament organisation and 
electrical activation. However, due to the current unmet clinical need for 
treatments targeting cardiac disease and therefore the demand for development 
of superior testing platforms and disease models, ultimately maturation of iPSC-
CM via any successful method is desirable. 
An important principle was established during the course of this project, which 
was the importance of quantification of both the current iPSC-CM and the 
intended adult cardiomyocyte phenotype. As displayed in Figure 4-1 and Figure 4-
2, the levels of GLUT1 and GLUT4 were estimated in both iPSC-CM and primary 
mouse cardiomyocytes. This permitted estimation of the absolute change in 
transporter expression required to achieve parity between phenotypes. This 
principle must be applied to other areas of iPSC-CM biology, and a range of 
standard principles agreed upon. This would turn the maturation of iPSC-CM into 
a quantifiable process, whereby values for the crucial identified parameters must 
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fall within the agreed standard range. Of course across a population of hearts, or 
even within a population of cardiomyocytes from the same heart, there is 
significant heterogeneity in phenotype between individual cells. However, 
through robust study of the gold standard human primary cardiomyocyte model, 
an appropriate range of acceptable standards can be generated. As introduced in 
chapter 5, the understanding of the regulation of glucose transport is not fully 
elucidated in the human heart, and this is undoubtedly true for other areas of 
study. Therefore further work is required to both clearly define these standards, 
and then properly move iPSC-CM towards the identified phenotype. 
The big question that requires answering is how iPSC-CM maturation will 
ultimately be achieved. Arguably the most promising advances with iPSC-CM have 
come from development of the capacity to insert these cells into the hearts of 
various animal models in vivo, as they integrate effectively to form contractile 
grafts that have a meaningful effect on cardiac function (Shiba et al., 2012). 
Logically, given that culture conditions designed to induce iPSC-CM maturation 
mimic this in vivo environment, it may be the case that this insertion protocol is 
also optimal to produce maturation of these cells. However, we cannot insert cells 
into a human (or any other species) heart, and then re-extract the cells at an 
appropriate time simply for the purpose of maturation. The number of cells that 
could be harvested from this approach would render this approach both highly 
inefficient and unethical. Therefore, advances must originate from within cell 
culture based approaches.  
The most up to date research using approaches introduced and/or utilised within 
this project are still showing progress. For example, culturing iPSC-CM in the 
presence of thyroid and glucocorticoid hormones during the initial differentiation 
period and subsequent transfer to a specially designed extracellular matrix 
induced the development of T-tubules, a critical feature normally lacking in these 
cells (Parikh et al., 2017). T-tubules are invaginations of the cell membrane that 
are critical for enabling uniform excitation across the whole cell. Accordingly, the 
timing of intracellular calcium release between different areas of the same cell 
became more synchronous in response to this intervention, unlike in control cells 
where areas closer to the myocyte membrane reached peak calcium concentration 
more rapidly. Interestingly, T3 was applied at a concentration of 100 nM, which is 
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almost 10x greater than what was utilised during work reported in this thesis. This 
suggests that previously recommended concentrations may have been suboptimal 
for the purposes of iPSC-CM differentiation. The authors also highlighted the 
potential importance of not only utilising appropriate stimuli, but also applying 
them in a specific order and only at appropriate times during the differentiation 
process. 
Despite this reported success, it was conceded that T-tubule density and 
orientation was still not fully representative of mature adult cardiomyocytes, and 
instead corresponded to that of early post-natal cells. Therefore, additional 
progress is still required, which may necessitate further innovation and 
development of novel techniques. Certainly, from the literature and evidence 
generated within this thesis, it seems unlikely that simply maintaining iPSC-CM 
within a 2D culture environment and exposing them to relevant stimuli thought to 
regulate cardiac development in vivo will be sufficient to induce the desired 
phenotype. The observation that primary cells tend to dedifferentiate in vitro 
perhaps gives insight into the importance of the immediate structural and 
biomechanical environment for cellular physiology, particularly in an organ such 
as the heart where functional capacity is so dependent upon organ level structure. 
These issues are partly addressed in the principles underlying 3D cell culture, 
however this idea needs to be extended and developed further. For example, 
perhaps a micro scaffold of suitable material could be devised within which iPSC-
CM could be inserted, whilst still permitting the regulation of the hormonal and 
metabolic environment. Critically, if excitation and rhythmic stretching of the 
simulated chambers could be induced then this would generate a highly 
representative artificial environment. Once a successful model was generated, 
the underlying principles could be adapted to enable a high throughput system 
amenable to generation of the substantial numbers of cells required to power 
significant amounts of research. 
Accordingly, the most successful recent iPSC-CM maturation based research 
published utilised a similar approach to that just described, within the realms of 
current technological limits. Ronaldson-Bouchard et al., (2018) generated a 
protocol whereby as soon as spontaneous contraction was detected in iPSC-CM 
they were used to form a section of cardiac tissue in combination with fibroblasts 
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within a hydrogel, which could be subjected to both external stretch and 
excitation. Importantly, the frequency of contraction of iPSC-CM can be easily 
regulated, but the corresponding force cannot be. The authors reported that 
initiating pacing at the earliest possible point, and inducing progressively higher 
workloads (from 2-6 Hz over 3 weeks), successfully induced structural and 
metabolic maturation. Critically, they provided quantification that detailed iPSC-
CM sarcomere length had elongated to 2.2 µM and mitochondrial density had 
increased to 30% of total cell area, distinct values associated with adult 
cardiomyocytes. Further evidence such as increased oxygen consumption was 
provided to display that metabolism had shifted to a more predominantly 
oxidative form, however no information was provided regarding GLUT4 or insulin 
sensitivity. Critically, whilst several parameters of excitation contraction coupling 
indicated maturation had occurred – including a decrease in resting membrane 
potential and the overall shape of the subsequently generated action potential – 
the improvement in contractile force generated was still far below values 
recorded from primary tissue in absolute terms. Therefore whilst this technique 
achieved significant progress, it still requires further optimisation. 
The alternative to physiological stimulus based iPSC-CM maturation is to use 
biomolecular tools to artificially manipulate the phenotype of iPSC-CM. In 
accordance with this, significant steps were taken towards the development of a 
lentivirus capable of increasing iPSC-CM GLUT4 protein expression, as reported in 
section 4.2.5. This is on the premise that a fundamental lack of GLUT4 protein 
expression is primarily limiting progression to a more mature metabolic status in 
these cells. Other physiological adaptations are also required, however increasing 
GLUT4 protein expression in appropriate tissues is a cornerstone of postnatal 
development, and may act as a trigger to induce these other changes within this 
experimental context. 
There are several benefits to utilising this approach. Most importantly, there is 
preliminary evidence to suggest that it can be successful in inducing GLUT4 protein 
expression to the levels recorded in primary adult cardiomyocytes. As displayed 
in Figure 4-20, iPSC-CM are susceptible to the strong overexpression of proteins 
via this technique (in this case Syntaxin 4). Additionally, the GLUT4 gene sequence 
at the core of the novel pCDH-GLUT4 plasmid (Figure 4-23) has already been 
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demonstrated within this project to effectively produce this protein within iPSC-
CM. With packaging into a more effective delivery method (lentivirus) it is 
anticipated that this will facilitate the approximate 10-fold overexpression of 
GLUT4 protein that is required. This approach is also efficient from a practical 
experimental point of view. After inevitable initial optimisation, sufficient 
overexpression of GLUT4 protein in iPSC-CM via lentivirus will be achievable within 
1 week post-plating via a protocol primarily dependent upon 1 variable (the 
continued efficacy of the lentivirus). This provides a relatively fast and simple 
technique to provide reproducible and robust outcomes, in contrast to a prolonged 
complex (and probably more expensive) protocol involving multiple factors e.g. 
different hormones and culture conditions.   
The main limitation of this approach is that it is highly targeted, rather than 
activating multiple intracellular signalling pathways in a manner analogous to 
certain relevant hormones. However, as alluded to, enhancing the metabolic 
phenotype of iPSC-CM may have positive follow on consequences for other areas 
of their physiology. Additionally, in all other major physiological processes within 
cardiomyocytes, either no single protein is primarily responsible for regulating 
that process, or where there is indeed one single protein responsible, it is present 
in iPSC-CM. In contrast, when considering insulin stimulated glucose uptake, 
cellular GLUT4 protein content is by far the most important factor. Therefore if 
any protein is to be selectively targeted in this manner, GLUT4 is an ideal 
candidate. Even if this approach does not result in global maturation, at minimum 
it would significantly advance our knowledge of the role of GLUT4 in cardiac 
biology. Alternatively, if an insulin stimulated glucose uptake response were 
induced by this approach it would transform our capacity to study the causes and 
mechanisms of cardiac IR.  
6.4 What next for the study of DCM? 
When considering the future of DCM research, the issue remains regarding a lack 
of a suitable experimental model. The maturation of the metabolic profile of iPSC-
CM is of utmost importance for this area of study, as they are by far the best 
candidate for the basis of any novel cellular model. More generally, in order to 
identify the areas relevant to this topic demanding immediate attention, the 
ultimate end goal must be considered, and then strategies can be devised to 
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bridge the gap from our current position. Clearly the overall aim of this research 
area must be to generate novel treatments that improve cardiac function in 
individuals suffering from DCM, in order to improve prognostic outcomes 
associated with the diagnosis of diabetes. When considering novel treatments, 
often the assumption is that this refers to novel pharmacological interventions 
targeting specific molecular mechanisms identified through prior research. This is 
a valid approach, however in this instance there may be an alternative strategy. 
DCM is a limitation of metabolic flexibility and contractile capacity in the heart. 
Arguably, the most potent stimulus to activate (acutely) and adapt (chronically) 
these factors in skeletal and cardiac muscle is exercise. This observation is the 
basic principle underlying the training of endurance athletes in a range of sports, 
where the objective is to develop the capacity to compete at high intensities for 
prolonged periods of time. In a clinical setting, exercise training has been shown 
to enhance whole body aerobic capacity and quality of life in patients after 
coronary artery bypass surgery (Moholdt et al., 2009). Similarly, several animal 
models have demonstrated the capacity of exercise to enhance/preserve cardiac 
function post-MI (de Waard et al., 2007; Wan et al., 2007). Of specific interest to 
this field of research is that exercise training protocols have also been found to 
restore cardiac/cardiomyocyte contractile function in the db/db mouse model 
(Stølen et al., 2009; Wang et al., 2015). These studies cited changes in the 
activation of PGC-1α, Akt, CamKII and PKA as contributing towards the 
normalisation of intracellular calcium handling and reduced cardiac fibrosis, 
however interestingly did not report any accompanying changes in whole body 
glucose homeostasis. 
This preliminary rodent data strongly suggests that targeted exercise programmes 
could be a valuable treatment option in patients with DCM. However, this work 
still raises several questions. First of all, it is notable that neither of the papers 
mentioned reported improvements in metabolic markers. This is surprising, given 
that in humans exercise training has previously been shown to increase skeletal 
muscle GLUT4 protein content and whole body insulin sensitivity (O’Gorman et 
al., 2006). A major challenge when attempting to interpret the significance of 
exercise based interventions in rodents for the application to human disease 
settings is that often the intensity and/or duration of stimulus applied is 
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unrealistic to attain in humans, particularly those that are poorly conditioned. For 
example, Stølen et al., (2009) designed an intervention whereby mice ran 4 
minute intervals at 90% of VO2max with 2 minutes recovery for 80 minutes per day, 
5 days per week. In humans this intensity would almost certainly be above the 
lactate threshold, therefore even well trained individuals would struggle to 
complete one of these sessions, let alone repeatedly over 5 consecutive days for 
13 weeks.  
One of the foundational principles of exercise training is specificity, whereby any 
stimulus applied elicits a specific response. The evidence introduced thus far 
indicates that exercise training has the capacity to improve contractile and 
metabolic outcomes in muscle, in individuals suffering from disease. Immediate 
future aims must be to perform clinical research in order to examine which 
protocols (duration/intensity/modality) are optimal to alleviate the symptoms of 
DCM. In order to achieve this, the mechanisms by which exercise can induce 
adaptation must be fully elucidated. Significant progress has already been made 
in this area. For example, increased calcium cycling during exercise activates 
CamKII, which has several downstream targets in order to enhance myocyte 
contractility, for example the SERCA inhibitor phospholamban (Rose et al., 2006). 
In addition to regulating the acute response to exercise, inhibition of CamKII was 
also found to nullify exercise training induced improvements in cardiomyocyte 
contractility in a mouse model (Kemi et al., 2007). However, there are several 
more theories and mechanisms that require investigation. 
Of greatest interest to the themes discussed within this thesis is evidence that 
SNARE proteins and ion channels may in some cell types be functionally coupled. 
For example, preliminary data indicates that complex formation involving SNAP25 
and Syntaxin 1 may directly regulate the activation of the voltage gated potassium 
channel (Kv2.1), which ultimately is critical to the release of insulin from 
pancreatic beta cells (Wolf-Goldberg et al., 2006). Interestingly, extensive work 
by Chao et al., (2011) indicates that a similar mechanism may be active in 
cardiomyocytes. They propose that SNAREs directly regulate the expression and 
excitability of Kv channels at the myocyte membrane, therefore having the 
potential to impact the overall membrane potential. Significant questions arise, 
for example if there is a similar regulation by SNAREs of membrane bound calcium 
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channels, given the critical role of calcium influx to excitation contraction 
coupling. Logically it would be efficient to have a mechanism of coupling an 
increase in glucose uptake with increased metabolic demands associated with 
contraction (and therefore increased excitation). The action of SNARE proteins in 
mediating GLUT4 trafficking and membrane excitability would achieve this aim, 
and would also have profound implications for the relevance of SNARE proteins in 
cardiac function both in health and disease.  
6.5 Conclusion 
Overall, this thesis has detailed several novel findings regarding the regulation of 
glucose uptake in iPSC-CM, and the efficacy of several interventions designed to 
achieve increased GLUT4 protein content and metabolic maturation. The 
progression of these interventions will be critical in attaining the ultimate 
experimental goal of developing a novel cellular model of DCM. The future of iPSC-
CM research in general relies upon novel maturation strategies, in order to 
increase the clinical relevance of work performed with these cells. However, 
significant progress has been achieved since their initial development, and 
interest in these cells is constantly expanding due to their potential. Similarly, 
novel mechanisms that regulate metabolism and contractility in the heart are still 
being uncovered, and will continue to inform future strategies contributing to the 
development of novel therapeutic interventions for the treatment of DCM. 
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7 Appendices 
  
 229 
 
7.1 Assessment of GAPDH as a loading control for 
immunoblotting of cardiac lysates 
In order to determine the validity of using GAPDH expression as a representative 
marker of total protein loading in lysates generated from 3T3-L1 adipocytes, iPSC-
CM, and primary mouse and human cardiomyocytes, two amounts of each lysate 
were probed for total protein expression and this was compared to generated 
GAPDH signals. It was determined that GAPDH expression should reflect relative 
differences between both different amounts of the same lysate, and also between 
lysates from different cell types. Qualitative analysis concluded that GAPDH was 
a robust representative of total protein for 3T3-L1 adipocytes and primary mouse 
cardiomyocytes. It was also considered acceptable for use with iPSC-CM, however 
it may slightly overestimate the total protein loaded. In contrast, there was a 
great disparity between the GAPDH signal obtained and total protein signals for 
primary human cardiomyocyte lysates. 
 
Figure 7-1 Assessment of GAPDH expression as a surrogate marker of total protein loading 
Lysates from 3T3-L1 adipocytes, iPSC-CM, primary mouse cardiomyocytes, and primary 
human cardiomyocytes were subjected to SDS-PAGE and transferred to a nitrocellulose 
membrane. Ponceau S stain was applied, prior to immunoblotting for GAPDH. Subsequently 
the blot was stripped and reprobed with a specialised LICOR total protein stain and imaged 
via the LICOR imaging system. For all samples, 2 amounts of lysate were loaded (1x, 2x), 
corresponding to the range loaded during quantification of GLUT1 and GLUT4 in these cell 
types as reported in section 4.2.1. 
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7.2 Basal and insulin stimulated glucose uptake in 3T3-
L1 adipocytes in the presence of GLUT1 and GLUT4 
inhibition  
Condition 
1 
Value 1 
Condition 
2 
Value 
2 
95% CI of 
difference 
Significant? P value 
Control 
Basal 3201 
Control 
Insulin 
9887 
-7279 to -
6093 
Yes <0.0001 
20 nM 
Basal 
2479 
20 nM 
Insulin 
6418 
-4532 to -
3346 
Yes <0.0001 
2 µM Basal 38 
2 µM 
Insulin 
451 -1006 to 179 No 0.3229 
Control 
Basal 
3201 
20 nM 
Basal 
2479 129 to 1315 Yes 0.0086 
Control 
Basal 
3201 2 µM Basal 38 
2570 to 
3756 
Yes <0.0001 
20 nM 
Basal 
2479 2 µM Basal 38 
1848 to 
3034 
Yes <0.0001 
Control 
Insulin 
9887 
20 nM 
Insulin 
6418 
2876 to 
4062 
Yes <0.0001 
Control 
Insulin 
9887 
2 µM 
Insulin 
451 
8843 to 
10028 
Yes <0.0001 
20 nM 
Insulin 
6418 
2 µM 
Insulin 
451 
5373 to 
6559 
Yes <0.0001 
Table 7-1 Summary of key statistical outcomes from [3H]-2DG uptake assays in 3T3-L1 
adipocytes in the presence of BAY-876 
Data displayed is output of post-test multiple comparisons following a 2-way ANOVA, where 
the identified factors were experimental day and drug treatment. Values expressed are mean 
of all replicates for each condition across 3 independent experiments, recorded in CPM. 
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